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ABSTRACT OF DISSERTATION

A MULTIDISCIPLINARY CHARACTERIZATION OF THE ENZYMOLOGY AND
BIOLOGY OF REVERSIBLE GLUCAN PHOSPHORYLATION IN TOXOPLASMA
GONDII
Toxoplasma gondii is an opportunistic, protozoan parasite of all warm-blooded
animals, infecting roughly one-third of humans worldwide. Humans acquire
infections by consuming T. gondii tissue cysts in undercooked meat or from
oocysts shed in cat feces. Encysted parasites convert into rapidly growing
tachyzoites that disseminate throughout the body, defining the acute phase of
infection. Under host immune pressure, tachyzoites convert into bradyzoites that
populate tissue cysts found in CNS or muscle tissue and persist for the lifetime of
the host, defining the chronic phase of infection. Tissue cysts are responsible for
transmission via carnivory, but also possess the ability to reactivate into
tachyzoites within their current host. In the context of immunosuppression,
reactivation manifests primarily as toxoplasmic encephalitis. Current therapeutic
options are poorly tolerated by many and effective only against tachyzoites. Thus,
there is a need for a better understanding of the chronic infection to develop new
treatments that eliminate tissue cysts or prevent reactivation.
The present work therefore examines the parasite’s utilization of amylopectin
granules (AGs), a morphological feature found in bradyzoites that distinguishes
them from tachyzoites. AGs, much like plant starch, are insoluble storage
molecules composed of branched chains of glucose and believed to fuel
bradyzoite replication, transmission, and reactivation. In plants, insoluble starch is
made enzymatically accessible by a cycle of direct, reversible glucan
phosphorylation. The addition of phosphate by a glucan kinase solubilizes the
starch surface to facilitate enzymatic glucose release, and the subsequent removal
of phosphate by a glucan phosphatase prevents hyperphosphorylation that would
obstruct enzyme access. The T. gondii genome encodes these opposing
enzymatic activities: the glucan, water dikinase, “TgGWD,” and the glucan
phosphatase, “TgLaforin.”
The work herein, along with recent studies, strongly suggests that the historical
understanding of AGs is lacking. There is mounting evidence that tachyzoites

contain small and rapidly metabolized glucans that are key to T. gondii biology.
Thus, an understanding of how T. gondii accesses its glucose stores throughout
the asexual cycle is needed. Perturbations of glucan phosphatase activity in plants
and animals result in significant defects in metabolism and glucan morphology,
suggesting the need to investigate reversible phosphorylation of T. gondii AGs. To
date, little has been done to characterize the enzymology or relevance of reversible
glucan phosphorylation in T. gondii.
Herein, the functions and unique structures of TgLaforin and TgGWD were
characterized using a wide range of biochemical and biophysical techniques.
Additionally, a role for TgLaforin in T. gondii was elucidated using protein
localization and knockout approaches. With these tools, it was demonstrated that
TgLaforin plays a vital role in both tachyzoites and bradyzoites, linking TgLaforin
to parasite metabolism, virulence, and development across the asexual cycle. The
data here suggests that the tachyzoite glucan may play a previously unappreciated
role in T. gondii. Thus, this work provides a unique window into the role of AGs
through the first multi-disciplinary characterization of reversible glucan
phosphorylation in T. gondii and establishes a framework for the development of
future therapeutic approaches.
KEYWORDS: Toxoplasma gondii, amylopectin granules, glucan phosphatase,
glucan dikinase, reversible glucan phosphorylation.
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CHAPTER 1. THE TURNOVER AND METABOLISM OF AMYLOPECTIN
GRANULES IN TOXOPLASMA GONDII
1.1 Introduction to T. gondii and its morphology
1.1.1 T. gondii, the model Apicomplexan
Toxoplasma gondii is an opportunistic, protozoan pathogen of humans and all
warm-blooded animals. It was first discovered in 1908 in two separate labs, one in
Tunisia and the other in Brazil, that each found this parasite in either gundis (from
which the parasite takes its name) or rabbits, respectively (1,2), immediately
suggesting its global distribution. Its ubiquity is now well recognized, as roughly
one-third of humans worldwide are estimated to be seropositive for T. gondii (3).
T. gondii is a member of the large Apicomplexan phylum, a collection of
intracellular pathogens with medical and veterinary significance such as
Plasmodium, Crytosporidium, Eimeria, Neospora, and Sarcocystis. Of these
pathogens, T. gondii is the most easily studied due to its ability to be propagated
indefinitely in cell culture, the establishment of animal models used to study both
parasite virulence in vivo and immune responses to its presence, and the
availability of a wide variety of cell markers and standard assays by which to
evaluate parasite fitness (4).
The T. gondii haploid genome also allows for ease of genetic manipulation
using well-established transfection protocols in generating mutants for which a
variety of selectable markers have been identified (5-7). Several conditional
knockdown systems have been developed in T. gondii including Cre-LoxP, Tet,
and, most recently, an auxin-inducible degron (8,9). Exciting new technologies
have also been adapted to T. gondii enabling a genome wide knockout screen
using CRISPR/Cas9 technology (10), subcellular localization of the entire T. gondii
proteome using hyperLOPIT (11), and single-cell transcriptomics that defined gene
expression profiles across both the cell cycle and asexual developmental stages
(12).
Importantly, the T. gondii research community has assembled these complex
data sets, alongside entire genome sequences and gene annotations, into
ToxoDB.org. Genes in T. gondii are easily identified using several strategies
including a BLAST functionality, common gene name queries, or specific
accession numbers. Within gene pages, all available genomic, transcriptomic,
proteomic, and localization data are displayed, along with many more gene
features and link-outs to common database with more information such as UniProt,
NCBI, etc. Moreover, the T. gondii community has collaborated on multiple books
such as Toxoplasma gondii: The Model Apicomplexan – Perspectives and
Methods that has served as a unified source of current T. gondii knowledge that is
now in its third edition (13). An invaluable collection of some of the most important
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methodologies in the field was also recently assembled in Toxoplasma gondii:
Methods and Protocols (14).
This chapter will serve as an introduction to the parasite that has motivated
such a dedicated community to undertake these herculean efforts to understand
its biology. As such, the basic biology of T. gondii first presented will then be used
as the context by which to present key discoveries in glucan composition, turnover,
and metabolism across life stages in T. gondii. Finally, the motivation for studying
the regulation of glucan degradation via reversible glucan phosphorylation in T.
gondii will be presented.
1.1.2 Basic biology and morphology of T. gondii
The T. gondii life cycle is complex and consists of many stages. Broadly
speaking, three stages within this cycle are considered transmissible: the
tachyzoite, the bradyzoite, and the sporozoite. Even though these forms of the
parasite are found in physically distinct locations (both within and outside of the
host) and at distinct stages of infection, their overall morphology is strikingly
similar. These stages are all commonly described as bow, crescent, or banana
shaped (contributing to the parasite’s name, from Greek: Toxon = arc/bow, plasma
= shape), and each is approximately 2-3 m wide and 7-9 m in length (15) (Figure
1.1a).
With regards to its ultrastructure, it has been known since the first EM studies
of T. gondii tachyzoites that it possesses standard eukaryotic organelles including
a nucleus, a single mitochondrion, a Golgi apparatus, an endoplasmic reticulum,
and ribosomes, as revealed in the first electron micrograph study of this parasite
(16). Follow up studies then expounded upon and detailed several unique
organelles that had been previously unknown (17). These organelles included
micronemes, rhoptries, and dense granules (18) (each of these unique organelles
is highlighted in Figure 1.1b). Since their discovery, these three organelles have
been characterized as possessing secretory functions (19), and the protein cargo
of each organelle has been extensively dissected and attributed to key stages in
the lytic cycle.
The small, rod-shaped micronemes (micro = tiny, neme = hairs) function
primarily in host cell egress, gliding motility, and host cell attachment through
secretion of perforins, adhesins, and proteases (20). The club-shaped rhoptries
(rhopos = club) secrete proteins that enable early moving junction formation
between the parasite and host cell, facilitating parasite invasion (21). Many of the
secreted rhoptry proteins also act as effector proteins that are injected directly into
the host cell for early manipulation by the parasite, and also decorate the outer
side of the parasitophorous vacuole membrane (PVM), the replicative niche of the
parasite (Figure 1.1a) (22). Finally, the dense granules secrete a wide variety of
proteins found throughout the infected cell: 1) found within the PVM lumen, 2)
anchored on the host cytosolic side of the PVM, and 3) released within the host
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cell cytosol and nucleus where they alter host transcription and halt cell cycle
progression (21,23,24). Perhaps most dramatically, proteins secreted from the
dense granules have been shown to be involved in recruiting the host cell’s
mitochondria to the PVM (25) where it makes very extensive contact (26). A role
for the rhoptry protein ROP2 has also been proposed to mediate PVMmitochondrial association (27).
The organization of the parasite’s plasma membrane and cytoskeleton are also
unique. T. gondii is a member of the alveolate superphylum, and thus contains an
intermembrane complex (IMC) composed of alveoli (flattened vesicles) stitched
together into a patchwork like network by suture components (28). The IMC
underlies the parasite’s plasma membrane, and this combination of alveoli +
plasma membrane is referred to as the “pellicle.” Underlying the pellicle are 22
microtubules that radiate out from an apical polar ring (APR) extending about 2/3
of the way down the parasite body, lending the parasite its distinctive shape (29).
Above the APR is a tubulin-based structure resembling a spring called the “conoid”
that rapidly extrudes and retracts during extracellular parasite motility and is
believed to be the gateway for invasion factor secretion (30). The rhoptries and
micronemes are commonly seen being docked in the conoid (Figure 1.1b), and
the combination of these organelles and cytoskeletal elements form the “apical
complex” from which the Apicomplexan phylum gets its name.
Other notable organelles in T. gondii have also been described, and include
the plant like vacuole that appears to act as a lysosomal compartment (31), the
acidocalcisome where calcium is stored (32), and, most notably, the apicoplast
(33). This distinctive four-membraned structure was recognized by TEM in both T.
gondii and Eimeria in 1965 and given the name “große Vakuole mit kräftiger
Wandung” (German for “large vacuole with thick walls”) long before its evolutionary
history was untangled (34). Over the course of the next several decades, many
more names were proposed for this structure, including “hohlzylinder” (German for
“hollow cylinder”) and “Golgi adjunct” (35). It was eventually recognized that T.
gondii and other apicomplexans contain a 35 kb segment of extrachromosomal
DNA outside of its mitochondrial genome (6-7 kb), and that this 35 kb segment
shared significant similarities with chloroplast genomes (36,37). Two studies
published in 1996 and 1997 utilized variations on in situ hybridization with portions
of this 35 kb DNA, one in conjunction with TEM in both T. gondii and Plasmodium
(33) and the other by fluorescence microscopy in T. gondii only (38). Both studies
showed localization of this DNA to the four-membraned structure. Thus, the final
name of this structure recognized its evolutionary past in calling it the
“apicomplexan plastid” or “apicoplast.”
Because the apicoplast is contained by four membranes, secondary
endosymbiosis of a red or green algal chloroplast was suspected (39).
Interestingly, the mystery surrounding its origin was unshrouded in studies that
sought to characterize the nature of starch-like amylopectin granule (AG)
metabolism in T. gondii (40). Due to the biochemical similarities of AGs in T. gondii
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to “floridean starch” in red alga (discussed in section 1.5.6), this study suggested
that T. gondii was of red algal origin.
In summary, it is now known that the apicoplast contains a highly reduced 35
kb genome, is no longer photosynthetic, and was responsible for lateral gene
transfer of algal/plant-like metabolic enzymes into the T. gondii genome (discussed
in section 1.5.6) (41,42). The apicoplast houses pathways for short-chain fatty acid
synthesis (primarily C14:0 and C16:0) via a FASII pathway, isoprenoid synthesis,
iron-sulfur cluster synthesis, and heme synthesis (43,44). Moreover, the apicoplast
is an essential organelle, as loss of the apicoplast genome results in parasites that
are ultimately unable to survive (45). Thus, the apicoplast has received targeted
focus for drug development, and some drugs such as clindamycin and doxycycline
specifically target the apicoplast (46,47).
Despite the presence of the aforementioned organelles throughout the invasive
stages of T. gondii, the stages also display key differences from one another.
Tachyzoites (tachos, from Greek = speed) replicate quickly during the acute phase
of a new infection (48) and reside within a non-fusogenic vacuole inside of the host
cell called the parasitophorous vacuole (PV) that is enclosed by the PVM (49). The
speed of tachyzoite replication enables efficient establishment of a new infection
and dissemination throughout a new host. Depending on the strain, tachyzoites
double in number through synchronous replication every 5-9 hours (50). This rapid
growth rate results in host cell egress roughly 24-48 hours after invasion (51). The
tachyzoite life stage is the most amenable to study, as it naturally propagates
under standard cell culture conditions at 37oC and 5% CO2, and is easily
cryogenically stored in glycerol or 10% DMSO (52).
Bradyzoites (brady, from Greek = slow) are the persistent form of T. gondii that
define the chronic phase of infection and are result from tachyzoite conversion
under immune pressure from the host (discussed in more detail in section 1.3.2.).
Bradyzoites reside in tissue cysts that are contained by a modified PVM known as
the cyst wall. Tissue cysts are typically found in the CNS (Figure 1.1c-d) or muscle
tissue of the host (most notably cardiac and skeletal muscle). These tissue cysts
vary in size, ranging from 10-100 m and contain hundreds or even thousands of
parasites (Figure 1.1e). Bradyzoites replicate more slowly than tachyzoites (53)
due to slowed progression through the cell cycle (54), but their asynchronous and
sporadic replication patterns preclude a precise determination of overall replication
rate (55). Bradyzoites are also morphologically distinct from tachyzoites as they
are typically slimmer, their nuclei are located at the posterior end of the cell, they
contain many more micronemes, and they contain numerous starch-like
polysaccharides known as amylopectin granules (AGs) in their cytoplasm (Figure
1.1f) (discussed extensively in sections 1.4, and 1.5.4.-1.5.6.).
Finally, T. gondii sporozoites, like bradyzoites, are organized in an
environmental cyst known as the oocyst and also contain AGs. Each oocyst
contains two sporocysts, each in turn containing four sporozoites (eight total
sporozoites per oocyst) (56). The oocyst is the product of sexual recombination
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within felids that is shed in cat feces. Oocysts are notable for their persistence in
the environment as they can survive for a year or more under suitable conditions
(57).
1.2 Key discoveries in T. gondii transmission and lifecycle
The involvement of these infectious stages in the life cycle of T. gondii was
worked out over the course of the 20th century and is presented in Figure 1.2 (58).
The first documented clinical case in a human in 1937 was a case of vertical
transmission of the parasite from mother to fetus, the least common but often most
devastating mode of transmission that can result in either spontaneous abortion or
severe ocular and mental defects in the newborn. Because vertical (i.e. congenital)
transmission results in such devastating consequences, these initial discoveries
motivated the intense research into T. gondii that has since followed (59). Interest
in the parasite has never waned due to the HIV/AIDS epidemic in the United States
that resulted in high rates of toxoplasmic encephalitis in immunocompromised
individuals (discussed in section 1.3.3.), and the increasing spotlight on areas
around the world in which infection with so-called “atypical strains” of T. gondii
results in a much higher disease burden than in the United States (60,61).
1.2.1 The discovery and initial characterization of T. gondii tissue cysts and their
transmission via carnivory
The first documented T. gondii tissue cysts were found in the brains of mice
and rabbits in the late 1920s (62). They were soon suspected as a latent form of
the parasite after asymptomatic, pregnant mothers gave birth to children infected
with T. gondii (63), ultimately leading to the hypothesis that mothers, and
asymptomatic individuals, could be carriers of the parasite. By 1939, several cases
of T. gondii infections in newborns were compiled and described (63). Notably, all
the described infants suffered seizures, and several presented with hydrocephaly
at birth. None of them lived longer than 7 weeks, and evidence of T. gondii
tachyzoites and encysted bradyzoites was found in necrotic tissue in the brain and
sometimes in the retina upon autopsy. While it is true that individuals can carry the
parasite for an indefinite amount of time, we now know that pregnant individuals
typically only transmit T. gondii to a developing fetus if acutely infected during the
course of pregnancy (64), not from a latent infection. For this reason, public health
officials often recommend pregnant individuals refrain from cleaning cat litter boxes
(CDC.gov).
More evidence supporting the theory that humans could asymptomatically
carry T. gondii accumulated in the 1940s when carriers of T. gondii were
discovered upon routine autopsies of deaths unrelated to toxoplasmosis. After a
14 year old boy died from an ailment described as “liver atrophy,” researchers
examined various tissues from his body during a routine autopsy, and they found
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what appeared to be a 48x20 m mass in his myocardial tissue that was described
as a tissue cyst (65). Following this report, another asymptomatic carrier who died
in a drowning accident was discovered by U.S. Army officials in Panama. Upon his
autopsy, T. gondii tissue cysts were also found in his myocardium (66). A few years
later, it was demonstrated that the brains of T. gondii infected rats retained their
infectivity for the entire length of a two year study, and together with the discovery
of asymptomatic humans with T. gondii infections, this evidence suggested the
parasite’s ability to establish asymptomatic infection and its ability to persist
indefinitely (67).
The development of a T. gondii complement-based serological test by Sabin
and Feldman in 1948 enabled researchers to survey a much wider number of living
people and animals for evidence of a latent T. gondii infection (68). In a survey of
1,747 people from around the world in 1956 using the Sabin-Feldman serological
test, researchers realized how prevalent asymptomatic carriers were with 31% of
tested individuals found to be seropositive for T. gondii (69). There were wide
ranges of seropositivity among different groups in this study ranging from 0% in
one geographic group up to 68% in another.
Around the same time, anti-Toxoplasma antibodies were being discovered in
many of the animals that humans consume including cows, pigs, goats, and sheep,
leading to the theory that meat might indeed be a major reservoir of T. gondii
infection (70). This hypothesis was demonstrated to be true in a study that found
T. gondii could be transmitted from rodent to pig, and from pig to humans through
carnivory (71,72). All of these discoveries were put into perspective by key
experiments demonstrating that tissue cyst walls are easily ruptured in artificial
digestive fluid containing pepsin, liberating the bradyzoites within (73). Importantly,
bradyzoites were shown to be pepsin resistant, retaining their infectivity after
pepsin exposure, whereas tachyzoites did not. Tissue cysts have also been
demonstrated to survive in meat several weeks at 4 oC (74).
Thus, with these early observations, the ability of T. gondii to be carried in
livestock, persist for long periods in the same host, and transmit via carnivory from
one host to another were established. The chain of transmission was thus far
demonstrated as (and summarized in the “carnivory”-labeled portions of Figure
1.2): a rodent infected with bradyzoites could be consumed by a pig, which, in turn,
would become infected itself and develop T. gondii tissue cysts in its skeletal
muscle that might persist for the lifetime of the animal. This undercooked muscle
in which cysts could survive for several weeks, when consumed by humans, could
then result in their subsequent infection.
1.2.2 The discovery and initial characterization of T. gondii oocysts and their
transmission through the environment
At this point, another major mystery remained to be solved related to the life
cycle—how did herbivores and vegetarians contract the parasite? Either arthropod
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or fecal transmission was suspected, but not until 1965 was it discovered that cat
feces contains an infectious form of T. gondii that retains its infectivity for at least
a year, although the infectious form of the parasite was not visualized upon first
being discovered (75). Interestingly, it was suggested in this study that T. gondii
passed into cat feces protected in the eggs of Toxocara cati (a feline roundworm),
which was not an unreasonable suggestion at the time considering that tissue
cysts could only survive a matter of days or weeks after death of the host, not an
entire year as seen in cat feces (73). Over the next several years, the infectious
material in cat feces was extensively characterized, and finally named the “oocyst”
once it was finally visualized due to its resemblance to Isospora bigemina oocysts
(76,77). Importantly to the elucidation of the T. gondii life cycle, oocysts retained
their infectivity in mice after separation from roundworm eggs by centrifugation
through a sucrose gradient. Moreover, kittens that had never been infected with T.
cati (and thus were incapable of containing their eggs) were shown to shed
infective oocysts after T. gondii infection in the lab, thus dispensing with the
roundworm co-transmission theory.
Continued characterization of oocysts revealed basic facts about their biology:
excretion begins 3-5 days after a cat consumes a tissue cyst, and they require 23 days at 24 oC to mature into fully sporulated oocysts that could then cause
infection (78) as mice that consumed oocysts before the sporulation point did not
contract T. gondii infections. Shortly after these seminal discoveries, the
developmental stages of the parasite within the cat intestinal epithelia were
characterized (79). These stages, distinct from the transmissible stages, were
named “merozoites” (mero, from Greek = partial or intermediate) and display more
similarity to tachyzoites than any of the other stages. After several days of
development through multiple morphological steps, merozoites convert into the
male and female gametocytes that ultimately recombine and produce oocysts shed
in cat feces, establishing felids as the definitive host of T. gondii (80). Why T. gondii
only undergoes sexual recombination in felids long remained a mystery in the field
after this discovery. Recently, however, it was determined that an excess of linoleic
acid in the felid gut triggers sexual development (81). Felids are the only mammal
that lack intestinal delta-6-desaturase activity, which is required for linoleic acid
metabolism, thus explaining why T. gondii restricts its sexual cycle to cats.
1.2.3 A description of T. gondii life cycle
The key aspects of the T. gondii life cycle are presented in Figure 1.2 and
summarized here: shortly after cyst-induced infection, cats (the definitive host)
shed T. gondii oocysts (the product of sexual recombination) in their feces. After
sporulation, T. gondii oocysts are infectious to all warm-blooded wildlife and
humans (the intermediate hosts) for up to a year. If humans consume unwashed
produce or scoop cat litter without washing their hands, oocysts can be consumed
directly from the environment. Common livestock also consume oocysts, become
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chronically infected, and then become a source of tissue cysts for human
consumption in raw or undercooked meat. Humans can also obtain T. gondii
infections via vertical transmission or organ transplant from an infected donor (82).
The T. gondii lifecycle is completed when a cat consumes a chronically infected
rodent and then generates new oocysts.
1.3 The role of the asexual stages in human infection and disease
Due to the wide variety of transmission options available to T. gondii and its
ability to infect any warm-blooded animal, it is estimated that one-third of humans
worldwide harbor this parasite (83). The prevalence of human infection is uneven
across the globe as was hinted at in early studies, with some countries having a
seroprevalence of <10%, and others reaching >70% (84). As the early
transmission studies revealed, horizontal transmission of the parasite occurs most
frequently through the consumption of raw or undercooked meat (tissue cysts),
and through the consumption of contaminated fruits, vegetables, and untreated
water (oocysts) (85). In rare instances, transmission of tachyzoites has been
suggested as possible through the consumption of raw milk (86). This section will
describe the asexual life stages after transmission of the parasite that define the
acute and chronic phases of infection and their role in toxoplasmosis. Of note, T.
gondii tachyzoites replicate rapidly by a specialized internal budding process
known as endodyogeny (18,87).
1.3.1 The acute phase of infection
Of particular concern to humans are the asexual stages of T. gondii that drive
the disease manifestations of toxoplasmosis in intermediate hosts: the tachyzoite
that defines the acute phase of infection, and the bradyzoite that defines the
chronic phase of infection. After ingestion of the parasite, most commonly an
oocyst (sporozoites) or tissue cyst (bradyzoites), the acidic environment of the
host’s digestive system rapidly releases the encysted parasite that is then able to
invade the epithelial cells lining the intestine (88). Once inside the epithelial cells,
the liberated sporozoite or bradyzoite then differentiates into a tachyzoite, initiating
the acute phase of infection (89). These early stages of infection in a new host are
not completely defined, but it is known that tachyzoites begin rapidly replicating
after conversion and will ultimately cross the intestinal epithelia. This process
occurs by a combination of three routes: 1) tachyzoites invade epithelial cells and
then exit into the lamina propria where immune cells are recruited, 2) tachyzoites
migrate between epithelial cell tight junctions without ever entering a cell, or 3)
immune cells migrate into the intestinal lumen where they are infected by
tachyzoites and then transport the parasites into the blood for subsequent
dissemination (90). Regardless of how the parasite encounters the immune
system, these immune cells are then used as Trojan horses for dissemination
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throughout the body of the host (91). In the early stages, the parasite can be
identified in many organs of the new host and throughout its blood flow (92,93). It
is also by this Trojan horse mechanism that T. gondii has been shown to cross the
blood brain barrier (94).
Repeated rounds of replication, host-cell egress, motility, and invasion define
the lytic cycle of the tachyzoite (48,95), and the dissemination of the tachyzoite is
greatly aided by its ability to invade any nucleated host cell. If a naïve mother is
infected during pregnancy, vertical transmission at this point of infection is possible
in which tachyzoites can cross the placenta and infect the fetus (64). Depending
on the trimester of gestation in which this occurs, the results of congenital infection
can range from mild/unnoticeable (typically third trimester) to premature
termination of pregnancy (often first trimester) with symptoms of varying severity
caused by a second trimester infection (3). Children that are infected congenitally
display a wide variety of neurological symptoms ranging from asymptomatic to
hydrocephaly, seizures, and mental deficits. Another major clinical manifestation
of congenital transmission is retinochoroiditis in which toxoplasmic lesions develop
within the eyes of children approximately 4-8 years after birth (3). In
immunocompetent hosts, outside of complications regarding vertical transmission,
the acute phase of infection typically causes very low to mild disease
manifestations that are self-limited.
1.3.2 The chronic phase of infection
As immune pressure mounts against the tachyzoite, it begins the process of
conversion into the slower-growing, persistent bradyzoite (96). The exact process
by which this occurs is still being defined, but a wide range of stresses induce
tachyzoite to bradyzoite conversion in vitro including alkaline or acidic stress,
interferon- and other cytokines, and nitric oxide (96,97). Additionally, cell type and
host metabolic state appear to play a role in bradyzoite induction in vivo—even
though T. gondii tachyzoites invade most cell types, bradyzoites within tissue cysts
are typically found only in long-lived cells such as muscle cells and neurons (98).
A study examining T. gondii conversion in muscle cells demonstrated that a host
cell that is withdrawn from the cell cycle, as is often seen in fully differentiated
neurons and muscle cells, results in stage conversion, although it is not yet clear
how parasites sense that they are in a terminally differentiated cell (99).
Upon bradyzoite conversion, morphological changes within the parasite occur
that are highlighted in section 1.1.2, including the accumulation of crystalline
starch-like amylopectin granules (AGs). In addition to these internal morphological
changes, the PVM surrounding the dividing tachyzoites develops into the tissue
cyst wall, becoming heavily glycosylated and studded with glycoproteins (100).
Within the cyst, bradyzoites are present in random assortments of numbers,
indicating that they no longer divide synchronously (55). While the view of
bradyzoites has traditionally been that they are inert and largely quiescent, recent
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data has indicated that bradyzoites do indeed replicate with evidence for varying
patterns of synchronous, clustered, and sporadic replication (55,101).
Occasionally, tissue cysts rupture, and bradyzoites can reinvade surrounding cells
and establish new tissue cysts. It is this process of tissue cyst rupture that is
believed to keep the immune system alert and primed to their presence, but also
presents no danger in an immunocompetent host (102).
In addition to morphological changes, significant molecular and metabolic
changes also occur during the conversion. Classically, conversion has been
monitored with a set of molecular markers (103). For example, tachyzoites express
a major GPI-anchored protein on their surface known as “surface antigen 1”
(SAG1) that is downregulated during tachyzoite to bradyzoite conversion
concurrent with the upregulation of “SAG1-related sequence 9” (SRS9), and there
are many more such markers that have been extensively described (104). One of
the major glycosylation markers on the surface of the tissue cyst wall, Nacetylgalactosamine, has classically been detected with the lectin Dolichos biflorus
agglutinin (DBA) (100). Additionally, several glycolytic enzymes are encoded by
multiple isoforms that are differentially regulated in these two stages: lactate
dehydrogenase 1 (LDH1) and enolase 2 (ENO2) are highly expressed in
tachyzoites whereas LDH2 and ENO1 are found in bradyzoites (105). Underlying
the changes in these classical molecular markers are massive transcriptional and
metabolic changes that are themselves regulated by Apicomplexan specific, plantlike ApiAP2 transcription factors (106). More recently, a Myb-like transcription
factor, bradyzoite formation deficient1 (BFD1), was identified as the master
regulator of differentiation in T. gondii, being both necessary and sufficient for
conversion (107). While BFD1 was shown to interact with many stage-specific
genes, its interaction with the AP2 transcription factors remains to be elucidated
(108).
1.3.3 Bradyzoite reactivation in acquired toxoplasmosis
In immunocompromised hosts, T. gondii bradyzoites can reactivate into
tachyzoites resulting in significant damage to the host’s CNS tissue that often
manifests as toxoplasmic encephalitis (TE) (109). Such damage is the result of an
uncontrolled tachyzoite lytic cycle in places where quiescent bradyzoites used to
reside. Early studies of this process first observed these reactivation events in the
context of cancer treatments (110). Case studies noted changes in patient
demeanor, speech, and behavior alongside seizures and symptoms of
encephalitis that began after chemotherapy and steroid treatment, all consistent
with significant neurological damage. Upon autopsy of patients that presumably
died from complications related to toxplasmosis, examination of their brains often
revealed large areas of total necrosis (in one case, a 4 cm clearing was observed).
In each of these brains, T. gondii tachyzoites were observed surrounding necrotic
areas, sometimes alongside tissue cysts that had not yet ruptured. Indeed, imaging
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of such lesions by either magnetic resonance imaging (MRI) or computer
tomography (CT) is a key diagnostic of cerebral toxoplasmosis in living patients
(111). Importantly, a study using retrospective analyses suggested that
immunosuppression was the driver of reactivation and not the various cancers
these patients had, as non-cancer patients treated with immunosuppressants also
developed toxoplasmosis (112).
At the beginning of the HIV epidemic in the early 1980s, cases of TE increased
dramatically in people living with HIV/AIDS (113). In the United States, between
10-40% of people living with HIV/AIDS were chronically infected with T. gondii.
Thus, the combination of plummeting immune protection and a latent parasitic
infection presented a situation akin to carrying ticking time bombs in which cyst
rupture events were not able to be controlled, allowing for reactivation. Indeed,
almost 100% of toxoplasmosis in people living with HIV/AIDS was due to tissue
cyst reactivation, as it was very rarely associated with a new infection (114).
Overall, it was estimated that about 25-50% of patients with AIDS who were
seropositive for T. gondii would go on to develop TE. By the end of the first decade
of the epidemic, T. gondii was recognized as being one of the most common
opportunistic pathogens with clinical manifestations in people living with HIV/AIDS
(113). While anti-Toxoplasma therapeutics were available during this time, fatality
rates were still incredibly high for hospitalized patients that received these drugs
(113). Therefore, significant declines in TE were seen only after anti-HIV combined
antiretroviral therapy (cART) became available in the mid-1990s. However, it was
estimated as recently as 2017 that over 13 million people around the world are
currently co-infected with HIV and T. gondii (115).
1.3.4 Anti-Toxoplasma therapeutic options
Treatment of toxoplasmosis has historically relied on targeting parasite folate
synthesis in cases of both acquired and congenital infection (116). The most wellknown T. gondii anti-folate was recognized as an anti-parasitic almost seventy
years ago and relies on the synergistic effects of combining pyrimethamine and
sulfadiazine (P/S) (117). Pyrimethamine inhibits dihydrofolate reductase (DHFR),
and sulfadiazine inhibits dihydropteroate synthetase (DHPS). The combination of
these two drugs ultimately blocks DNA synthesis in the parasite, but this
combination also targets metabolically active host tissue. To circumvent this, P/S
is commonly given with folate supplementation without any decrease the
antiparasitic effects of P/S (118). Alternatives to this regimen include cotrimoxazole
as a monotherapy (another antifolate), pyrimethamine in combination with various
protein synthesis inhibitors (spiramycin, clindamycin, clarithromycin, and
azithromycin) or in combination with a T. gondii-specific electron transport chain
inhibitor (atovaquone) (116). None of these regimens, however, have been
demonstrated to be more effective than P/S as it is still considered the gold
standard by which all other anti-Toxoplasma therapeutics are judged (119).
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Spiramycin is an incredibly important option in the clinic for pregnant
individuals. Because pyrimethamine has been demonstrated to be teratogenic, an
acute infection that is acquired during pregnancy is instead treated with spiramycin
which uniquely accumulates in the placenta without crossing it, thus providing a
difficult barrier for T. gondii to overcome (120). If, however, the fetus itself should
become infected at any time during pregnancy, it is recommended that the
newborn remain on P/S for the 1-2 years after birth (121).
While P/S is currently the first-line option, it also has the potential to result in
severe toxicity in patients related to its ability to cause bone marrow suppression
and dermatologic complications. Moreover, sulfonamides occasionally result in
allergic reactions. In fact, adverse events related to these drugs result in high rates
of discontinuation (up to 32% in some studies) and the need to switch to drugs that
have been considered as less effective (113). All of this taken together indicates
that the current options for treating toxoplasmosis are toxic and old. Moreover, they
are only effective against tachyzoites. There are currently no approved drugs that
target bradyzoites or prevent their reactivation (122), although there is an ongoing
and considerable effort to develop them (123). Clearly, there is a continued need
for the exploration of drug development against T. gondii as the only drugs
developed against this parasite are least useful in those who need them the most.
1.4 Amylopectin granules (AGs): a mysterious T. gondii polysaccharide
Based on the function of polysaccharides elsewhere throughout nature, AGs
are believed to play a role in energy storage that can be tapped into for bradyzoite
replication, persistence, transmission, and reactivation into tachyzoites. A
complete understanding of AGs and their utilization across the asexual cycle still
awaits a complete characterization. This section will describe the first observations
of this glucan, and the following sections will describe the modern understanding
of AGs.
1.4.1 The early years
The first studies documenting a glucan in T. gondii bradyzoites were actually
studies characterizing the tissue cyst wall. At this time, there was a debate
surrounding the nature of the cyst wall, and if T. gondii formed true cysts (i.e., a
cyst generated wholly by the parasite) or “pseudocysts” (i.e., a cyst derived from
host cell components). One study, in fact, proposed avoiding this debate altogether
by naming the cyst a “terminal colony” (124). Thus, the first studies noting the
glucan within the bradyzoites were focused on demonstrating that the cyst wall is
a distinct structure by showing that it is argyrophilic (staining with silver) and that it
stains faintly with periodic acid-Schiff (PAS), and it was also noted that the
bradyzoites within are PAS+ as well (containing a polysaccharide) (125,126). This
was the first time a glucan had been described in bradyzoites, and it was termed
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“glycogen” at the time (126). In 1958, a study used these characteristics to
definitively distinguish T. gondii tachyzoites in their “pseudocysts” (the term PV
was not in use yet) from bradyzoites that occupied a true cyst (127).
The first electron micrographs of T. gondii tissue cysts allowed visualization of
the glucan within bradyzoites [seen in studies (128,129)]. It is important to note,
however, that in these two studies, there was no mention of the glucan within
bradyzoites. In the context of discussion in the field with regards to pseudocysts
versus true cysts, these studies were more concerned with highlighting the unique
nature of the cyst wall. In fact, structures that appear to be a glucan within
bradyzoites were either not recognized at all (129), or described as “polygonal
inclusions” and termed either “vacuoles” or “precursor vacuoles” (128). Indeed,
studies on another Apicomplexan parasite were needed to characterize this glucan
within the encysted parasites.
1.4.2 Recognition of amylopectin granules in another coccidian parasite
In parallel with discoveries being made in T. gondii, a detailed characterization
of Eimeria tenella, a closely related parasite that causes coccidiosis in chickens,
was also occurring. Of note, E. tenella gametocytes were recognized in the 1940s
as containing a glucan that was then also described as glycogen by iodine staining
(130). However, 25 years later the polysaccharide from E. tenella sporozoites and
merozoites was more thoroughly characterized using biochemical and PASadapted electron microscopy techniques (131). The polysaccharide was isolated
using the Pflüger method—parasites were boiled in 30% KOH and then the glucan
was precipitated using ethanol. Acid hydrolysis of the isolated polysaccharide
revealed that it contained only glucose, and -amylase/debranching enzyme
treatment demonstrated the presence of -1,6-glycosidic bonds. Using the
products of these enzymatic digests, it was estimated that the average glucan
chain length was 12-17 glucose units, slightly longer than glycogen and more
similar to amylopectin (these enzymes, glucans, and their linkages are described
in detail in section 1.5).
While such a study was not conducted in T. gondii at the time, electron-lucent
inclusions seen in electron micrographs of T. gondii within both sporozoites
(132,133) and bradyzoites (134) were beginning to be labeled as polysaccharide
granules (PGs). Ultimately, by the end of the 20th century, these PGs were labeled
as amylopectin granules (AGs) even without a proper biochemical characterization
(15). The first study that verified the polysaccharide nature of these inclusions was
performed in 2003 using a TEM technique in which ultra-thin sections of resinembedded T. gondii tissue cysts were stained with a PAS-based techniques
compatible with EM (135). These studies demonstrated that the electron lucent
structures that had long been visualized in T. gondii were indeed a polysaccharide
by their dark gray staining.
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1.5 Structure, synthesis, and degradation of glucose-storage molecules
More recently, AGs in T. gondii have been described biochemically and much
of their enzymology is beginning to be dissected. This section will first provide a
brief overview of two of the major storage glucans found across the plant and
animal kingdoms: starch and glycogen, respectively. The structure, synthesis, and
degradation of each will also be described. Finally, the first biochemical studies of
AGs in T. gondii will be described in the context of these two major storage
macromolecules alongside a description of the specific enzymology related to AG
turnover.
1.5.1 Biochemical structure of starch and glycogen
Starch—Despite its seemingly simple composition as a homopolymer of
glucose, starch is an incredibly complex energy storage molecule synthesized
primarily by plants, algae, and some protists. Its complex and highly regulated
structure results in its characteristic semicrystalline nature [thoroughly reviewed in
ref. (136)]. Starch is practically unlimited in size, ranging from 500 nm up to 100
m in some roots (137). In fact, the size of starch granules appears limited only by
the physical constraints imposed by the organelle in which it resides and the
number of starch granules surrounding it (138). Fundamentally, glucose units
within starch are linked through either -1,4 or -1,6 glycosidic bonds to form both
linear and branched glucose connections, respectively (Figure 1.3a).
Starch is composed of two types of glucans: amylose and amylopectin (139).
Amylose, the simpler molecule of the two, is primarily linear with many fewer
branchpoints and thought to serve more of a space-filling role within the starch
granule (140). Amylopectin, on the other hand, is a moderately branched glucan
that is the primary constituent of starch, making up approximately 70-90% of the
granule (141). The -1,6 branchpoints within amylopectin make up approximately
5% of its glycosidic bonds, which are placed non-randomly throughout the
molecule and tend to be found in clusters (142). This clustered pattern allows for
long uninterrupted chains, with an average length of 20-25 glucose units, to wind
around their neighbors, forming helices that exclude water and contribute to the
crystallinity of starch (140) (Figure 1.3b). The chains themselves also pack with
each other in parallel, and their arrangements (also known as “allomorphs”) are
usually one of two types: A-allomorphs that are composed of densely packed
helices and exclude more water, and B-allomorphs that are arranged in a
hexagonal lattice, creating space for more water between the neighboring helices
(143) (Figure 1.3b). Importantly, A-allomorphs are more often associated with
“storage starch” that is found in non-photosynthetic plant tissue, and B-allomorphs
are more frequently found in the “transitory starch” of leaves and other
photosynthetic tissue (144).
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Glycogen—Like starch, glycogen found in animals is a branched glucan
connected through -1,4 and -1,6 glycosidic bonds. Unlike starch, however,
glycogen contains shorter glucan chains (an average of 13 glucose units per chain)
and is more frequently branched with -1,6 branchpoints making up approximately
8% of total glycosidic bonds (145). Moreover, these branches are evenly
distributed throughout the molecule, preventing extensive glucan helix formation
as seen in starch (146). Combined, these properties result in the increased watersolubility of glycogen relative to amylopectin (147). Additionally, the evenly
distributed branching pattern of glycogen results in a molecule that is organized
into tiers defined by each new set of branches on each chain (Figure 1.3c)
[modeled in (148) based on the crystal structure of maltoheptaose, and reviewed
alongside other competing models in (149)]. This tiered structure imposes a
physical limit on the size of glycogen of 12 tiers (roughly 55,000 glucose units), or
about 44 nm in diameter. This limit is due to an exponential increase in glucan
chains within each tier that would lead to eventual molecular overcrowding and
subsequent enzyme inaccessibility in a theoretical 13 th tier (150,151). These 44
nm glycogen molecules are referred to as -particles and can aggregate into larger
units known as -particles that are seen primarily in the liver (152). It has been
speculated that these differing organizations of glycogen result in either slower (particle) or faster (-particle) degradation due to their surface area differences
(153). A recent study found that glycogen contains covalently bound glucosamine
as well (154). Strikingly, glucosamine levels varied depending on the source of the
glycogen, with glycogen from liver, muscle, and brain tissue containing 0.1%, 1%,
and 25% glucosamine, respectively. The source of glucosamine in glycogen was
demonstrated to be glycogen synthase itself, as it was demonstrated to be capable
of incorporating glucosamine, in addition to glucose, into glycogen.
1.5.2 Glucan synthesis
Starch—In plants and green algae, starch synthesis occurs entirely in the
chloroplast and begins with the synthesis of ADP-glucose. First,
phosphoglucomutase (PGM) converts glucose-6-phosphate (G6P) to glucose-1phospahte (G1P). G1P is then a combined with ATP by ADP-glucose
pyrophosphorylase (AGPase) to form the activated sugar nucleotide, ADP-glucose
(155) (Figure 1.4, right side). This reaction is made effectively irreversible by the
simultaneous release of pyrophosphate that is rapidly hydrolyzed within the cell,
preventing the reverse reaction from occurring (156). The formation of ADPglucose, therefore, considered the committed step in starch synthesis under
physiological conditions (157).
To synthesize amylopectin, starch synthase (SS) adds the glucose moiety from
ADP-glucose onto the non-reducing end of an existing glucan chain by forming an
-1,4 glycosidic bond (157). Branching enzymes (BEs) work along SS, creating
branch points by removing -1,4 linked chains and reattaching them at C6
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positions to form -1,6 glycosidic bonds, maintaining the branching pattern
characteristic of amylopectin (158). Finally, debranching enzymes (DBEs)
participate in perfecting the amylopectin structure by removing excess branches
(159). Careful curation of these branchpoint locations results in their clustering
such that the long, unbranched chains can wind around each other (summarized
Figure 1.4, right side). The synthesis of linear amylose relies solely on the action
of granule-bound starch synthase (GBSS) that also utilized ADP-glucose (160). In
plants, many of these enzyme activities (SS, BE, and DBE) are encoded by
multiple isoforms such that they each have subtly, and sometimes dramatically,
different functions.
Glycogen—In animals and fungi, glycogen synthesis is initiated in the cytosol
by the protein glycogenin (161). Glycogenin functions as a dimer and first
glycosylates itself before extending a glucose chain of about 8 glucoses from this
initial O-linked glucose (162). Glycogenin uses a different sugar nucleotide, UDPglucose that is generated by UDP-glucose pyrophosphorylase (UGPase) for both
autoglycosylation and glucan chain synthesis (163). This initial protein-linked chain
acts as a primer for glycogen synthase (GYS), a highly regulated protein with two
isoforms found either in the muscle/brain (GYS1) or liver (GYS2), that elongates
glucan chains by forming additional -1,4 glycosidic bonds using UDP-glucose as
a substrate (164). Much like starch synthesis, a glycogen branching enzyme (GBE)
is required to curate the structure of the macromolecule by cleaving -1,4
glycosidic bonds and attaching the cleaved chain (a minimum of six glucose units)
at the C6 of a nearby chain forming an -1,6 glycosidic bond (165). It is worth
noting that branching enzymes, through their role in creating distinct branching
patterns, are believed to be largely responsible for the crystallinity and solubility of
starch and glycogen, respectively (166).
1.5.3 Glucan degradation
Starch—insoluble starch degradation is facilitated by a cycle of direct,
reversible glucan phosphorylation. Phosphate is directly esterified to the C6 and
C3 hydroxyl groups of glucosyl moieties within glucan chains by the glucan, water
dikinase (GWD) and the phosphoglucan, water dikinase (PWD), respectively
(167,168) (Figure 1.4, left side). The addition of phosphate disrupts the crystalline
helices on the starch surface, allowing further enzyme access (169,170).
Estimates of starch phosphate content ranges from one phosphate group per 100
or 1000 glucosyl units in Arabidopsis leaf starch and potato tuber starch,
respectively (171). After the addition of phosphate, endo- and exo-acting amylases
(- and -amylases, respectively) are then more easily able to cleave -1,4
glycosidic bonds, releasing maltose (-amylase) and longer, branched
oligosaccharides (-amylase) (172). Eventually, the phosphate groups added by
GWD and PWD becomes a steric hindrance to these amylases, and a glucan
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phosphatase is required to remove the phosphate to allow for further rounds of
degradation (173).
In plants, these glucan phosphatases are known as starch excess4 (SEX4)
(174) and like sex four2 (LSF2) (175). Glucan phosphatases employ a wide variety
of glucan binding platforms that are discussed extensively in section 3.1. As a
result of their unique binding platforms, SEX4 dephosphorylates both the C6 and
C3 positions (176), but prefers C6, while LSF2 exclusively dephosphorylates the
C3 position (177). Branch points in addition to phosphate groups also inhibit the
actions of amylases, so DBEs are also needed in starch degradation to cleave 1,6 glycosidic bonds in addition to their role in synthesis (summarized in Figure
1.4, left side). In starch degradation, these are typically direct debranching
enzymes, such as isoamylase, that remove an entire branch in one step. Other
enzymes can also act on starch, such as starch phosphorylase (-glucan
phosphorylase) that releases G1P, and disproportionating enzyme (D-enzyme)
that can transfer maltosyl units from one -1,4 glycosidic linkage to another,
potentially creating better substrates for enzymes in both synthesis and
degradation (178).
Glycogen—Like its synthesis, glycogen degradation can occur in the cytosol,
but also occurs through autophagy in the lysosome (termed “glycophagy”) (146).
In the cytosol, degradation occurs by phosphorolysis through the actions of
glycogen phosphorylase. There are three isoforms of phosphorylase throughout
the body, wish muscle, liver, and brain isoforms represented highly in their
namesake tissue (179). Glycogen phosphorylase transfers glucose from glycogen
to inorganic phosphate, forming G1P. In the reverse pathway to synthesis, G1P
can then be funneled into glycolysis through the action of PGM that converts G1P
into the glycolytic intermediate G6P. Glycogen phosphorylase can also catalyze
the reverse reaction by adding the glucose group from G1P back into glycogen
when G1P concentrations are high (180). Importantly, glycogen phosphorylase is
unable to release glucose from glycogen within 4 glucosyl residues of a
branchpoint, so glycogen debranching enzyme (GDE) is required to transfer a
glucan chain from a branchpoint onto the reducing end of a linear chain, extending
the substrate for phosphorylase to act upon (181). GDEs first transfer a chain
consisting of three glucosyl units using its transferase activity, leaving a single
glucose attached at the branchpoint. It then releases a free glucose by hydrolyzing
using amylo--1,6-glucosidase activity, and is thus known as an indirect
debranching enzyme (182).
Like starch, glycogen also contains covalently bound phosphate, ranging from
one phosphate per 500-5000 glucosyl units depending on the glycogen source
(183). The function of the phosphate in glycogen is not entirely clear, and its origins
are also unclear as no glucan kinase has been identified in animals. Regardless,
animals contain one glucan phosphatase known as laforin, encoded by the EPM2A
gene (184). Mutations in EPM2A have been extensively classified and result in the
neurodegenerative childhood dementia and progressive epilepsy, Lafora disease
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(LD; discussed more below) (185), in which a defining characteristic is
hyperphosphorylated glycogen containing much longer glucan chains than normal
glycogen (186). These aberrant glycogen molecules are known as lafora bodies
(LBs) and are more like amylopectin in size and their insolubility (187). Curiously,
mutations in another gene, EPM2B that encodes the E3 ubiquitin ligase known as
malin, also leads to LB formation (188). Malin appears to play a role in glycogen
metabolism by forming a complex with laforin that targets other enzymes involved
in glycogen metabolism for ubiquitination (189,190). However, the precise
functions of laforin and malin, their role in glycogen metabolism, and the
relationship between phosphate content and chain length all remain open
questions.
It has more recently been suggested that phosphate is occasionally
incorporated into glycogen through a rare glycogen synthase side reaction (191),
although this claim has been the subject of debate (183,192). Regardless,
phosphate may serve as a molecular method by which to date glycogen that has
been broken down and resynthesized several times, resulting in longer chains
(193). Thus, a role for glycogen-bound phosphate has been proposed in the
second major glycogen degradation pathway: glycophagy. Such a mechanism was
elegantly detailed in a recent review (194) and is briefly summarized here: as an
older glycogen molecule accumulates more phosphate from repeated rounds of
synthesis and develops longer glucan branches (which laforin has been shown to
prefer), laforin recruits malin to those glycogen molecules nearing their point of
precipitation into LBs, malin ubiquitinates nearby proteins via K63 linkages, this
attracts autophagy machinery, and glycogen is targeted for the lysosomal
compartment. Within the lysosome, lysosomal acid -glucosidase (GAA)
hydrolyzes both -1,4 and -1,6 glycosidic bonds, rapidly releasing free glucose
(195).
1.5.4 T. gondii glucan structure
The first biochemical characterizations of the glucan within T. gondii were
performed by Dr. Stanislas Tomavo’s lab (40,196,197). Importantly, generation of
the T. gondii glucan in each of these studies utilized acid stress on the RH strain
of T. gondii by growing it in HepG2 cells that naturally acidify their own cell culture
media. It was demonstrated by TEM that parasites under acid stress were
producing polysaccharides in their cytoplasm (197), but revealed by western blot
analysis that these acid-stress parasites retained their tachyzoite identify, i.e.,
these parasites had not converted to bradyzoites. RH parasites have a low
bradyzoite conversion rate, so this finding was not surprising. The presence of an
abundance of crystalline AGs in tachyzoites, however, was not something that had
been previously demonstrated. At this point, this set of studies diverged in how the
polysaccharide was purified and subsequently analyzed.
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In the first two studies (40,196), the polysaccharide was purified under mild
conditions by disrupting the tachyzoites with a French press, centrifuging the lysate
to pellet insoluble material containing the glucan, and then isolating the glucan by
passing the insoluble material over a 90% Percoll gradient. Only something like
starch would be able to pellet through such a dense gradient, as water-soluble
glycogen requires ultra-centrifugation for pelleting even in the absence of Percoll
(198). Both studies then examined the chain lengths of the uncharacterized
polysaccharide by first treating the glucan with isoamylase that cleaves -1,6
glycosidic bonds, only leaving linear chains of glucose. The lengths of these chains
were then analyzed utilizing high performance anion-exchange chromatography
coupled with pulsed amperometric detection (HPAEC-PAD) that relies on the
increasingly negative charge of successively longer glucose chains to separate
them for detection, or by using capillary electrophoresis (CE), another gel-filtration
based technique that separates glucan chains on the basis of charge. In both
cases, the chain length distributions (CLDs) were found to be more similar to plant
amylopectin than to animal glycogen with the average chain length being 8-12
glucosyl units but ranging up to 36. X-ray analysis revealed that this glucan was
also the more hydrated B-type allomorph, a characteristic typical of transitory
starch found in leaves. Moreover, NMR and size-exclusion analysis of the
undigested glucan demonstrated that no amylose (unbranched chains of glucose)
was present in these molecules. Thus, the T. gondii glucan had been characterized
as true amylopectin, finally warranting the name “amylopectin granules.”
In a follow up study from the same lab (197), AGs were purified from T. gondii
tachyzoites using a harsher method—parasites were lysed in hot water,
contaminants were removed by repeated phenol and chloroform/methanol
washes, and AGs were once again analyzed using HPAEC-PAD. Interestingly, the
CLD shifted toward shorter chain lengths in this study, with the majority of chains
falling into the shorter (DP7) category. However, there were still a large number
of long chains (8-16). These differences were attributed to the harsher purification
technique that might have resulted in a disruption of the longer glucan chains.
Importantly, there was a very low proportion of -1,6 linkages (<4%) relative to the
linear -1,4 glycosidic bonds as determined by methylation analysis, thus
confirming the amylopectin nature of this glucan.
1.5.5 Synthesis and degradation of AGs in T. gondii
Since the first biochemical characterization of AGs in T. gondii, most enzymes
related to AG synthesis and degradation have been identified, and are summarized
in Table 1.1 and visualized in Figure 1.4 (199). Notably, many of these enzymes
are expressed in tachyzoites, where AGs have not been observed by EM
(ToxoDB.org). This section will serve to highlight these T. gondii enzymes in the
context of the enzymes previously introduced in starch/glycogen synthesis and
degradation. All enzymes involved in AG synthesis and degradation were
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determined to be “dispensable” by a genome wide CRISPR knockout screen,
meaning that loss of any one of these genes does not impose an appreciable
fitness defect on the parasite (10). It should be noted, however, that this screen
was conducted under ideal, nutrient-replete cell culture conditions in tachyzoites
only, and following its publication, many of these AG-related genes have been
demonstrated to be critical virulence and cyst-forming factors in mice.
Synthesis—T. gondii encodes the enzymes needed to produce UDP-glucose:
two PGM isoforms (PGM1/2) and a UGPase (ToxoDB.org). PGM1/2 in T. gondii
have been characterized for their parafusin-related activity in calcium signaling and
secretion, and PGM1 was ultimately renamed parafusin-related protein 1 (PRP1)
(200). It was shown the PGM1/2 were truly dispensable and simultaneous deletion
of both genes had no effect on parasite virulence in mice. Deletion of PRP1 did,
however, result in defective microneme secretion in response to the calcium
ionophore A23187, suggesting a potential link between amylopectin metabolism,
calcium signaling, and egress-related secretion. The UGPase has not been
studied, but it has been confirmed that T. gondii primarily incorporates glucose
from UDP-glucose into AGs (40). Despite synthesizing crystalline amylopectin, T.
gondii also expresses a glycogenin orthologue that was also characterized outside
of the glucan synthesis pathway in its role as a glycosyltransferase that acts on
Skp1 [(201) that was originally published under a different title (202)].
The glucan synthase (TgSS) in T. gondii is referred to interchangeably as
“starch synthase” and “glycogen synthase” in the literature, and its knockout
resulted in loss of glucan synthesis in T. gondii tachyzoites and bradyzoites,
verifying its function (203). TgSS parasites also displayed a mild growth defect in
cell culture tachyzoites, lower tissue cyst numbers in mouse brains, and a
decreased ability to reactivate from bradyzoites back into tachyzoites in vitro.
Moreover, SS is only found in other coccidian parasites that synthesize starch-like
polysaccharides such as Neospora and Eimeria. The role of TgSS and what it
reveals about the role of AGs in central carbon metabolism will be discussed in
section 1.6.3. T. gondii also encodes two putative branching enzymes
(ToxoDB.org), but how they specifically remodel the branchpoints in AGs remains
to be determined. Finally, as would be expected, T. gondii does not encode a
granule-bound starch synthase (GBSS), an amylose synthesizing enzyme, which
is consistent with the observation that it synthesizes a true amylopectin containing
no amylose.
Degradation—T. gondii encodes all the enzymes needed in AG degradation
alongside the cycle of reversible phosphorylation that facilitates degradation with
some key differences. As in plants, T. gondii encodes both a glucan phosphatase
and a glucan, water dikinase. The glucan phosphatase was previously named
TgLaforin based on its domain orientation (204,205) (Figure 1.5). Mammalian
laforin contains a carbohydrate binding module (CBM) N-terminal to its dualspecificity phosphatase (DSP) domain, while the plant glucan phosphatase SEX4
is arranged in the opposite orientation with a DSP N-terminal to its CBM (Figure
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1.5). Moreover, the CBMs found in laforin and SEX4 are from different families,
with laforin possessing a CBM20 and SEX4 possessing a CBM48. Accordingly, T.
gondii laforin, or TgLaforin, contains a unique CBM20 N-terminal to its DSP domain
like human laforin (this CBM20 is dissected extensively in section 3.2.3 and 3.2.4).
Opposing TgLaforin activity is a GWD orthologue, TgGWD, containing at least two
CBM45 domains and a PPDK domain (discussed in section 4.1 and 4.2). Neither
of these proteins had been characterized in vivo, or extensively in vitro, until the
writing of this dissertation. T. gondii does not possess orthologues to the other
plant-like glucan phosphatase, LSF2, to the C3-specific glucan dikinase PWD, or
to the E3 ubiquitin ligase, malin, found in humans.
In addition to the enzymes involved in reversible phosphorylation, T. gondii also
encodes the enzymes needed to release glucose from AGs. Debranching enzyme
was characterized in T. gondii (named “Aa16GL”) in two Aa16GL lines of
parasites—one in Type I parasites (RH strain) and one in Type II parasites (Pru
strain). In both cases, parasites displayed significantly slower growth as evidenced
by plaque assays with tachyzoites but appeared to have no obvious morphological
defects related to AGs. Moreover, Aa16GL parasites displayed no acute
virulence defect in mice but did form significantly fewer cysts.
T. gondii also contains two classes of enzymes that cleave glycosidic bonds:
-amylases (endo-acting) and a glycogen phosphorylase ortholog, but T. gondii
does not contain -amylases (exo-acting). Interestingly, loss of either -amylase
or glycogen phosphorylase (TgGP) activity resulted in overaccumulation of AGs in
both tachyzoites and bradyzoites, and, once again, lower cyst formation in mice
while not affecting the acute phase of infection (206). Interestingly, the posttranslational regulation of TgGP via phosphorylation was determined by mutating
a phospho-site, S25, to either an alanine (S25A; unable to be phosphorylated) or
a glutamate (S25E; constitutively “phosphorylated”). The phosphomimetic S25E
displayed no AG accumulation or cyst formation penalty compared to WT, but the
S25A mutant resulted in both AG-excess and a significantly lower cyst burden
mice, demonstrating the importance of this phosphorylation site, possibly by the
kinase CDPK2 (discussed below), in the regulation of AG metabolism.
1.5.6 The hybrid nature of T. gondii AG metabolism and its red algal lineage
It is worth noting that enzymes involved in T. gondii AG metabolism are either
plant- or animal-like (Figure 1.6). T. gondii utilizes UDP-glucose (not ADPglucose) to synthesize AGs in its cytoplasm (not in its plastid), which are both
features of animals. The end product, however, is a crystalline AG with low
branching frequency, which is plant-like. With regards to enzymology, the cycle of
reversible phosphorylation includes a glucan, water dikinase (plant-like) opposing
a laforin-like glucan phosphatase (animal-like). T. gondii also encodes a
glycogenin ortholog (animal-like) whose activity relative to AG metabolism has not
been established. It does not appear that T. gondii possesses the glycogen21

degrading lysosomal enzyme GAA (animal-like), which implies that glycophagy
may not occur in this parasite.
This unique combination of characteristics from different kingdoms of life
provides evidence for its red algal ancestry. A T. gondii ancestor is believed to
have participated in a secondary endosymbiotic event that resulted in its
obtainment of the apicoplast. While the cytoplasm of the ancestral red alga was
lost, its plastid remained in the form of the four-membraned apicoplast, a result of
the original double-membraned chloroplast obtaining two additional membrane
leaflets upon its engulfment. Thus, like T. gondii, red algae, such as
Cyanidioschyzon merolae, also display characteristics of a plant/animal hybrid
starch machinery as they also synthesize an amylopectin-like molecule in their
cytoplasm with UDP-glucose, not in their plastids with ADP-glucose (207). In
addition, C. merolae and T. gondii share the similarity that both of have highly
simplified mechanisms of starch synthesis and degradation when compared to
plants or green algae where 30-40 genes have been identified in starch turnover
(199). C. merolae and T. gondii each contain 15 or fewer genes in synthesis and
degradation combined. As an example of the simplification of starch synthesis in
these unicellular organisms, Arabidopsis thaliana (representative of land plants)
and Chlamydomonas reinhardtii (representative of green algae) contain 5 and 7
starch synthases, respectively, whereas C. merolae and T. gondii only contain 1
starch synthase each. Moreover, land plants and green algae also contain GWD
and PWD along with SEX4, whereas both C. merolae and T. gondii contain only
GWD opposing a laforin orthologue.
1.6 A new role for AGs in T. gondii tachyzoite metabolism
Until recently, a role for AGs in tachyzoites had not been considered.
References to AGs in early literature typically note their abundance in bradyzoites
by TEM, and typically noted their relative absence/rarity in tachyzoites, despite the
fact that tachyzoites were observed to stain with the PAS, the glucan stain, as early
as 1956 (125). This section will serve to highlight the recent recognition that AGs
play a role in tachyzoite central carbon metabolism. As such, an overview of T.
gondii metabolic concepts will first be presented, followed by a recent
understanding of AGs in tachyzoite metabolism.
1.6.1 General metabolic themes in T. gondii
T. gondii central carbon metabolism is largely intact as it encodes a complete
set of enzymes needed to fuel glycolysis (208), gluconeogenesis (209-211), the
pentose phosphate pathway (PPP) (212), the TCA cycle (ToxoDB.org), and
oxidative phosphorylation (OX-PHOS) (213). Major metabolites and enzymes in
these pathways discussed in this section are illustrated in Figure 1.7. Several
enzymes that participate in these pathways are encoded by multiple genes that
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are regulated in a stage specific manner such as lactate dehydrogenase (214-216)
and enolase (217,218). Moreover, while tachyzoites utilize glycolysis and the TCA
cycle, there is evidence that bradyzoites downregulate mitochondrial metabolic
pathways such as the TCA cycle and OX-PHOS, and therefore depend more on
glycolysis (105,219). The evidence for this, however, is largely based on in vitro
bradyzoite conversion that results from treatment with oligomycin, a mitochondrial
ATP synthase inhibitor (53). Tachyzoites, on the other hand, have been shown to
be dependent on a functional TCA cycle, as inhibition of aconitase with sodium
fluroacetate (NaFAc) results in complete inhibition of tachyzoite growth (220).
There are key differences, however, in T. gondii central carbon pathways from
conventional pathways. For example, T. gondii encodes a pyruvate
dehydrogenase (PDH) complex that resides in its apicoplast, but does not encode
a mitochondrial PDH isoform for the conversion of pyruvate to acetyl-CoA to enter
the TCA cycle. Only relatively recently was it discovered that the mitochondrial
branched chain ketoacid dehydrogenase (BCKDH; Figure 1.7) could perform this
function, allowing for glucose-derived carbon to flow from glycolysis into the TCA
cycle (221). T. gondii also encodes a plant-like sedoheptulose bisphosphatase not
found in mammals that provides an alternative route for incorporation of glycolytic
carbon into the PPP (222). Finally, T. gondii does not encode a standard OXPHOS pathway found in mammals as it lacks a Type I proton-pumping NADH
dehydrogenase (complex I), instead encoding for two non-proton pumping Type II
NADH dehydrogenases (223). Such differences between pathways make for
attractive drug targets (224).
1.6.2 Glucose and glutamine metabolism
T. gondii is both flexible with its utilization of the carbon backbones of glucose
and glutamine and also dependent on these two molecules to fuel its central
carbon pathways. This was first demonstrated by the knockout of the only plasmamembrane glucose transporter in T. gondii, TgGT1 (Figure 1.7) (225).
Surprisingly, TgGT1 tachyzoites only demonstrated a moderate growth penalty,
forming plaques in a host-cell monolayer ~70% the size of WT parasites. This was
shown to be both the result of a slower replication rate and almost completely
abolished extracellular motility that was ~10% of the WT level. Importantly, these
defects could be replicated in WT parasites by starving them of glucose. The
motility defect could be rescued in TgGT1 parasites with glutamine
supplementation, suggesting that T. gondii can utilize glutamine to substitute for
glucose in times of nutrient starvation.
These observations were expanded upon in a follow-up study that used stable
isotope labeling of TgGT1 parasites with both 13C-glucose and 13C-glutamine to
tease out the precise metabolic contributions of glucose and glutamine (226). In
TgGT1 parasites, incorporation of exogenous glucose into glycolytic, PPP, and
TCA pathways was significantly decreased as would be expected. Importantly,
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incorporation of 13C-glutamine was highly elevated in TgGT1 parasites
throughout all of the aforementioned pathways, suggesting that T. gondii increases
flux of glutamine into central carbon metabolism through glutaminolysis and
gluconeogenesis (Figure 1.7; red arrows) (209,220). Glutaminolysis in T. gondii
was shown to be unique in that it can utilize a GABA shunt whereby glutamine is
converted into GABA and ultimately incorporated into the TCA cycle by conversion
into succinate, providing a two routes including the conventional funneling of
glutamine into -ketoglutarate (Figure 1.7) (220). Depletion of glutamine from
TgGT1 tachyzoites resulted in highly attenuated growth, the inability to survive
extracellularly for any extended period, and an impaired ability to invade host cells.
A complementary study was performed in which loss of the mitochondrial
gluconeogenic enzyme, phosphoenolpyruvate carboxykinase (TgPEPCK) that
converts oxaloacetate into phosphoenolpyruvate, was examined (Figure 1.7)
(210). Tachyzoites tolerated loss of TgPEPCK with no gross growth defects in cell
culture, but knockdown of TgPEPCK resulted in a decreased flux of 13C-glutamine
through gluconeogenesis. Consistent with this, TgGT1 parasites were unable to
tolerate simultaneous knockdown of TgPEPCK, as this results in a complete loss
of carbon flow through both glycolysis and gluconeogenesis.
Because TgGT1 parasites could theoretically retain the ability to operate
glycolysis, another study examined “glycolysis deficient” parasites by knocking out
hexokinase, “Tghk” (Figure 1.7) (211). Tghk parasites largely recapitulated the
phenotypes seen in the TgGT1 strain—a moderate growth defect, upregulation
of gluconeogenesis, and an increased dependence on glutamine. While the
previous studies did not show how loss of glycolysis might impact virulence in
mice, this study demonstrated that Tghk mutants remained virulent in mice, but
only at a high parasite inoculum. Moreover, they were severely compromised in
their ability to form cysts. Interestingly, this study also demonstrated that inhibition
of glutaminolysis with a glutamine analogue, azaserine, was detrimental not only
to Tghk mutants, but also to WT parasites. Thus, glutamine appears to be an
essential nutrient, even in the presence of glucose.
Similar models have been proposed in these studies regarding parasite
utilization of glucose and glutamine (210,211). Under normal conditions, T. gondii
utilizes glucose to fuel glycolysis and the first reactions of the TCA cycle, and
glutamine-derived-carbon to fuel the remainder of the TCA cycle (Figure 1.7;
glucose fueled reactions: blue; glutamine fueled reactions: red). However, if
deprived of either nutrient, the parasite demonstrates plasticity in its nutrient
utilization. Under glutamine deprivation, the parasite funnels glucose-derived
carbon through glycolysis into the TCA cycle to make up for the loss of glutamine.
Under glucose deprivation, T. gondii utilizes glutaminolysis to fuel the TCA cycle
through glutamine conversion to either -ketoglutarate or succinate via the GABA
shunt to then supply carbon to the glycolytic reactions via gluconeogenesis through
functional PEPCK, pyruvate carboxylase (TgPyC), and fructose-6-phosphate
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bisphosphatase (FBPase). Moreover, T. gondii growth is severely impacted in the
absence of both nutrients, but not completely ablated.
Interestingly, it appears that while T. gondii can tolerate absolute glucose
starvation (as evidenced by TgGT1 parasites), it cannot tolerate total glutamine
starvation via pharmacological methods (211). This suggests that host cells
generate glutamine when it is removed from the media in “glutamine starvation
experiments” that the parasites are ultimately able to scavenge, explaining their
ability to survive without supplemented glutamine. The reason underlying this is
unclear, but could be due to nitrogen deprivation in glutamine’s absence or its
importance in protein synthesis as demonstrated by glutamine-derived carbon’s
incorporation into protein by 14C-labeling (226). Notably, a glutamine transporter in
T. gondii has not yet been identified (227).
1.6.3 A new understanding of AGs in T. gondii metabolism
Outside of applying acid stress, the presence of AGs or functional AG
metabolism in tachyzoites had not been significantly discussed until recent
exploration of the role of plant-like calcium-dependent protein kinase2, CDPK2
(228). CDPKs regulate a wide variety of processes in T. gondii related to calcium
signaling such as egress (CDPK1 and 3) (229,230), invasion (CDPK1) (231), and
replication (CDPK7) (232). Each CDPK contains a kinase domain, a calmodulinlike domain composed of multiple EF-hands for calcium binding, and a variable Nterminal region (233). In the case of CDPK2, its N-terminus contains a CBM20,
immediately suggesting its involvement with polysaccharides. Indeed, it was
demonstrated that CDPK2 targets to multiple, small puncta within the T. gondii
cytoplasm via its CBM as this localization disappears with the mutation of key
carbohydrate binding residues in the CBM (228). This CDPK2 study was the first
modern study to demonstrate small punctate AG staining within tachyzoites by
PAS. The deletion of any of the three domains in CDPK2 resulted in parasites
containing large AG accumulations on their basal end and within their residual
bodies (a remnant from replication), strongly suggesting a link between calcium
signaling and carbohydrate metabolism, as did the PGM1/2 knockout (section
1.5.5).
In the CDPK2 study, pulse-chase analysis of 13C-glucose into and out of
amylopectin in tachyzoites indicated that the WT parasites rapidly synthesize and
degrade AGs, and CDPK2 parasites synthesized AGs at a faster rate and
degraded them at a slower rate than WT parasites, thus resulting in an AG excess
phenotype (228). This demonstrated that CDPK2 has roles in regulation of both
AG synthesis and degradation. The metabolic profile of the parasites was altered
as well with an upregulation of glucose incorporation into glycolysis, although the
reasons underlying this are unclear. Moreover, several putative targets of CDPK2’s
kinase activity related to AG metabolism were demonstrated including TgGWD,
Aa16GL (debranching enzyme), TgGP, a branching enzyme, and an -amylase.
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Finally, CDPK2 parasites were less virulent in mice and resulted in the formation
of no tissue cysts.
After this report, a number of studies were subsequently published examining
some of the putative targets of CDPK2. Thus far, the only two enzyme knock outs
that resulted in a similar AG-excess phenotype and a decreased cyst burden in
mice were TgGP (206) and -amylase (234), but neither of these studies examined
parasite central carbon metabolism. -amylase mutants were much less virulent
in mice, and further explored as a potential vaccine candidate as infection with
these mutants protected mice against further challenges with WT parasites. While
the mechanism is not understood, inducible knockdown of pyruvate kinase (PYK)
(Figure 1.7) is the only other mutant that has demonstrated an overaccumulation
of AGs in tachyzoites at the time of writing this dissertation (235). A remarkable
observation from this study demonstrated that AG excess remained under
glucose-starved conditions while PYK was knocked down, suggesting that AGs
can be synthesized from glutamine-derived carbon.
Studies of starch synthase (TgSS) in T. gondii demonstrate the role of AGs in
central carbon metabolism most clearly (203). Loss of TgSS resulted in loss of
AGs in tachyzoites and bradyzoites by PAS staining, no virulence defect in mice,
and a slightly lower cyst burden. Curiously, loss of TgSS resulted in higher
bradyzoite conversion efficiency in vitro, and larger cysts in vivo. This study also
provided the first direct evidence of AG involvement in bradyzoite reactivation by
demonstrating that TgSS parasites were impaired in turning off bradyzoite
markers in an in vitro reactivation assay. Importantly, flux of glucose-derived
carbon through glycolysis, the TCA cycle, and the PPP in TgSS parasites was
significantly decreased. While it was not examined here, decreased glucose flux
through central carbon metabolism implies the simultaneous upregulation of
glutamine metabolism. This study therefore provided significant evidence that AGs
play a role in glucose allocation in T. gondii tachyzoites, that the effective removal
of AGs results in dysregulation of glucose allocation, and that AGs are needed in
bradyzoite reactivation.
1.7 Regulation of AG metabolism in T. gondii
As the importance of AGs in tachyzoites is currently being elucidated, the
regulatory mechanisms underlying their usage is still unknown. The critical
regulatory role of reversible phosphorylation of both starch and glycogen has been
recognized over the past 25 years by two distinct fields, plant biologists and
neurobiologists, whose findings often complemented and informed each other
during the early days of discovery (236).
1.7.1 The importance of direct, reversible glucan phosphorylation in plants in
animals

26

While the presence of covalently bound phosphate has been recognized in both
glycogen and starch, it was treated as either a contaminant or a curiosity (237)
until knockdown of GWD (then known as “R1 protein”) in 1998 resulted in a starchexcess phenotype alongside reduced phosphate content in A. thaliana leaves
(238). Following this, it was soon recognized that R1 was a glucan, water dikinase
(GWD) (167), and predicted that direct phosphorylation of starch facilitated its
breakdown by other enzymes (237). Simultaneous to the discovery of the
importance of starch-bound phosphate, an A. thaliana mutant that displayed a
striking starch-excess (SEX) phenotype was characterized, and the gene related
to this phenotype was named SEX4 (239). Notably, the SEX4 line of plants
displayed no decrease in enzymatic activity of other starch degrading enzymes
(239), and it was demonstrated that the SEX phenotype developed progressively
as plant leaves aged (240). Independent of this study, the protein encoded by this
gene was identified in an A. thaliana phosphatase screen and classified as a
protein tyrosine phosphatase (PTP) due to the presence of its catalytic CX 5R motif
in its phosphatase domain (241). This study also classified a domain downstream
of the PTP domain as a “kinase interaction sequence (KIS).” Several years later,
a study mapped the SEX4 locus to this protein, identified that the KIS was indeed
a CBM, and demonstrated that recombinant SEX4 could bind glycogen (242).
Prior to these studies in plants, scientists were grappling with the molecular
underpinnings of Lafora disease (LD) in humans. LD was first described in 1911
by Dr. Gonzalo Lafora who discovered amyloid-like deposits in the brains of young
patients with a neurodegenerative epilepsy at autopsy (243). These deposits were
subsequently shown to be glucose-based polymers that were amylopectin-like in
nature and termed “Lafora bodies” (LBs) (244,245). In 1998, mutations in one of
two genes causing LD (EPM2A) was identified and classified as a protein-tyrosinephosphatase (the family to which DSPs belong) (184). Subsequently, laforin’s
CBM was identified, and the CBM was shown to target laforin to glycogen (246),
making it the only human phosphatase to possess a CBM (236).
Notably, the study that demonstrated the ability of SEX4 to bind carbohydrates
also recognized the similarities between SEX4 and mammalian laforin, speculating
that their shared functions allowed them to bind carbohydrates and
dephosphorylate proteins related to carbohydrate metabolism (242). That same
year, a study was published demonstrating that laforin could instead
dephosphorylate amylopectin in vitro, possessing a target and function that had
not yet been predicted—namely, that laforin is a glucan phosphatase (247).
Studies immediately followed demonstrating that loss of laforin in epm2a-/- mice
resulted in hyperphosphorylated glycogen, speculating that hyperphosphorylation
is what lead to the aberrant branching characteristic of LBs (186). It was then
confirmed that laforin and SEX4 were functional equivalents, as complementation
of laforin into SEX4 plants resulted in rescue of the SEX phenotype; this was both
visualized by iodine staining and quantified in total starch content in the leaves
(204). These complementary fields describing glucan phosphorylation came full
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circle by demonstrating that SEX4 also behaved as a glucan phosphatase in vitro
and in vivo, as SEX4 plants accumulated hyperphosphorylated starch breakdown
intermediates (174). Following these foundational findings in the LD field, it has
been shown that loss of laforin has an impact beyond the glycogen molecule,
extending into metabolism (248) and glycosylation defects (154).
1.7.2 Laforin in protists and motivation for the project
At the same time that glucan phosphatase activity was described and
established in both plants and animals, laforin orthologues were recognized in
many Apicomplexan protists of red algal descent including T. gondii, Neospora,
Sarcosystis, and Eimeria among others (204,205). Indeed, a priori criteria to
determine if protists contain laforin were developed: the protist must 1) contain an
insoluble glucan, 2) contain a true mitochondrion, and 3) be of red algal descent.
Importantly, all the identified protists in these studies also encyst for some portion
of their life cycle, implying the importance of glucan storage, and thus its regulation
via reversible phosphorylation, in each protist’s life cycle.
Given the importance of direct reversible phosphorylation across kingdoms of
life in proper glucan degradation and central carbon metabolism, and the clear
roles of AGs in metabolism and energy storage across asexual (tachyzoite and
bradyzoite) and sexual (sporozoite) life stages of T. gondii, we sought to further
characterize the enzymes involved in AG regulation via an understanding of
reversible glucan phosphorylation in T. gondii.
In Chapter 3, to accomplish this task, we first provide a detailed
characterization of recombinant TgLaforin by 1) elucidating the organization of its
unique CBM, 2) providing evidence for its DSP-mediated dimerization, 3)
demonstrating its activity as a glucan phosphatase that dephosphorylates
amylopectin in vitro with preference for the C3 position, and 4) developing a glucan
phosphatase inhibitor with specificity to TgLaforin.
In Chapter 4, we next characterized TgGWD in vitro as a true glucan, dikinase
that 1) utilizes the -phosphate from ATP to autophosphorylate itself before, 2)
phosphorylating amylopectin on the C6 position, and 3) releasing AMP that we
detected using a novel capillary electrophoresis-based assay to detect.
In Chapter 5, we finally demonstrate that TgLaforin does indeed play a critical
role in AG metabolism in T. gondii tachyzoites and bradyzoites using
CRISPR/Cas9 to both tag and knockout TgLaforin. We demonstrate that 1)
TgLaforin localizes to AGs in tachyzoites, 2) that loss of TgLaforin results in a
dependence on glutamine, decreased virulence in mice, and decreased cystforming ability, and 4) loss of TgLaforin results in the selective over-accumulation
of AGs in bradyzoites and not tachyzoites.
The impact of each of these studies will be discussed in the chapter in which it
is presented, and a discussion regarding where these studies push our
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understanding of AGs and their role throughout the T. gondii asexual life stages
will be presented in Chapter 6.
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Table 1.1 Enzymes required for AG synthesis and degradation.
All identified enzymes in AG turnover are listed in this table, alongside ToxoDB.org
accession numbers.
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Figure 1.1 Morphology of asexual stages of T. gondii tachyzoites and
bradyzoites.
A, Phase image of four T. gondii tachyzoites in human foreskin fibroblasts (HFFs),
demonstrating their overall arc-like morphology. The parasitophorous vacuole
membrane (PVM) that contains tachyzoites is highlighted. Scale bar = 10 m. B,
TEM of tachyzoite with secretory organelles labeled. Scale bar = 1 m. C, Coronal
slice of CBA/J infected brain. D, Zoom of blue box from (C), PAS+ tissue cysts
indicated with arrowheads. E, Phase image of T. gondii tissue cyst isolated from
the brain of a mouse containing hundreds of individual bradyzoites; cyst wall (CW)
labeled. Scale bar = 10 m. F, TEM of bradyzoites within tissue cysts from brain
of infected mouse containing amylopectin granules (AGs) and an increased
number of micronemes (M). Scale bar = 1 m. Abbreviations: AG = amylopectin
granule; C = conoid; CW = cyst wall; DG = dense granule; HN = host nucleus; N =
parasite nucleus; M = micronemes; PAS = periodic acid-Schiff; R = rhoptries.
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Figure 1.2 The T. gondii life cycle and common sources of human infection.
Evidence for each mode of transmission is presented in section 1.2.1 and 1.2.2. A
compact description of the entire lifecycle is presented in section 1.2.3.
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Figure 1.3 The molecular underpinnings of amylopectin and glycogen
organization.
A, Both amylopectin and glycogen are composed of glucose joined by -1,4- and
-1,6-glycosidic bonds that result in linear bonds and branchpoints, respectively.
B, The low frequency and clustered arrangement of branchpoints in amylopectin
allows glucan chains to wind around each other, excluding water. The top-down
view of chains demonstrates their packing beside one another, resulting in either
A-type amylopectin (excluding more water) or B-type (incorporating more water).
C, The increased frequency of branching in combination with evenly distributed
branchpoints in glycogen results in a tiered structure that exponentially increases
in glucose content with each tier. This arrangement prevents extensive chainwinding, resulting in a water-soluble glucan.
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Figure 1.4 The enzymology of insoluble glucan synthesis/degradation.
The right side depicts the generation of the substrate for starch synthesis, an
activated sugar-nucleotide, and its incorporation into growing glucan chains that
ultimately wind around each other excluding water. The left side depicts starch
degradation via a cycle of reversible glucan phosphorylation. Red circles
symbolize phosphate. Abbreviations: AGPase = ADP-glucose pyrophosphorylase;
BE = branching enzyme; DBE = debranching enzyme; HK = hexokinase; PGM =
phosphoglucomutase; UGPase = UDP-glucose pyrophosphorylase.
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Figure 1.5 Domain composition and orientation of glucan phosphatases.
Ruler below corresponds to the amino acid length of each protein/domain.
Abbreviations: CBM = carbohydrate binding module; CT = C-terminal domain; cTP
= chloroplast Targeting Peptide; DSP = dual specificity phosphatase domain.
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Figure 1.6 T. gondii AG metabolism combines animal glycogen and plant
starch characteristics.
Schematic of both animal and plant glucan localization, synthesis, and
degradation, and the properties of each that are found in T. gondii. Abbreviations:
ADP = adenosine di-phosphate; GAA = acid--glucosidase; GWD = glucan, water
dikinase; PWD = phosphoglucan, water dikinase; UDP = uridine di-phosphate.
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Figure 1.7 Glycolysis, gluconeogenesis, and the TCA cycle in T. gondii.
Reactions typically filled by glucose are depicted with blue arrows, and those filled
by glutamine are depicted with red arrows. Similarly, glycolytic enzymes are in blue
font, and glutaminolytic/gluconeogenic reactions are in red font. Abbreviations:
BCKDH = branched-chain ketoacid dehydrogenase; Fru-6-P = fructose-6phosphate; Fru-1,6-P2 = fructose 1,6-bisphosphate; Glc-6-P = glucose-6phosphate; PEPCK = phosphoenolpyruvate carboxykinase; PYK = pyruvate
kinase; TgFBP2 = fructose-1,6-bisphosphatase; TgGT1 = glucose transporter 1;
Tghk = hexokinase; TgPyC = pyruvate carboxylase.
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CHAPTER 2. MATERIALS AND METHODS
2.1 Biochemical, biophysical, and structural studies of TgLaforin and
TgGWD
2.1.1 Sequence alignments, secondary structure predictions, and
transcriptomics
The amino acid sequences of TgLaforin (TGME49_205290) and TgGWD
(TGME49_214260) were obtained using ToxoDB.org. The sequences of other
glucan phosphatases and glucan dikinases were obtained from UniProt (249).
Domain boundaries of proteins were defined using a combination of previously
published literature (250-254), the “Family and Domains” section in UniProt, and/or
the NCBI’s Conserved Domain Database (255). UniProt accession numbers and
amino acid numbering corresponding to each glucan phosphatase domain are
listed in Table 2.1. UniProt accession numbers of glucan, water dikinases and
domain boundaries are listed in Table 2.2. Amino acid sequences of the CBM
domains, DSP domains, and His-domains within each were aligned separately
from each other using ClustalW with default settings (Gonnet Matrix, Open Gap
Penalty: 10, Extend Gap Penalty: 0.2, Delay Divergent: 30%) and prepared using
MacVector 18. Secondary structure predictions of TgLaforin were obtained using
the Jpred 4 server (256) and compared to HsLaforin secondary structures (253).
Transcriptomics datasets were obtained from ToxoDB.org for TgLaforin,
TgGWD, and SRS9 (TGME49_320190). Log2(RMA) values were plotted in Prism
9 (GraphPad) along with their reported standard deviations.
2.1.2 AlphaFold2 modeling of TgLaforin
The three-dimensional models for TgLaforin were obtained by running
AlphaFold2 via the DeepMind official Colab server using AlphaFold v2.1.0
(https://colab.research.google.com/github/deepmind/alphafold/blob/main/noteboo
ks/AlphaFold.ipynb) (257,258). For the TgLaforin monomer structure prediction,
model confidence was assessed by the predicted Local Distance Difference Test
(pLDDT) score (258), whereas a weighed combination of predicted TM-score
(pTM) and interface pTM score (ipTM) was used to assess the reliability of the
TgLaforin dimer model (257). In both cases, top ranked models were used for
subsequent analysis. Structural models were analyzed, and figures were made
using PyMOL 2.2.3 (Schrodinger).
2.1.3 Cloning and expression of TgLaforin and TgGWD
Cloning: The cDNA sequences of TgLaforin (TGME49_205290) and TgGWD
(TGME49_214260) were obtained from ToxoDB.org. The sequences were then
codon optimized, synthesized, and cloned into pET28b+ using NdeI/XhoI digest

sites by GenScript. The catalytically inactive mutants [TgLaforin-FL C452S (C/S)
and the TgGWD-FL H1241A (H/A)] and all CBM constructs were also generated
by GenScript using site-directed mutagenesis. TgLaforin was further subcloned
into ppSUMO, a vector containing a small ubiquitin-like modifier (SUMO) that fused
TgLaforin-FL to an N-terminal His6-SUMO tag, and into pFastBac-HTA (Invitrogen)
using NdeI/XhoI restriction digest sites (New England Biolabs). All plasmids used
in this study are listed in Table 2.3.
For BL21 E. coli expression: 50 ng each plasmid was transformed into
chemically competent BL21 (DE3) E. coli cells (New England Biolabs). E. coli was
next plated on LB agar plates containing kanamycin and chloramphenicol, and
single colonies were selected for protein expression the next day. Colonies were
suspended in 7 mL LB containing kanamycin (50 g/mL) and chloramphenicol (25
g/mL) and rotated at 225 rpm for ~16 hr at 37 oC. Saturated cultures were then
directly added to 1 L 2xYT media each in a 4 L flask, rotated at 180 rpm at 37 oC,
and induced to produce protein with 400 M isopropyl -D-1-thiogalactopyranoside
(IPTG; GoldBio) when the OD600 of the culture reached 0.6. At the point of
induction, cells were placed on ice for 20 min to slow growth, and then shaken at
180 rpm overnight at 16 oC. Induced E. coli cells were then pelleted at 5,000g for
20 min at 4 oC and flash frozen with liquid nitrogen before storing at -20 oC.
For co-expression of TgLaforin with chaperone proteins: BL21 E. coli
containing TgLaforin in pET28b+ expression vector were subsequently transfected
with pG-KJE8 (Table 2.3, TaKaRa). dnaJ and grPE were expressed under an
arabinose-inducible promotor, and groES and groEL were expressed a
tetracycline-inducible promotor. Chaperone expression was induced with 0.5
mg/mL arabinose and 5 ng/mL tetracycline.
For refolding experiments: 6xHis-TgLaforin in pET28b+ was expressed in BL21
E. coli and purified from inclusion bodies as described in section 2.1.4.
For expression in Sf9 insect cells: The bacmid and baculovirus used in
TgLaforin expression were created using the manufacturer’s product specifications
(Invitrogen, MAN0000414) with several modifications. Briefly, the TgLaforin
bacmid was created by transforming pFastBac-HTA (Table 2.3) containing
TgLaforin into DH10Bac cells (Invitrogen) where transposition of TgLaforin into a
bacmid occurred over the course of 48 h on LB-agar (50 g/mL kanamycin, 7
g/mL gentamycin, 10 g/mL tetracycline). Successful transposition was selected
for by using blue/white colony screening, and only white colonies were chosen for
bacmid purification. The bacmid was then purified from a transformed colony after
overnight growth in SOC media using alkaline lysis followed by isopropanol
precipitation.
The baculovirus was subsequently produced by transfecting 2 g of purified
bacmid into 106 adherent Sf9 insect cells (Invitrogen) in a 6-well plate using
Cellfectin II reagent (Invitrogen), and the supernatant containing the initial
baculovirus was harvested 72 h later. Serial passage of the baculovirus through
insect cells in suspension was used to increase viral titer. This was done by
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repeatedly infecting Sf9 cells in log phase of growth (1.5-2.5x106 cells/mL) at a
ratio of 1:10 (viral stock to insect cell volume) and harvesting supernatant
containing baculovirus 72 h later. Final viral stock infection volume was optimized
by infecting insect cells in log phase at various concentrations (1:100-1:2000) and
measuring cell viability and morphology after 72 h using Trypan blue staining. Ideal
viral concentrations resulted in >80% living cells, the majority of which were
enlarged as determined on a hemacytometer. An effective infection ratio was
determined to be 1:1000 (v/v) of the P3 TgLaforin baculovirus into log-phase insect
cells. Protein production was then initiated using the optimized volume ratio of
viral stock to infect log-phase insect cells. After 72 h, insect cells were pelleted at
500g for 10 min at 4 oC, washed once with PBS to remove media, and then flash
frozen and stored at -20 oC until purification. Throughout study, insect cells were
cultured in ESF 921 protein-free media (Expression Systems) at 27 oC rotating at
135 rpm without antibiotics and maintained between 106 and 107 cells/mL.
2.1.4 Purification of TgLaforin and TgGWD protein constructs
To generate highly pure and active protein, several purification schemes were
tested throughout this study. Regardless of protein construct or expression system,
all protein constructs were first purified using immobilized metal affinity
chromatography (IMAC). To purify, cells (E. coli or Sf9) were resuspended in lysis
buffer (50 mM HEPES, 100 mM NaCl, 15 mM imidazole, 2 mM DTT, 0.1% TritonX100, pH 8.0). Cells were lysed by sonication, lysate was clarified by centrifugation
at 14,000g for 30 mins at 4 oC, and supernatant containing protein was harvested.
Protein was purified from the lysate using IMAC with Ni-agarose beads (Sigma).
Protein bound to beads was washed three times with purification buffer (lysis buffer
without TritonX-100) and eluted in elution buffer [purification buffer containing 300
mM imidazole (Sigma)].
For the further purification of His6-SUMO-TgLaforin construct from E. coli,
contamination with other E. coli protein following IMAC purification was a
significant issue. Moreover, the protein contaminants were of a similar molecular
weight (MW) to TgLaforin, so anion-exchange (AEX) chromatography was used
instead of size-exclusion chromatography (SEC). Briefly, protein was first bound
in purification buffer to a 5 mL HiTrap Q HP exchange column (Cytivia) fitted to an
ÄKTA pure fast protein liquid chromatography (FPLC) system and then washed
with two column-volumes of purification buffer. Protein was then eluted from the
AEX column by increasing ionic strength with a gradient of 100 to 500 mM NaCl
and then collected in 2 mL fractions. TgLaforin eluted at a concentration of 320
mM NaCl.
For the purification of TgLaforin-FL (WT and C452S) from insect cells, TgGWDFL (WT and H1241A) from insect cells, and all TgLaforin CBM constructs from E.
coli, protein was purified to >95% homogeneity via SEC using an ÄKTA pure FPLC
system fitted with a Superdex 200 16/200 column (GE Healthcare). IMAC elution
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buffer was exchanged on column with storage buffer (purification buffer containing
10% glycerol), and 2 mL fractions were collected at a rate of 0.5 mL/min.
In all cases, protein was analyzed for purity by SDS-PAGE with 10% MiniPROTEAN TGX stain-free precast gels (BioRad) imaged on a GelDoc. Only
fractions containing pure protein were combined and concentrated to 1-3 mg/mL
using Amicon centrifugal filters with an appropriate MW cutoff value (10 kDa for
CBM constructs and 30 kDa for TgLaforin-FL and TgGWD). Final protein
concentration was calculated using absorbance at 280 nm, the MW of each
protein, and the extinction coefficient of each protein (; calculated using Expasy
ProtParam online tool) on a Nanodrop (ThermoFisher). Protein was flash-frozen in
liquid nitrogen and stored at -80 oC.
For purification of His6-TgLaforin from inclusion bodies (IBs), cells were
resuspended in lysis buffer as described above, lysed by sonication, and IBs were
collected by centrifugation at 14,000g for 30 mins at 4 oC. Supernatant was
discarded, and IBs were washed 4x with 2M Urea containing 2% Triton X-100. IBs
were extracted in 6M guanidine containing 2% Triton X-100. IB extract was then
rapidly diluted by 20-fold resulting in a final concentration of 0.1 mg/mL as
described previously (259) in a 96 different buffer conditions contained in 96-well
deep well plate (Figure 2.1), and then allowed to refold for 36 h at 4 oC. Insoluble
material was then pelleted in the deep-well plate and supernatant containing
soluble protein was analyzed by SDS-PAGE and Coomassie blue staining. Wells
containing soluble protein were then further analyzed by differential scanning
fluorimetry (section 2.1.5).
2.1.5 Differential scanning fluorimetry
Thermal stability of refolded TgLaforin, Sf9-genrated TgLaforin and TgGWD,
and TgCBM constructs in the presence of oligosaccharides was determined as
previously described (260,261). Briefly, DSF was performed using a CFX96 RealTime PCR system (BioRad) with the FRET channel excitation and emission
wavelength set to 450-470 nm and 560-580 nm, respectively. Melting temperature
of each protein (2 M final concentration) was measured in 40 L volumes in DSF
buffer (50 mM HEPES, 100 mM NaCl, 2 mM DTT, pH 7.5) in the presence of 5X
SYPRO Orange (final concentration; Invitrogen). Thermal denaturation curves
were obtained by measuring fluorescence intensity in the FRET channel as the
temperature was increased from 20 to 95 oC at a rate of 1 oC/min. The melting
temperature (Tm) of each protein with and without carbohydrate was obtained by
calculating the first derivative of the fluorescence melt curve, fitting the derived
curve with a Gaussian peak using Prism 9, and determining the mean of the peak
which corresponded to the Tm (the inflection point of the original melt curve).
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2.1.6 Size-exclusion chromatography with multi-angle light scattering
SEC-MALS analysis was performed as previously described (262). Proteins
were run on an ÄKTA Pure system using a Superdex 75 Increase 100/300 column
(TgCBM) or a Superdex 200 10/300 column (full-length TgLaforin; GE Healthcare
Life Sciences), miniDAWN TREOS, and Optilab T-rEX (Wyatt Technologies, Santa
Barbara, CA) arranged in sequence with one another. The columns were first
equilibrated with the purification buffer used for each protein (described in section
2.1.4). Then, 500 L of 2 mg/mL protein was loaded and run at 0.5 mL/min, and
elution profiles were monitored using UV-Vis absorbance. Light scattering data
was analyzed on ASTRA software (Wyatt Technologies). The MW of each protein
was determined by analyzing peaks at half height using the refractive index to
determine accurate protein concentration. UV and MW data was exported and
plotted in Prism 9.
2.1.7 Hydrogen Deuterium Exchange Mass Spectrometry
HDX-MS experiments were performed using a Synapt G2-SX HDMS system
(Waters). For the partially deuterated samples, 3 μL of TgLaforin (1 mg/mL) was
diluted with 57 μL of labeling buffer (20 mM Tris, 100 mM NaCl, D2O, pH 7.4), the
deuteration reactions were incubated at 20 °C for 15 s, 150 s, 1500 s and 15000 s
in triplicate. To quench, 50 μL of reaction solution was mixed with 50 μL of cold
quench buffer (100 mM phosphate, H2O, pH 2.5) and incubated at 0 °C. 95 μL of
the quenched sample were then loaded onto an UPLC system for on-line pepsin
digestion (Waters Enzymate Beh Pepsin column, 2.1 mm x 30 mm) and MS data
acquisition. The nondeuterated samples were incubated with equilibration buffer
(20 mM Tris, 100 mM NaCl, H2O, pH 7.4). To measure the maximum hydrogendeuterium exchange rate, a fully deuterated sample was prepared by incubating
TgLaforin in D2O buffer (1% (v/v) formic acid) for 24 h at room temperature. All the
other steps were the same as the partially deuterated samples. HDX-MS was
performed using a robotic autosampler (LEAP), thus the experimental variations
were minimized. Back exchange was corrected as described previously (263,264).
Data were processed using ProteinLynx Global Server and DynamX (Waters).
2.1.8 pNPP phosphatase assays
Hydrolysis of pNPP to 4-nitrophenylphosphate (4NP) was performed in 50 L
reactions containing phosphatase buffer (0.1 M sodium acetate, 0.05 M bis-Tris,
0.05 M Tris-HCl, and 2 mM DTT at pH 5.5) at 37 oC. pNPP concentration was
equivalent to the Km value determined for each phosphatase under these reaction
conditions containing 50 nM enzyme (unless otherwise indicated). Reactions were
terminated by the addition of 200 μL of 0.25 N NaOH at indicated timepoints, and
the production of 4NP was determined by measuring the absorbance at 410 nm
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using a Synergy HTX Multi-Mode Reader (BioTek). Absorbance was converted to
nmol phosphate released (1:1-phosphate:4NP ratio) using a 4NP standard curve.
Vmax and Km were calculated by varying pNPP concentrations and measuring
absorbance in the linear range of enzyme activity. K m values are as follows for
each enzyme: TgLaforin=0.71 mM, PTP1B=0.990 mM, VHR=2.53 mM, calf
intestinal phosphatase=53.75 M. Parameters were calculated using the
Michaelis-Menten nonlinear curve-fitting function in Prism 9 software. The optimal
pH (5.5) for TgLaforin was selected by testing reaction pH from 5.0-9.0 and
determining the specific activity at each pH.
2.1.9 Malachite green phosphatase assays
Release of phosphate from potato amylopectin was determined as done
previously (204,247,260,265) with the following modifications. Briefly, phosphate
release was monitored using the PiColorLockTM Phosphate Detection Reagent
(Novus Biologicals), a malachite green based assay. Recombinant TgLaforin (50
nM) was incubated with 1.125 mg/mL solubilized potato amylopectin (Sigma) in
phosphatase buffer (pH 6.5) in a final volume of 80 L at 37oC. Potato amylopectin
was supplied as a powder from the manufacturer and solubilized to make a stock
concentration of 5 mg/mL using the alcohol/alkaline method (also referred to as
the “Roach method” in Ref. (265)). Reactions were terminated by the addition of
20 μL (0.25 initial reaction volume) Gold Mix (PiColorLock Gold solution mixed with
Accelerator in a 100:1 ratio). After 5-min incubation at room temperature, 8 μL
stabilizer solution (0.1 initial reaction volume) was added and reaction was allowed
to develop for 30 mins at room temperature before the absorbance of each reaction
was measured at 635 nm using a Synergy HTX Multi-Mode Reader (BioTek).
Absorbance was converted to Pi released using a Pi absorbance standard curve.
2.1.10 Radiolabeled Starch Phosphatase Assay
Position-dependent phosphate release from 33P-labeled starch was performed
as previously described (251,252,260,261). The substrate for this assay was
generated by phosphorylating phosphate-free Arabidopsis sex1-3 starch with 33P
labeled ATP (Hartmann Analytic, Braunschweig) at the C6 and C3 positions
sequentially. The starch granules were phosphorylated at the C6 position using
purified recombinant StGWD enzyme. The granules were next phosphorylated at
the C3 position using purified recombinant AtPWD enzyme.
To determine the site-specificity of TgLaforin, 42 nM enzyme was incubated
separately with 0.6 mg both C6- and C3-33P-labeled starch in phosphatase buffer
(pH 6.5) containing 1 mg/mL bovine serum albumin (BSA) in a final volume of 150
L. Dephosphorylation was allowed to proceed for 15 mins with shaking at room
temperature. The reaction was terminated with 50 L 10% SDS (2.5% final), and
starch was pelleted by centrifugation at maximum speed for 5 min. Supernatant
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was then transferred to 3 mL scintillation fluid. The amount of phosphate released
from each starch suspension was quantified by measuring counts per minute
(CPM) of the supernatant on a 1900 TR liquid scintillation counter (Packard). CPM
measurements were then converted to % phosphate release by dividing CPM in
the supernatant (released phosphate) by initial CPM on starch (bound phosphate).
2.1.11 Inhibitor Assays
L319-M21-M49 stock solutions were prepared by resuspending the inhibitor in
DMSO at a concentration of 20 mM. Various concentrations of inhibitor were
prepared by serial dilution in DMSO such that stock concentrations were 50X the
working concentration, and the final concentration of DMSO in each assay was 2%
(v/v). The efficacy of L319-M21-M49 against various phosphatases was
determined using the assay conditions described above. Enzymes were preincubated with L319-M21-M49 for 5 min on ice before initiating the assay with the
addition of substrate. All inhibitor assays were performed within the linear
time/concentration range of phosphatase activity.
2.1.12 In vitro radiolabel phosphorylation assay
TgGWD-WT and TgGWD-H/A (5 pmol each) were incubated in freshly
prepared 3X phosphorylation buffer [10X phosphorylation buffer (500 mM HEPESKOH, pH 7.5, 10 mM EDTA, 60 mM MgCl2, and 0.5% TritonX-100), 5 mM ATP,
0.1 M DTT, and 10 mg/mL BSA] with A. thaliana sex1-3 phosphate free starch
(final concentration of 5 mg/mL), 0.25 mCi -P33-ATP or -P33-ATP (Hartmann
Analytic)—in a final volume that adjusted the 3X buffer to 1X. Starch was prepared
by first washing it twice in 1 mL 0.05% TritonX-100, once in water, and then
resuspending it in water at a concentration of 20 mg/mL before adding it to the
reaction. Reactions were agitated slowly by vortexing for the time indicated at room
temperature. 10% SDS was added to terminate the reaction, with a final
concentration of 2%. Starch was then pelleted at 5000g for 5 mins, the supernatant
was removed, and starch was washed 5-7x with wash buffer (2% SDS, 2 mM ATP)
until radiolabel counts were reduced to a low, unchanging level (60-90 CPM).
Radiolabeled starch was then resuspended in a final volume of 100 L H20, and
50 L was then measured (corresponding to 0.25 mg starch) in 3 mL scintillation
fluid. The CPM of the starch was then determined on a Packard 1900 TR
scintillation analyzer. Background of the reaction was determined with a noenzyme control.
2.1.13 Water dikinase autophosphorylation assay
TgGWD-WT and TgGWD-H/A were incubated with both -P33-ATP and -P33ATP as has been described previously (266) with the following modifications. In
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this reaction, 5 g enzyme was incubated with 2.2 Ci radiolabeled ATP (either or -P33) in 2X autophosphorylation buffer (50 mM HEPES-KOH, pH 7.5, 1 mM
EDTA, 6 mM MgCl2, 10% glycerol) at a final concentration of 1X. Reaction was
terminated after 30 min at room temperature with 4X Laemmli sample buffer and
incubated for 20 mins at 30 oC. Samples were then separated from radioactive
ATP by SDS-PAGE on 10% Mini-PROTEAN TGX stain-free precast gels (BioRad)
and total protein was imaged on a GelDoc (BioRad). Radioactive
(autophosphorylated) protein was then visualized by exposing gel to a phosphor
screen (GE Healthcare) for 4 h before imaging it on a Typhoon FLA 9500 Imager.
For all imaging steps, radioactive gel was wrapped in Saran wrap so as not to
contaminate lab equipment with radioactive material.
2.1.14 Glucan, water dikinase site specificity assay
TgGWD-WT and TgGWD-H/A (5 pmol) were separately incubated in freshly
prepared 3X phosphorylation buffer (section 2.1.12) with A. thaliana sex1-3
phosphate free starch (final concentration of 5 mg/mL) and -P33-ATP (final
concentration of 5 Ci/L) for 6 h and then spiked with an additional 5 pmol protein
before incubating overnight. The sequential addition of protein and long incubation
time ensured a high level of radiolabel incorporation into starch for downstream
analysis. To terminate the reaction, 10% SDS was added to a final concentration
of 2%. Radiolabeled starch was pelleted by centrifugation at 5000g, supernatant
removed, and starch was washed with wash buffer (2% SDS, 2mM ATP) until
radioactivity of supernatant dropped below 100 CPM (5-7 washes). This extensive
washing ensures a low background. Total CPM on starch was then determined by
adding 0.2 mg of labeled starch to 3 mL scintillation fluid and determining total
CPM/mg starch.
TgGWD-labeled starch (WT or H/A) was then treated with glucan
phosphatases with known site specificities to determine the position on which
TgGWD phosphorylated the glucose within the phosphate free starch (Figure
4.3b). The glucan phosphatases used in this experiment were either AtSEX4
(C6:C3 specificity=2:1), LSF2 (entirely C3 specific), or their catalytically inactive
counterparts as controls (SEX4- and LSF2-C/S). Because SEX4 has the capability
of removing phosphate from both C6 and C3 positions, each aliquot of radiolabeled
starch was treated with both glucan phosphatases in sequence to ensure
specificity was accurately determined (e.g., starch was treated with LSF and then
SEX4, and vice versa). Catalytically inactive C/S controls were used to determine
background radioactivity levels. Labeled starch (0.6 mg/reaction; 4 mg/mL final
concentration) was incubated in 5X phosphatase buffer (0.5 M sodium acetate,
0.25 M bis-Tris, 0.25 M Tris HCl, pH 6.5), 2mM DTT, 1 mg/mL BSA, and 0.0025%
TritonX-100 (v/v) with a glucan phosphatase (7.5 ng/mL final) at a final
concentration that diluted the 5X buffer to 1X. Reactions were constantly and
slowly agitated by vortexing for 15 mins at room temperature, reactions were
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terminated with 10% SDS (2.5% final concentration), and centrifuged at maximum
speed for 5 mins. Three-quarters (150 L) of supernatant was removed and added
to 3 mL scintillation fluid before CPM was determined on a Packard 1900 TR
scintillation analyzer. Specificity was determined by calculating % phosphate
removed by comparing CPM in supernatant to total CPM on starch.
2.1.15 CE-based AMP release assay
CE-based detection of AMP is pictured in Figure 4.5a, and based on a
previously developed protocol for whole capillary stacking (267). Briefly, starch
was phosphorylated in the presence of TgGWD as described in section 2.1.14. for
the times indicated and terminated by the addition of 10% SDS to a final
concentration of 2%. Starch was pelleted at 14000g for 5 mins at room
temperature, and supernatant containing reaction mixture, including AMP, was a
used for further analysis. Protein was then filtered from reaction mixture using
centrifugal filtration with unit containing a filter with a 30 kDa molecular-weight-cutoff (Amicon Ultra, Millipore). Filtrate was then analyzed on an Agilent 7100 CE
system equipped with a UV detector fitted with a fused silica capillary. Capillary
was first preconditioned with 50 mM carbonate (pH 9.6) before sample injection.
Sample was injected via vacuum for 10 mins at 1 Pa to completely fill capillary.
Sample stacking then proceeded by applying a voltage of -18 kV for 15 mins. The
nucleotides in the sample were then separated at a voltage of +18 kV for 22 mins
and absorbance at 256 nm was monitored with a UV-Vis detector. Capillary was
extensively washed with carbonate buffer between runs. Data was exported,
plotted, and analyzed in Prism 9.
2.1.16 TgLaforin yeast two-hybrid screen
Yeast two-hybrid screening for putative in vitro TgLaforin interacting partners
was conducted by Hybrigenics Services (www.hybrigenics-services.com; Paris,
France) using their patented ULTImate-Y2H Screen. Briefly, codon-optimized
TgLaforin cDNA used in insect-cell expression (section 2.1.3) was fused to an Nterminal LexA or N-terminal Gal4 DNA binding domains to generate the TgLaforinbait construct. TgLaforin bait was screened against a library of T. gondii (TGRH)
prey encoded by 800-1000 bp inserts (average size of a protein domain) fused to
activator domains. Prey fragments from positive interactions were amplified by
PCR and sequenced to identify the proteins in the GenBank database. Confidence,
a protein biological score (PBS) ranging from A to E, was assigned to each
interaction and presented in Table 6.1.
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2.2 Generation of T. gondii mutants and in vitro characterization of TgLaf
parasites
2.2.1 Fibroblast and parasite culture and maintenance
All parasite lines were maintained in human foreskin fibroblasts (HFFs; ATCC)
in Minimal Essential Media- (MEM-; Gibco) supplemented with 7% heatinactivated fetal bovine serum (Gemini Bio), 100 U/mL penicillin, 100-g/mL
streptomycin, and an additional 2 mM L-glutamine (Gibco; 4 mM total L-glutamine
in media). Cells and parasites were incubated at 37 oC and 5% CO2 in a humidified
incubator. Genetically modified parasites were maintained in MEM- containing
7% dialyzed FBS (Gemini Bio) and either pyrimethamine (1 M), mycophenolic
acid/xanthine (MPA: 25 g/mL, xanthine: 50 g/mL), or 6-thioxanthine (80 g/mL).
Assays analyzing the effects of glutamine deprivation used DMEM. Both
glutamine replete (Gibco, 11966025) and depleted (Gibco, 11054020) DMEM
were supplemented with 7% dialyzed FBS. Glutamine replete media from the
supplier also lacked other key nutrients and was further modified to contain 5 mM
glucose, 1 mM sodium pyruvate, and 4 mM L-glutamine.
2.2.2 Generation of T. gondii mutant lines
Type II ME49HXGPRT (“WT”—the parental line utilized to generate all other
lines in this study, depicted in Figure 5.1): To disrupt the hypoxanthine-xanthineguanine phosphoribosyl transferase (HXGPRT) gene in T. gondii Type II ME49
parasites, a shotgun CRISPR-Cas9 strategy was employed in which multiple
sgRNA constructs were transfected into T. gondii to disrupt the gene with several
Cas9 cut sites (known as protospacer-adjacent motifs; PAMs). A single plasmid
containing both Cas9-GFP and an interchangeable sgRNA scaffold was used for
this purpose (pSAG1::CAS9-U6::sgUPRT; Table 2.3) (268). Three previously
identified sgRNAs (10) targeting three separate exons (2,3, and 5) in the HXGPRT
gene were chosen, and used to replace the sgRNA sequence in the CRISPRplasmid to make three separate plasmids (Table 2.4) using a Q5 site-directed
mutagenesis kit (New England BioLabs). Mutagenesis primers were designed
using NEBaseChanger (Table 2.5). The three modified sgRNA/Cas9-GPF
plasmids (8 g each) were transfected into 1.4x107 T. gondii parasites by
electroporation with a time constant between 0.16 and 0.20 msec (BioRad Gene
Pulser II). HFFs were then infected with electroporated parasites to allow the
parasites to recover. After 24 h, surviving parasites were syringe-passaged from
infected HFFs with a 27G needle to lyse host cells, and gravity filtered through a
10 m filter to remove host-cell debris. Successful transformants were then
enriched by use of fluorescence activated cell-sorting (FACS; Sony SY3200,
installed in a biosafety level II cabinet) to select parasites expressing Cas9-GFP
from the transfected plasmid by isolating GFP+ parasites only. HFFs were infected
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with GFP+ parasites, and then placed in 6-thioxanthine media 24 h later to select
for HXGPRT mutants. After 10 days of culturing parasites in 6-thioxanthine (about
3 passages), the parasites were cloned by limiting dilution into a 96-well plate
containing confluent HFFs. Wells containing single plaques were picked 7 days
later and further expanded. Genomic DNA was extracted using a Proteinase K
treatment detailed elsewhere (9), and the HXGPRT locus was sequenced to verify
a successful knockout.
TgLaforin-3xHA-HXGPRT (depicted in Figure 5.3): TgLaforin was epitope
tagged at the C-terminus utilizing a CRISPR-Cas9 strategy by disrupting the
TgLaforin 3’UTR immediately downstream of the endogenous stop codon. This
approach promoted homologous recombination (HR) with a co-transfected
TgLaforin-HA construct as has been done previously (269). Briefly, the sgRNA
adjacent to a PAM sequence immediately downstream of the TgLaforin stop codon
was designed using the EuPaGDT design tool (http://grna.ctegd.uga.edu). The top
hit for this region was selected and used to replace the sgRNA scaffold in
pSAG1::CAS9-U6::sgUPRT as was done above (Tables 2.4 and 2.5). The
TgLaforin-HA tagging construct was generated by amplifying the 3’ end of the
TgLaforin-HA construct generated for complementation (see generation of COMP
line below and Table 2.3) along with the connected HXGPRT selectable marker.
Both the PCR-amplicon and the CRISPR-Cas-GFP plasmid containing the sgRNA
toward TgLaforin were transfected into 1.4x10 7 T. gondii ME49HXGPRT
parasites (2:1 insert:plasmid molar ratio; 30 g DNA total) as was done above.
After 24-hours, parasites were then isolated, sorted by FACs, and GFP+ parasites
were again allowed to infect HFFs and grow for 24 h before drug selection with
media containing MPA/xanthine. After 10 days of culturing parasites in
MPA/xanthine (about 3 passages), the parasites were cloned by limiting dilution
into a 96-well plate. Wells containing single plaques were picked 7 days later and
expanded. Successful tagging of TgLaforin was verified using sequencing,
immunoblot, and immunofluorescence.
ME49HXTgLaforin (“TgLaf”; depicted in Figure 5.5): The TgLaforin ORF
was disrupted using a CRISPR-Cas9 mediated strategy as detailed above, with
several differences. Briefly, a single sgRNA was designed to target the first exon
of TgLaforin with the top hit from EuPaGDT (Table 2.4). To disrupt TgLaforin with
a selectable drug marker, a pyrimethamine-resistant mutant of the dihydrofolate
reductase (DHFR*) gene containing a 5’-NcGra7 promotor and DHFR 3’UTR was
amplified from pJET-NcGra7_DHFR (Table 2.3). Amplification utilized primers
containing 40 nt extensions homologous to the 5’- and 3’-UTR of TgLaforin to
encourage HR-mediated whole-gene replacement with the drug cassette (Table
2.5). Both the PCR-amplified DHFR* homology cassette and the CRISPR-CasGFP plasmid were transfected and FACS-sorted as described above. GFP+
parasites underwent drug selection in pyrimethamine. Parasites were then cloned
and expanded as detailed above. Successful integration of the DHFR* cassette
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into the TgLaforin locus was verified using PCR with inside/out primer pairs to the
chimeric, interrupted gene (Table 2.5).
ME49HXTgLaforin+ChrVI-TgLaforin (“COMP”, depicted in Figure 5.8):
Complementation of TgLaforin was also executed using a CRISPR-mediated
strategy. A sgRNA to a neutral locus on Chromosome VI identified previously (270)
was generated using the same mutagenesis strategy as above. A full length
TgLaforin cDNA containing its endogenous 5’UTR (2000 bp upstream from gDNA)
was synthesized by GenScript and inserted into the pHA3x-LIC vector (Table 2.3)
containing a C-terminal HA tag and a DHFR 3’UTR, linked to the HXGPRT
selectable marker (named “TgLaforin-HA3x-LIC”; also used above for endogenous
tagging to create TgLaforin-HA line). The entire construct (5’UTR:TgLaforincDNA:DHFR-3’UTR:HXGPRT) was amplified from the vector and co-transfected
into TgLaf parasites with the CRISPR-Cas9 plasmid as done above. Successful
transformants that received the HXGPRT marker were selected with
MPA/xanthine. Successful insertion of TgLaforin along with its promoter was
verified using PCR, by immunoblot analysis, and immunofluorescence with an antiHA antibody (Abcam).
2.2.3 Western blotting
Parasites were syringe lysed from host cells, pelleted, and 2x10 6 parasites
were resuspended in SDS-PAGE sample buffer and boiled before being run on a
single lane of a 10% polyacrylamide gel for 30 mins at 225 V. Lysate was then
transferred from gel to 0.2 m PVDF membrane (BioRad) using a Turbotransfer
System (BioRad) for 7 min at 25 V. The PVDF membrane was then blocked in
either 5% (w/v) non-fat milk (for HRP-conjugated secondary antibodies) or 3%
(w/v) BSA (for fluorophore conjugated antibodies) in PBS for 20 mins before being
probed with a primary antibody in either non-fat milk or BSA overnight at 4 oC (Cell
Signaling C29F4). Blot was then washed 3x with TBST (0.1% Tween-20, 5
min/wash) before probing with one of the following secondary antibodies for 45
min at room temperature: HRP-conjugated -rabbit/mouse-IgG (Jackson
Laboratories), DyLight488 (-mouse) or DyLight680 (-rabbit). Blot was washed
3x in TBST once more, and then developed for 5 min using SuperSignalTM West
Pico PLUS (Thermo Scientific) for HRP-conjugated antibodies and visualized on a
GelDoc station (BioRad).
2.2.4 Immunofluorescence (IF)/histology staining
HFFs were grown on coverslips in a 24-well plate until confluent and
subsequently infected with 104 parasites/well. At the indicated time post-infection,
the infected HFFs were fixed with either methanol (MeOH) (100%, -20oC) or
methanol-free paraformaldehyde (PFA) (4% in PBS; Electron Microscopy
Sciences) as indicated for each antibody. Infected HFFs fixed with PFA were
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permeabilized in 0.1% TritonX-100 in PBS++ (PBS containing 0.5 mM CaCl2 and
0.5 mM MgCl2) for 10 mins at RT. Primary and secondary antibodies were diluted
in 3% (w/v) bovine serum albumin (BSA; Fisher) in PBS++. Samples were first
incubated with the primary antibody at RT for 45 mins, washed 3x with PBS++,
and then incubated with fluorescent secondary antibodies (1:2,000) and DAPI (300
nM final) for 45 mins. Secondary antibodies (Invitrogen) were conjugated to either
Oregon Green or Texas Red fluorophores and specific to the species and class of
primary antibody used. Samples were then washed 3x with PBS++ before
mounting the coverslip on a glass slide using MOWIOL mounting media.
IF staining was visualized using a Zeiss AxioVision upright microscope with a
100X 1.4 numerical-aperture oil immersion objective, and images were acquired
using a grayscale Zeiss AxioCam MRM digital camera. Grayscale images were
pseudo-colored in ImageJ using magenta (red fluorophore), yellow (green
fluorophore), and cyan (DAPI), and further alterations to brightness and contrast
were also made in ImageJ when deemed appropriate. For all assays in which
staining intensity was compared across treatments and parasite lines,
concentrations of antibodies, exposure times, and alterations to
brightness/contrast were standardized.
Colocalization of fluorescent antibodies/reagents was quantified using
Pearson’s coefficient calculated with the JACoP plugin on ImageJ (271).
2.2.5 Periodic acid-Schiff staining
Periodic acid-Schiff (PAS) staining was done on coverslips with infected HFFs
fixed in 4% PFA. After removing PFA, samples were permeabilized as above.
Coverslips were then washed 3x in tap water before the addition of 1% periodic
acid (Sigma-Aldrich) for 5 mins. Coverslips were then washed 3x in tap water, and
Schiff’s reagent (diluted 1:4 in tap water) was added for 15 mins. Coverslips were
subsequently washed 10x with tap water to develop stain before being incubated
with DAPI in tap water for 10 mins. Stained coverslips were then mounted as
above. All reagents were utilized at room temperature during PAS staining. PAS
stained samples were visualized using fluorescent microscopy (excitation: 545 nm,
emission: 605 nm). When PAS was costained with antibodies, primary antibodies
were incubated with PAS stained slides overnight in BSA at 4 oC before standard
secondary staining. Specificity of IF staining in the presence of PAS was verified
using secondary-only controls.
Samples treated with amyloglucosidase (GAA) (from Aspergillus niger, >260
U/mL, Sigma) were incubated with GAA after permeabilization. GAA was diluted
1:50 in 50 mM sodium phthalate buffer, pH 5.5 and samples were treated for 24 h
at room temperature. Untreated controls were incubated in phthalate buffer without
GAA. Samples were then stained with PAS or mAb IV58B6 as described above or
in section 2.2.4.
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2.2.6 In vitro bradyzoite conversion assay
Tachyzoites were converted to bradyzoites in vitro using alkaline stress as has
been done previously with several modifications (Figure 2.2a) (272). HFFs grown
on coverslips were infected with tachyzoites in standard cell culture media. 4 h
later, media was replaced with RPMI 1640 (Gibco 31800022) supplemented with
50 mM HEPES, no sodium bicarbonate, and adjusted to pH 8.2 with NaOH.
Parasites were then cultured for 2-6 days at 37 oC, ambient CO2, and wrapped in
Parafilm. Media was replaced every other day to maintain the basic pH. Parasites
were fixed in PFA and stained with either fluorescein conjugated Dolichos biflorus
agglutinin (DBA; 1:1000, Vector Laboratories) and PAS. Images were obtained in
grayscale on a Zeiss AxioVision upright microscope as described above using
identical exposure times across sample sets.
To determine the degree of labeling with DBA or PAS, the Fiji distribution of
ImageJ (273) was used to create a binary mask outlining cysts that was applied to
the original DBA/PAS-stained image to measure the greyscale intensity of each
ROI (i.e. each individual cyst) (Figure 2.2b). The mask was created with DBA
staining by adjusting the threshold of each image to include all cysts, creating a
binary image that outlined each cyst, and then applying the watershed algorithm
to separate cysts in contact with one another.
2.2.7 Transmission electron microscopy of in vitro tachyzoites and bradyzoites
Transmission-electron microscopy (TEM) was performed as done previously
(26). Briefly, HFFs in 10-cm cell culture dishes were infected and harvested at the
timepoint indicated or converted to bradyzoites for 6 days as described above. To
harvest, media was removed, and cells were washed with PBS twice and then
fixed in the 10 cm dish with 3% glutaraldehyde (GA) (Electron Microscopy
Sciences) in 100 mM sodium cacodylate, pH 7.4, for 1 h at room temperature. After
1 h, fixative was removed and replaced with 1 mL 1% BSA in 100 mM sodium
cacodylate. Cells were then scraped from surface of plate, collected into the BSA,
transferred to 1.5-mL Eppendorf tubes, and then centrifuged at 1000g to pellet.
Supernatant was carefully removed, and the pellet was transferred to a 10 cm Petri
dish using a wooden spoon. A razor blade was used to chop the pellet into blocks
that were each <1mm3, and blocks were transferred into GA/cacodylate fixative
overnight at 4 oC.
The remaining steps were executed in the University of Kentucky’s Imaging
Center in the College of Arts and Sciences. Blocks were washed with 100 mM
sodium cacodylate buffer 3x before post-fixation in 2% osmium tetroxide for 1 h on
ice. Blocks were then washed in water 3x before being washed 3x in 50 mM
sodium maleate (pH 5.2). Next, blocks were stained in 1% uranyl acetate in
maleate buffer for 1 h at RT, washed again in water 3x, and then dehydrated in a
series of washes with increasing ethanol concentrations (70%, 95%, 100%). Pellet
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was next washed twice with propylene oxide, left in propylene oxide for 20 mins,
then incubated in a 1:1 mixture of Epon and propylene oxide overnight. Tubes were
left open for 2 h before Epon was removed, replaced with fresh Epon, and rotated
4 h on mixing wheel. Finally, blocks were transferred to fresh Epon in molds and
left at 60 oC overnight before trimming and thin sectioning on an ultramicrotome
with a diamond knife. Sections were placed on copper grids and then contrast
stained with lead citrate. Micrographs were collected at the University of
Kentucky’s Electron Microscopy Center on a Talos F200X TEM (Thermo) operated
at 200 kV accelerating voltage with a 50 m objective aperture inserted to enhance
contrast using a 16M pixel 4k x 4k CMOS camera (Ceta, Thermo Scientific).
2.2.8 Plaque assays
HFFs were grown in 12-well plates until confluent. HFFs were subsequently
infected with 200 parasites/well in the media indicated. Any indicated media
changes were done 4 h post-infection to allow for invasion, and residual invasion
media was washed away with two changes of PBS. Plates remained undisturbed
for 7-10 days before the infected HFFs were fixed with 100% MeOH for 20 mins,
stained with 1% crystal violet solution for 20 mins, and then the plaques were destained with repeated washes with tap water. Thus, zones of lysis (white clearings)
could be visualized against intact cells (purple). Images of plaques were obtained
by scanning plates on an Epson Perfection V600 photo scanner at a resolution of
600 dpi. The plaques were measured by pixel area using ImageJ and presented
in arbitrary units.
2.2.9 Ionophore and zaprinast-mediated egress assays
HFFs were grown to confluency in 35 mm glass bottom dishes (MatTek, P35G0-14-C). Two days before infecting HFFs on glass bottom dishes, both HFFs and
parasites were independently pre-treated in either glutamine-replete or -depleted
media (see above for media formulations). After 48 h pre-treatment, 105 parasites
of each line (WT, TgLaf, and COMP) in each condition (gln+/-) were added to 3
dishes each and allowed to grow for 48 h so that most vacuoles contained >32
parasites each. Several hours before egress, media in each infected plate was
adjusted to 1.5 mL and allowed to equilibrate at 37 oC in 5% CO2. The calcium
ionophore A23187 (Cayman Chemical Company) was prepared as a 2 mM stock
in DMSO and diluted in (+/-) gln media to make a 4X concentration of 12 M and
maintained at 37 oC throughout the assay. Zaprinast was likewise prepared as a
100 mM stock in DMSO, and diluted into media at a 4X concentration of 2 mM.
Egress was triggered by the addition of 0.5 mL 4X A23187 to infected HFFs (3.0
M final concentration) or 0.5 mL 4X-zaprinast (500 M final concentration).
Egress was monitored on a Nikon Eclipse Ti2 inverted microscope with a 40X
phase air objective modified with a 1.5X optivar. Five fields containing vacuoles
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were selected from each plate, and an image was obtained 10 s after triggering
egress from each field once every 5 s for 5 mins (61 images/field) on a Nikon DSRi2 color camera. Videos of each field were assembled on NIS Elements software.
Egress was monitored using standard deviation of pixel intensity (Figure 2.3a) and
determined by inflection point of change in standard deviation of pixel intensity
(Figure 2.3b-c). Inflection point was calculated by fitting a gaussian curve to the
first derivative of the standard deviation in pixel intensity and calculating the mean
of the curve. Technical replicates (fields on each plate) were averaged for each
biological replicate (average of fields from each plate). Data analysis, preparation,
and statistics were performed using GraphPad Prism 9.
2.2.10 Replication assay
HFFs were grown on untreated glass coverslips in a 24-well plate until
confluent. Two days before infecting HFFs on coverslips, both HFFs and parasites
were independently pre-treated in either glutamine-replete or -depleted media.
After pre-treatment, 104 parasites of each line (WT, TgLaf, and COMP) in each
condition (gln+/-) were added to 3 coverslips each. 24 hours later, infected HFFs
were fixed in MeOH and stained with Rb--SAG1 (1:10,000) and DAPI for ease of
visualization as detailed in section 2.2.4. Counting of parasites/vacuole was
performed blindly for each line/condition such that identifying information was
removed before counting was not revealed until the completion of counting.
2.2.11 Metabolomics
Confluent HFFs were infected with parasites at an MOI of 2 to achieve a high
density of parasites after 48-hours of growth (>80% cells containing >32 parasites
each). Plates containing infected HFFs were placed on ice, media removed, and
monolayer was wash 2X with ice-cold PBS. Cells were scraped from plate surface,
resuspended in PBS (8 plates cell-equivalents per 50 mL PBS), and centrifuged at
1000g for 10 mins at 4 oC. PBS was removed, cell pellet was resuspended in 2 mL
PBS, and syringe passaged successively in 23 G and 27 G needles and then host
cell lysate was removed by centrifuging filtering by centrifugation. The pellet was
resuspended in 5 mL PBS and host-cell debris was removed by syringe-filtering
suspension through a 5 m filter (Whatman). Filtered parasites were then pelleted,
resuspended in 1 mL PBS, and counted on a hemacytometer. Parasites were
pelleted a final time at 14,000g for 30 s at 4 oC, supernatant was removed, and
pelleted parasites were flash frozen in liquid nitrogen and stored at -80 oC until
metabolite extraction.
Polar metabolite extraction: Polar metabolites were extracted in 0.5 mL -20 oC
50% methanol (MeOH) containing 20 M L-norvaline (procedural control) for 30
mins on ice. During the 30 min incubation, samples were regularly vortexed.
Samples were then centrifuged at 14000g for 10 mins to pellet insoluble material
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(protein, DNA, RNA, and glycans). Supernatant containing polar metabolites and
pellet were dried separately on a SpeedVac (Thermo) at 10 -3 mBar until MeOH
was completely sublimated and only dried pellet remained.
Pellet hydrolysis and extraction: Dried fraction containing protein was
hydrolyzed by resuspending the pellet in 2 N HCl (final concentration) at 95 oC for
2 h. Hydrolysis was quenched, and hydrolyzed amino acids were extracted by the
addition of an equal volume of 100% MeOH with 40 M L-norvaline such that the
final concentration was 50% and 20 M, respectively. Extraction and drying then
proceeded as described above.
Sample derivatization: Dried samples (both polar and hydrolyzed protein) were
derivatized in 70 L 20 mg/mL methoxyamine hydrochloride in pyridine for 90 mins
at 30 oC. Samples were then centrifuged at 14000g for 10 mins to remove any
particulate, and 50 L of the methoxyamine superantent was mixed with 80 L Nmethyl-N-trimethylsilyl trifluoroacetamide (MSTFA) and incubated for 30 mins at
37 oC. Samples were then transferred to amber glass chromatography vials and
analyzed by GCMS.
GCMS analysis: Metabolites were analyzed on an Agilent 7800B GC coupled
to a 5977B MS detector. GCMS protocol was identical to one described previously
(274). Automated Mass Spectral Deconvolution and Identification System (AMDIS)
was used to analyze metabolites by matching metabolites to the FiehnLib
metabolomics library via retention time and fragmentation pattern. Quantification
of metabolite levels was performed in Mnova. Sample abundance was normalized
to L-norvaline (procedural control) and protein from protein pellet (experimental
control).
2.3 Establishing the role of TgLaforin in the acute and chronic infection of
mice
2.3.1 Mouse infection with T. gondii
4 to 6 week old male and female CBA/J mice from Jackson Laboratories (Bar
Harbor, ME) were injected intraperitoneally (IP) with either 100 ME49 tachyzoites
(parasite lines generated in section 2.2) or 20 tissue-cysts from brain homogenate
from previously infected mice. In either case, parasites were suspended in 0.2 mL
serum-free, Opti-MEM media (Gibco). Mice were then monitored and assigned a
body index score once or twice a day throughout the course of infection (Table
2.6). When symptomatic, mice were administered gel diet and wet chow on the
cage floor and given 0.25-0.5 mL saline solution subcutaneously if dehydrated.
Moribund mice were immediately euthanized. Euthanasia of both moribund mice
and mice sacrificed at the time of tissue cyst harvest was performed by CO2
asphyxiation, followed by cervical dislocation. All protocols were carried out under
the approval of the University of Kentucky’s Institutional Animal Care and Use
Committee (IACUC).
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2.3.2 Tissue cyst purification
Tissue cysts were purified as done previously (55,275). Briefly, mice were
dissected immediately following euthanasia and brains were harvested. Brains
were then homogenized in pairs in ice-cold PBS containing 0.3% Tween-80 (final
concentration) using a mortar and pestle, and then homogenate was sequentially
passaged through needles ranging from 16 G to 23 G. Homogenate was layered
onto a discontinuous Percoll gradient (Sigma) (90%:9-mL / 40%:4.5mL /
20%:4.5mL) in a 50 mL conical tube. Homogenate was then centrifuged at 2200
rpm for 18 min at 4 oC on a Beckman Allegra tabletop centrifuge with a swinging
bucket rotor using the high brake setting. Cysts were collected in 1 mL fractions
from the bottom of the centrifuged Percoll gradient using a peristaltic pump
adjusted to a flow rate of 2 mL/min. To count cysts, 10-20 L of each fraction was
placed into 100 L PBS in the well of a 96-well plate. The 96-well plate was
centrifuged at 1000g for 5 min at 4 oC. Cysts were then counted in each well using
an inverted microscope at 20x magnification (Nikon), and the number of cysts in
each well was used to determine the total number of cysts in each fraction. Total
cysts per mouse were calculated by summing the total number of cysts in each
fraction and dividing the total by two to adjust for brain homogenization in pairs.
Each pair of mice was presented as a single averaged data point.
To fix tissue cysts onto microscope slides for further analysis, fractions
containing tissue cysts were combined and diluted between five- and ten-fold using
PBS. Diluted cysts were then centrifuged at 1000g for 15 mins at 4 oC. Diluted
Percoll was carefully removed, leaving ~0.1 mL at the bottom of the tube. Pelleted
cysts were then resuspended in PBS at 300-600 cysts/mL. 0.5 mL cyst suspension
was spun onto glass slides using a Cytospin (Shandon Cytospin 4) at 750 rpm for
5 mins with medium acceleration and brake. Slides were then immediately
submerged in ice-cold 100% MeOH and stored in an explosion-proof freezer until
time of staining.
2.3.3 Staining and analysis of tissue cysts
Tissue cysts were stained as described previously (55). Briefly, cysts fixed on
glass slides were washed 3x in PBS++ in a Coplin jar to remove MeOH. Slides
were then briefly air-dried before drawing a wax circle around the area containing
the tissue cysts. This wax circle created a hydrophobic barrier that could then
contain antibody solutions. PAS or IF staining otherwise proceeded as described
in section 2.2.4 by adding staining solutions into the area contained by the wax
circle. If washing damaged the wax circle, it was redrawn before secondary
antibodies were added. After labeling, coverslips were then mounted onto slide by
the addition of MOWIOL and a coverslip directly over the cysts.
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2.3.4 Preparation of tissue cysts for TEM imaging
To prepare T. gondii tissue cysts generated in vivo for TEM, cysts were isolated
from the brains of infected mice as detailed in section 2.3.2 through the counting
step. Fraction containing mouse red blood cells (RBCs) was saved for further use
in this protocol. After combining Percoll fractions containing tissue cysts and
diluting with PBS to a volume of 15 mL (maximum of 2 mL combined fractions
before dilution), cysts were pelleted for 15 mins at 1000g at 4 oC. To maximize cyst
recovery, 10 mL supernatant was removed, and then the bottom 5 mL was divided
into 1 mL fractions for the top 4 mL, and the final 1 mL directly above the cysts was
sub-fractionated into 100 L volumes. Typically, the majority of cysts were
localized to within 300 L of the pellet. Sub-fractions containing cysts were once
again combined and diluted (typically 200-300 L diluted with 1-mL PBS) in a 1.5
mL Eppendorf tube, and then pelleted in a swinging-bucket rotor for 10 min at
1000g and 4 oC. Leaving the pellet undisturbed, all but 50 L of the supernatant
was removed. A small volume (~5-10 L) of RBC fraction was added to the
remaining volume for ease of visualizing the pellet throughout the remaining steps.
To ensure the detection of the relatively rare cyst population, a previously
described protocol (276,277) was adapted to concentrate the cysts into a small
agarose block. A 1.33X solution of GA in cacodylate buffer was prepared
containing 4% GA and 133 mM sodium cacodylate. 150 L fixative solution was
then added to sample, bringing the total volume to 200 L such that the final
concentration of GA was 3% and sodium cacodylate was 100 mM. Cysts were
then incubated at room temperature for 1 h in fixative. While cysts were in fixative,
4% low-melt agarose (BioRad) was prepared in 100 mM sodium cacodylate buffer
and kept liquid at 70 oC until needed. After fixation, cysts were pelleted again at
1000g for 10 mins at room temperature in a table-top centrifuge. All but 50 L
supernatant was once again removed, and 200 L warm low-melt agarose was
slowly added on top of fixed, pelleted cysts (3.2% agarose, final concentration).
Suspension was then centrifuged again at 1000g for 10 mins at 30 oC to keep the
agarose semi-liquid, and then placed on ice for 20 mins to solidify agarose. After
solidification, entire agarose plug was removed from tube with a small a wooden
dowel that had been whittled into a thin scoop. Agarose plug was placed in a Petri
dish, and the pellet was carefully cut out of the plug with a razor blade to create a
1 mm3 block. The agarose block was then stored in 3% GA/cacodylate buffer
overnight at 4oC. Processing of the block from post-stain onward was then identical
to TEM processing described in section 2.2.7. During sectioning, thick sections
were examined on a light microscope to verify the presence of tissue cysts before
proceeding with ultra-thin sectioning.
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2.3.5 Determination of cyst diameter and packing density
Tissue cysts fixed on slides (described in section 2.3.2.) were co-stained with
DAPI and DBA to obtain nuclear profiles for bradyzoites and an outline of the cyst
for diameter measurement. The diameter was determined in Fiji (ImageJ) by
drawing a circle around the cyst and computing the diameter. Packing density was
determined as described previously (55). Briefly, DAPI images of cysts were
opened in BradyCount1.0, and threshold levels were adjusted as needed to
capture all nuclear profiles. After BradyCount1.0 provided the number of
bradyzoite nuclei, the packing density was determined by dividing the number of
bradyzoites by the volume of the section. The formula describing this calculation
is: PD = N / (r2 x h) where PD=packing density, N = # of bradyzoites, r = radius
calculated from cyst diameter, and h = height of section (0.22 m throughout this
study).
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Table 2.1 Glucan phosphatases used in this study.
The accession number of each glucan phosphatase used in CBM/DSP alignments
is listed here, along with its UniProt accession number, and the domain boundaries
that were assigned to the CBM and DSP within each (if applicable).
Accession No.
Name
(UniProt)
CBM
DSP
H. sapiens laforin
O95278
1-136
137-331
A. carolinensis laforin G1KGK2
1-140
141-304
G. gallus laforin
Q5ZL46
1-136
137-319
D. rerio laforin
E9QCC5
2-131
132-294
X. laevis laforin
Q6GPD8
1-124
125-313
A. thaliana SEX4
Q9SRK5
253-340
84-252
A. thaliana LSF2
Q9FEB5
N/A
75-232
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Table 2.2 Glucan, water dikinase sequences used in this study.
The accession number of each glucan, water dikinase used in this study is listed
here, along with its UniProt accession number. The domain boundaries that were
assigned to the CBM and His-domain are also indicated.
Including transit peptide
Name
Accession No.
CBM45
His-catalytic site
(UniProt)
Solanum tuberosum
1: 127-203
1059-1080
I0DFJ7
GWD (StGWD)
2: 458-538
Arabidopsis thaliana
1: 120-196
994-1015
Q0SAC6
GWD (AtGWD)
2: 394-473
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Table 2.3 Plasmids used in this study.
Name
Use
Source
Expression of TgLaforin CBM
pET28b+
Novagen
truncations
Expression of 6xHis-SUMO-TgLaforin in
ppSUMO
Jack Dixon, UCSD
E. coli
pG-KJE8

Co-expression of TgLaforin with
chaperone proteins

pFastBac-HTA

Generation of bacmid for expression of
TgLaforin and TgGWD in Sf9 insect
Invitrogen
cells

pSAG1::CAS9U6::sgUPRT
pJET-NcGra7_DHFR
pHA3x-LIC
TgLaforin-HA3x-LIC

Genetic modifications in T. gondii
TgLaforin knockout via DHFR-TS*
knock in
Tagging and complementation of
TgLaforin
Tagging and complementation, derived
from pHA3x-LIC
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TaKaRa

David Sibley,
Washington
University
Peter Bradley,
UCLA
Peter Bradley,
UCLA
GenScript

Table 2.4 sgRNA sequences used in this study.
Target
Use
Sequence
HXGPRT (exon 2)
ATGGTCTCCACCAGTGCTCC
HXGPRT (exon 3) HXGPRT knockout
GACAAAATCCTCCTCCCTGG
HXGPRT (exon 5)
CTTCTTCGAGCACTATGTCC
TgLaforin 3'UTR
TgLaforin epitope tag GCTTAGCGTGTGAACAGCAG
TgLaforin (exon 1) TgLaforin KO
GAAGTCCCGATAACCTACGC
TgLaforin
Chromosome VI
complementation
GCCGTTCTGTCTCACGATGC
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Strand
+
+
+
+
+

Table 2.5 Primers used in this study.
Mutagenesis primers are presented in uppercase where the primer binds directly
to the template, and in lowercase-bold where new sequence is being introduced.
Name
Use
Sequence (5’ to 3’)
HXGPRT_sgRNA_E2_F
HXGPRT_sgRNA_E2_R
HXGPRT_sgRNA_E3_F
HXGPRT_sgRNA_E3_R
HXGPRT_sgRNA_E5_F

ctcgaagaagGTTTTAGAGCTAGAAATAGC
sgRNA
mutagenesis for
each construct
used in HXGPRT
knockout

HXGPRT_sgRNA_E5_R
TgLaf_3'UTR_sgRNA_F

TgLaf_3'UTR_sgRNA_R
TgLaf_exon5_homology_F
TgLaf_3'UTR_HX+homology_R
TgLaforin_sgRNA_E1_F
TgLaforin_sgRNA_E1_R
TgME49_ChrVI_sgRNA_F
TgME49_ChrVI_sgRNA_R
TgLAF_WT_F
TgLAF_WT_R
DHFR*_R
TgChrVI_WT_F
TgChrVI_WT_R

TgLaf_COMP_F

cactatgtccAACTTGACATCCCCATTTAC
tcctccctggGTTTTAGAGCTAGAAATAGC
ggattttgtcAACTTGACATCCCCATTTAC
tggagaccatGTTTTAGAGCTAGAAATAGC
ccagtgctccAACTTGACATCCCCATTTAC

sgRNA
mutagenesis for
TgLaf-HA epitope
tagging

tgaacagcagGTTTTAGAGCTAGAAATAGC

Generation of
TgLaf-HA tagging
construct

AGAGGAGGCGGAGGAGAG

sgRNA for TgLaf-KO
sgRNA for ChrVI
used in TgLaf
complementation
Amplification of
the first exon of
TgLaforin,
uninterrupted
Binds to drug
cassette from pJETNcGra7_DHFR
Amplification of
WT Chr VI locus
Binds to HXGPRT
cassette within
complementation
construct (derived
from pHA3x_LICs
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cacgctaagcAACTTGACATCCCCATTTAC

TCCGTATCGCCCCCTCTCGTCTGACACGCCCTC
TTTCCTCCAGCACGAAACCTTGCATTC
taacctacgcGTTTTAGAGCTAGAAATAGC
tcgggacttcAACTTGACATCCCCATTTAC
ctcacgatgcGTTTTAGAGCTAGAAATAGC
acagaacggcAACTTGACATCCCCATTTAC
TCCTACATTCTGGAGCGAAG
AAAGCCACTTTCTCCAGGAG
GCATTATGAGGAAAGCCCsAC
CAGGAAATATGCTGCGAGGA
TGTGTCTGCTCTTGAAGGTG

TGCAAGCCCTACATTGACAA

Table 2.6 T. gondii-infected mouse body index scoring guide.

Healthy
Progression
of acute
illness
Moribund/
deceased

Stage 0
Stage 1
Stage 2
Stage 3
Stage 4
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Figure 2.1 Refolding conditions for TgLaforin.
Refolding screen with minor modifications was adapted from (259). Abbreivations:
ARG = arginine; DTT = dithiothreitol; EtOHHN2 = ethanoloamine; GSH/GSSG =
reduced/oxidized glutathione; NaCl = sodium chloride; NDSB = non-detergent
sulfobetaines; PEG = polyethylene glycol; ZWITT = zwitterionic detergent.
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Figure 2.2 ImageJ analysis of in vitro bradyzoite conversion.
A, Tachyzoites were converted to bradyzoites in vitro using alkaline stress for 2-6
days. During this time, classic bradyzoite markers detected with DBA and PAS are
upregulated. B, Determination of DBA and PAS intensity using a four-step ImageJ
workflow.
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Figure 2.3 Video monitoring and automated analysis of T. gondii induced
egress.
A, Vacuoles in each field are identified (left panels) as ROIs in which the standard
deviation in intensity is monitored (right panel). Representative states of vacuoles
are pictured, and each state (1-4) is labeled on the tracking graph. State 3 is the
point of egress, as parasites begin to emerge from vacuole, and this corresponds
to the inflection point on the standard deviation in intensity tracking graph. B,
Gaussian fit of the first derivative of the curves from (A). C, Overlay of (A) and (B)
as validation that analysis generating data in (B) reflects the inflection point from
(A).
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CHAPTER 3. THE TOXOPLASMA GLUCAN PHOSPHATASE, TGLAFORIN,
UTILIZES A DISTINCT FUNCTIONAL MECHANISM ENABLING INHIBITOR
IDENTIFICATION
3.1 Introduction
Toxoplasma gondii is an obligate, intracellular, protozoan parasite that can
infect any warm blooded animal and chronically infects one-third of humans
worldwide (3). Infection with the parasite occurs through several routes, including
ingestion of environmental oocysts shed through cat feces, consumption of tissue
cysts in raw or undercooked meat, or through vertical transmission from an acutely
infected individual to their fetus (77,85). Upon consumption, the cyst-forms
(oocysts and tissue cysts) of the parasite eventually convert into the rapidly
dividing tachyzoite that disseminates throughout the body of the host, defining the
acute stage of infection (278). Under host immune pressure, a small number of
tachyzoites evade host defenses by converting into bradyzoites that populate
tissue cysts located in the central nervous system or muscle tissue of the host
(83,120). If the host becomes immunocompromised during the course of the lifelong chronic infection, spontaneous reactivation of bradyzoites into tachyzoites
can result in symptomatic toxoplasmosis that primarily manifests as the lifethreatening toxoplasmic encephalitis (114). The current first-line treatment is a
combination of pyrimethamine and sulfadiazine that targets folate synthesis in
tachyzoites during the acute phase of infection or after reactivation. However, this
treatment regime only targets tachyzoites, results in serious side effects, must be
taken for long periods of time, and cannot be administered to pregnant individuals
(123). Notably this drug combination does not reduce the overall cyst burden.
Other drugs, targeting the parasite mitochondrion result in a partial clearance of
tissue cysts, without achievement of a sterile cure. The potential for AG
metabolism as a target for drug intervention provides a unique molecular target for
T. gondii therapeutics that has not been explored.
A distinguishing feature of T. gondii bradyzoites is their accumulation of large
glucose-based polymers known as amylopectin granules (AGs) (101,196,279).
AGs are believed to function as an insoluble form of glucose storage for use in
bradyzoite persistence, replication, transmission, and reactivation, analogous to
starch utilization during the night in plants (55,101,144). Purified AGs were found
to be similar to plant amylopectin, the major glucose component of starch, with
respect to glucose chain-length and branching frequency, demonstrating that the
structure of AGs is more similar to plant starch than to animal and fungal glycogen
(40,196,197). Unexpectedly, it was demonstrated that AGs are synthesized from
UDP-glucose, similar to the sugar nucleotide used in fungal and animal glycogen
synthesis, rather than ADP-glucose, which is used by plants (40). Additionally, T.
gondii AGs reside in the cytoplasm, which is also characteristic of fungal and
animal glycogen, and are visible by transmission electron microscopy (TEM) in

encysted bradyzoites but not the rapidly dividing tachyzoites (Figure 1.1b and
1.1f). The presence of AGs in the cytoplasm is noteworthy given that Toxoplasma
retains a plastid remnant organelle termed the apicoplast that has its origins in red
alga.
These seemingly disparate findings regarding AGs are consistent with the fact
that the T. gondii proteome contains a hybrid molecular machinery exhibiting
characteristics of plants, fungi, and animals (280,281). This hybrid machinery is
exemplified in T. gondii’s putative cycle of reversible glucan phosphorylation
(Figure 1.4 and 1.6). In plants, the cycle begins with the actions of glucan, water
dikinase (GWD) and phosphoglucan, water dikinase (PWD) that use ATP to
phosphorylate glucose at the C6- and C3-hydroxyl positions within the glucan,
respectively (167,168). The presence of covalently attached phosphate disrupts
the crystalline organization of starch, thus solubilizing the surface glucose chains
and enhancing access of multiple amylases that release glucose, maltose, or other
oligosaccharides (169,170,172). To allow processive hydrolysis, the activity of a
glucan phosphatase is required to remove the residual phosphate groups and
reset the cycle (173,174,247). The T. gondii genome contains sequences that
encode putative enzymes with these activities: a glucan, water-dikinase (TgGWD
(TgME49_214260); plant-like), multiple amylases and debranching enzymes, and
the glucan phosphatase T. gondii laforin (TgLaforin (TgME49_205290); animallike), along with all of the enzymes needed in glucan synthesis (Figure 1.4, Table
1.1) (40,204,205,212).
The mechanism regulating the utilization of AGs in the T. gondii lifecycle is only
beginning to be defined. The critical regulatory role of reversible phosphorylation
of both starch and glycogen has been increasingly recognized, leading to
potentially unique insights and molecular targets in the T. gondii system (154,282).
Notably, glucan phosphatases are a family of carbohydrate-specific enzymes that
play a critical role in controlling polyglucan utilization in both plants and animals.
Glucan phosphatases are required for efficient starch catabolism as loss of starch
excess4 (SEX4), the prototypical glucan phosphatase found in plants, leads to
aberrant starch accumulation and morphology (174,239). Strikingly, mutations in
human laforin (HsLaforin), the glucan phosphatase in humans, results in
hyperphosphorylated and aberrantly branched glycogen that is the driver of Lafora
disease (LD), a fatal epilepsy and childhood dementia (184,187,283).
Glucan phosphatases are an enzyme family that dephosphorylate glucans via
a dual specificity phosphatase (DSP) domain coupled with either a carbohydrate
binding module (CBM) domain or carbohydrate surface binding sites (204,247).
Glucan phosphatases are members of the protein tyrosine phosphatase (PTP)
superfamily within the DSP clade (284-286). Previous work has demonstrated that
glucan phosphatases employ a wide variety of platforms that allow them to bind
and dephosphorylate carbohydrates (261,287-289). In land plants, SEX4 binds
and dephosphorylates carbohydrates by utilizing an integrated binding pocket
formed by the CBM/DSP interface (250,252,260). Like Sex Four-2, LSF2, another
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plant glucan phosphatase, lacks a traditional CBM and instead binds
carbohydrates through surface binding sites within its DSP domain (251). Human
laforin is an antiparallel dimer with a spatially separated CBM and DSP that are
each capable of binding to carbohydrates independently (253). While they are not
orthologs, SEX4 and laforin are functional equivalents as complementation of
laforin into sex4 A. thaliana plants rescues the starch excess phenotype (204).
In this study, we build on our understanding of glucan phosphatases and
reversible phosphorylation in T. gondii by defining the biophysical and biochemical
properties of TgLaforin. We identified an atypical CBM in TgLaforin, defined
TgLaforin’s oligomerization status, and determined its activity. Moreover, we
developed and characterized the first reported TgLaforin inhibitor. These findings
demonstrate the value of a detailed examination of the enzymology related to
glucan metabolism in T. gondii and open new doors for anti-Toxoplasma
therapeutics.
3.2 Results
3.2.1 Expression of recombinant, full-length TgLaforin
To express recombinant TgLaforin in BL21-DE3 E. coli, an E. coli codonoptimized cDNA was fused with an N-terminal, 6x-His-tagged small ubiquitin-like
modifier (SUMO) protein. SUMO protein is believed to act as a protein folding
initiator that increases protein solubility (290). While a significant portion of the
protein remained insoluble, a fraction of soluble SUMO-TgLaforin was successfully
expressed in E. coli and purified using immobilized metal affinity chromatography
(IMAC) (Figure 3.1a; panel 1, “E”). Moreover, the SUMO-tag was readily
removed with ubiquitin-like-protease (ULP) treatment. However, recombinant
TgLaforin was not pure as several other proteins were also co-purified alongside
it. Because many of these proteins were in a similar molecular weight (MW) range,
size-exclusion chromatography (SEC) was not utilized for further purification.
Instead, anion exchange chromatography (AEX) was chosen due to the predicted
pI of TgLaforin (6.47). To elute TgLaforin, a salt gradient of 100 mM→500 mM
NaCl was used, and TgLaforin eluted at ~320 mM NaCl (Figure 3.1a; panel 2).
While some bands of lower MW were successfully eliminated from the purified
protein, several contaminants still remained. Regardless, protein purified from E.
coli
demonstrated
activity
against
the
artificial
substrate
paranitrophenylphosphate (pNPP) (Figure 3.2c), but further purification strategies
were pursued to generate highly pure protein for use in downstream studies in
which biophysical properties and conformational dynamics could be determined.
Because a significant amount of TgLaforin remains insoluble upon expression
(Figure 3.1b, panel 1, “+IPTG”), it was reasoned that co-expression of TgLaforin
with several chaperones might aid in its proper folding without the attachment of a
large fusion protein such as SUMO. Therefore, TgLaforin was co-expressed in
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BL21 E. coli with 4 chaperones: DnaK, GroEL, DnaJ, and GrpE (Figure 3.1b).
Each chaperone or set of chaperones was under the control of differentially
inducible promoters, so the induction of each chaperone with either arabinose or
tetracycline, or all three in combination was first verified (Figure 3.1b, panel 1,
“+arab/+tet”). The solubility of 6xHis-TgLaforin (a 61.5 kDa protein) alongside
these chaperones was obscured by the expression of GroEL (a 60 kDa protein).
Further purification with IMAC revealed almost no soluble protein (Figure 3.1b,
panel 2, “E”). To determine if any of the protein in the IMAC eluate was soluble,
protein fractions analyzed were western blot analysis with an -His antibody
(Figure 3.1b, panel 3). Alongside these four chaperones, TgLaforin remained
insoluble, and no soluble protein was detected by western blot.
To take advantage of the high levels of insoluble protein, refolding of TgLaforin
in E. coli inclusion bodies (IBs) was attempted as IBs have been demonstrated to
be a relatively pure source of protein (291). IBs were first washed of soluble protein
with 2M Urea and 2% Triton X-100 before being solubilized in 6M guanidine,
resulting in relatively pure, soluble protein (Figure 3.1c, “Ex”). Protein was then
rapidly diluted in a range of buffers at various pHs with or without multiple additives
and reducing agents. This screen was designed around 96 total conditions
previously identified by Dechavanne, et al. 2010 (259); (detailed in section 2.1.4)
(Figure 3.1d and Figure 2.1). Rapid dilution of protein has been demonstrated to
be effective in protein refolding (292) as opposed to slower refolding by dialysis,
and was thus selected for the purposes of a large-scale screen. Indeed, several
conditions resulted in soluble protein (Figure 3.1d). To determine if the soluble
protein was properly folded, differential scanning fluorimetry (DSF) was used. DSF
is a technique that monitors protein unfolding in the presence of SYPRO orange.
Hydrophobic, interior residues of protein bind SYPRO during the unfolding
process, and a melt-curve with an inflection point, from which the melting
temperature (Tm) is derived, indicates the presence of folded protein. In general,
the presence and relative value of the melting temperature can be used as a
surrogate for protein stability. DSF analysis of soluble TgLaforin revealed that none
of the soluble protein identified by the refolding screen possessed a fluorescence
inflection point that allowed for the identification of a Tm (Figure 3.1e; c.f. Figure
3.3a), indicating that the protein may not have been folded despite its solubility.
It was then reasoned that a eukaryotic expression system with more extensive
protein post-translational modifications might benefit the solubility and purity of
TgLaforin. Therefore, baculovirus-induced expression in Sf9 insect cells was
selected to express 6xHis-TgLaforin. After increasing viral titer through three
passages, various baculovirus:Sf9-cells (v/v) were tested, and an optimal ratio of
1:1000 was selected (Figure 3.2a). Western blot analysis with an -His antibody
confirmed the identity of the expressed protein (Figure 3.2b). Isolation of protein
from Sf9 cells and subsequent IMAC purification yielded pure protein. Moreover,
SEC or AEX polishing steps resulted in equally pure protein (Figure 3.2a), so SEC
was selected for its convenience and increased control over final buffer
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composition, yielding >95% pure protein. When compared to protein produced in
E. coli (purified by AEX, Figure 3.1a), the specific activity of TgLaforin remained
the same when adjusted for total TgLaforin across expression systems (Figure
3.2c), but the purity was greatly increased. The enzymatic activity of TgLaforin will
be further dissected in section 3.2.6.
3.2.2 Recombinant Sf9-expressed TgLaforin is stably folded
To determine if the baculovirus-expressed TgLaforin was indeed stably folded
in solution, DSF was once again utilized (Figure 3.3). DSF analysis of TgLaforin
expressed in Sf9 insect cells yielded a standard melting curve (Figure 3.3a). By
taking the first derivative of the melt curve and fitting the first derivative with a
gaussian curve, a Tm could be determined at maximum of the fitted curve (Figure
3.3b). Without any ligand, the Tm of full-length TgLaforin was 47.6 oC (Figure 3.3c).
To define TgLaforin carbohydrate binding, TgLaforin was incubated with various
carbohydrates and analyzed with DSF. An increase in Tm is associated with
increased protein stability due to protein-ligand interaction (185,293). When
incubated with DP4 (four linear glucose units) or DP7 (seven linear glucose units),
TgLaforin was robustly stabilized (Figure 3.3b-c). Moreover, TgLaforin was also
stabilized in the presence of complex carbohydrates such as amylopectin and
glycogen (Figure 3.3b-c). The stabilization of TgLaforin with these carbohydrates
was demonstrated to be dose dependent (Figure 3.3d-e), demonstrating that Sf9expression of TgLaforin yielded both pure and folded protein.
3.2.3 Bioinformatic evidence for a split-CBM20 in TgLaforin
T. gondii AG metabolism employs reversible glucan phosphorylation where the
plant-like TgGWD dikinase and animal-like TgLaforin phosphatase are utilized
(Figure 1.4 and 1.6). In addition to this plant-like versus animal like axis, TgLaforin
is also unique in its domain organization. We previously predicted that the T. gondii
genome encodes for a glucan phosphatase that is more similar to human laforin
than other glucan phosphatases based on its domain orientation with an Nterminal CBM family 20 (CBM20) followed by a DSP domain (204,205). However,
TgLaforin contains 523 amino acids, and the combined length of a typical CBM
(90-120 amino acids) and DSP (150 amino acids) is only 240-270 amino acids,
leaving approximately half of the protein uncharacterized. Bioinformatic analyses
suggested that TgLaforin contains two unusual inserts within its CBM20 domain
(Figure 3.4a) (294).
Rather than pursuing protein crystallography with the Sf9-generated protein,
the architecture of TgLaforin and its CBM were predicted utilizing AlphaFold2 (258)
to generate a putative three-dimensional model of TgLaforin. The model generated
by AlphaFold2 predicted that TgLaforin contains a single CBM20 over the span of
325 amino acids. With high confidence (predicted Local Distance Difference Test
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(pLDDT) score >70%), AlphaFold2 modeled a core CBM that consists of -strands
from the three distally located sub-domains of the CBM region. The model predicts
that the unusual inserts form large unstructured linker regions connecting the core
structured CBM regions (Figure 3.4b). The unstructured portions of the CBM20
modeled with low confidence (pLDDT<50%) (Figure 3.4b). A canonical DSP
domain (reviewed in (284)) was also modeled in TgLaforin containing the
characteristic DSP + structure with a central -sheet consisting of five twisted
-strands (Figure 3.5a). TgLaforin contains the canonical CX5R motif with C452
serving as the catalytic cysteine (Figure 3.5a-b), and R458 that coordinates the
three non-bridging oxygens of the incoming phosphoryl substrate. This catalytic
motif is located between a -strand and -helix as expected. DSP domains also
contain a critical, upstream aspartate (D421 in TgLaforin) that defines the D-loop
and functions as an acid-base catalyst, modeled in TgLaforin as participating in
the active site (Figure 3.5). The presence and location of these residues places
TgLaforin in the PTP superfamily (295).
To validate the AlphaFold2 model of TgLaforin, we utilized full-length TgLaforin
expressed in Sf9 insect cells and purified by SEC (Figure 3.2a) in hydrogendeuterium exchange (HDX) mass-spectrometry (MS) experiments. This technique
has previously been used to illuminate conformational dynamics of proteins by
demonstrating areas of high and low solvent accessibility (253,296). We first
determined deuterium uptake across the entire protein from 15-15,000 s (Figure
3.6) and mapped the results onto the AlphaFold2 model (Figure 3.4c). Critically,
the core CBM20 -sandwich exhibited low uptake of deuterium while the CBM
insert regions that were modeled with low confidence displayed much higher rates
of deuterium uptake (Figure 3.4c-d). These regions with high deuterium exchange
are thus more mobile and less structured. Conversely, -sheets within the core
CBM were among the structural elements with the lowest deuterium uptake. Within
the DSP domain, core structural elements had low uptake while elements of the
DSP active site, known to undergo conformational changes required for substrate
interaction (253,297), displayed higher uptake. These active site regions included
the recognition domain, variable loop, D-loop, PTP-loop, and R-motif (Figure 3.4d
and Figure 3.6) that have previously been reported as exhibiting higher solvent
accessibility in SEX4 and laforin (253,264).
3.2.4 Integrated CBM is required for carbohydrate binding
To further define the nature of the unique split-CBM domain found in TgLaforin,
we aligned the TgLaforin CBM with other glucan phosphatases containing a
CBM20 (Figure 3.7a). The three regions of the TgLaforin CBM20-domain, split
over 325 amino acids and interrupted by linker regions, each contain a part of the
key consensus amino acids predicted to be critical to glucan binding. However,
none of the individual regions contain a complete array of consensus amino acids
that would allow it to be an individual CBM domain. Moreover, these three
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subdomains contain the predicted number of -strands that are typically identified
in a CBM that are predicted to come together to form two anti-parallel -sheets,
comprising the canonical -sandwich fold that is characteristic of CBM20 domains
(Figure 3.7b). Each sub-domain contains one of the three conserved amino acids
involved in either aromatic glucose stacking interactions (W29 and W278) or
hydrogen bonding with glucose rings (K206) that are each critical to glucan binding
(298). Conversely, the linker regions do not contain the key conserved glucanbinding residues. Importantly, the three critical carbohydrate binding residues
(W29, K206, and W278) are organized into a single three-dimensional binding site
similar to other CBM20s (Figure 3.7c and Figure 3.8a).
To further test if TgLaforin contains a single integrated CBM, we expressed
each of the three sub-domains (CBM20-1, -2, and -3) separately and in different
combinatorial arrangements (Figure 3.8b). Each of the constructs encoding
individual portions of this region were either not expressed, not folded, or
aggregated (Figure 3.8c-e). However, we were able to express and purify the
predicted full TgCBM comprising all three subdomains with the two linkers,
TgCBM123 (referred to simply as “TgCBM”) (Figure 3.8d).
We next analyzed TgCBM using size exclusion chromatography coupled with
multi-angle light scattering (SEC-MALS) to define its oligomerization state. SECMALS analysis demonstrated that TgCBM has a MW of 36.6  6.8 kDa, compared
to the predicted monomeric mass of 35.6 kDa, indicating that the TgCBM is a
stable monomer in solution (Figure 3.9a). To define TgCBM carbohydrate binding,
DSF was utilized as described in section 3.2.1 (185,293). We incubated TgCBM
with the linear oligosaccharide maltohexaose and observed a robust dosedependent stabilization of TgCBM with an Kd,app=20  4 mM (Figure 3.9b).
To further probe the glucan binding of TgCBM, we designed alanine mutants
of the three predicted critical carbohydrate-binding residues. K206A and W278A
were produced and purified to near homogeneity, while W29A was deleterious to
protein folding. We then tested the effect of the K206A and W278A mutations on
carbohydrate binding. Strikingly, neither mutant was able to bind to maltohexaose,
demonstrating their key function in carbohydrate binding (Figure 3.9b). If
TgLaforin contained two distinct CBMs, then carbohydrate binding should have
been only partially reduced by each independent mutant. Taken together, these
data demonstrate the structure, dynamics, and carbohydrate binding of the split
CBM20 of TgLaforin.
3.2.5 TgLaforin is an antiparallel dimer
Previous work demonstrated that glucan phosphatases utilize unique platforms
to bind and dephosphorylate carbohydrates (287). While the plant glucan
phosphatases SEX4 and LSF2 are monomeric, dimerization is a critical feature of
human laforin activity and stability, and dimerization is mediated through the DSP
domain resulting in an antiparallel dimer (253). To determine the glucan binding
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platform employed by TgLaforin, we analyzed the oligomerization status of fulllength TgLaforin and found that TgLaforin eluted as a single species from SEC
(Figure 3.10a). However, like other glucan phosphatases, it was significantly
shifted in elution volume due to interactions with the carbohydrate-based SEC
matrix and eluted at a higher volume than would be expected when compared to
SEC standards (262). We therefore utilized SEC-MALS to determine the
oligomeric state of TgLaforin. SEC-MALS demonstrated that TgLaforin has a MW
of 136.6  0.6 kDa, twice the predicted size of the 61.5 kDa monomeric protein,
signifying it exists in solution as a stable dimer (Figure 3.10a). When considered
alongside the fact that TgLaforin-CBM is a monomer in solution (Figure 3.9a), this
is highly suggestive that dimerization of TgLaforin is mediated through the DSP
domain. To test this, we utilized the multimer modeling functionality of AlphaFold2
(257). We predicted the structure of a homodimer of TgLaforin, which produced an
anti-parallel dimer model which was exclusively DSP-driven (Figure 3.10b). The
core CBM and DSP domains were modeled with high confidence (pLDDT>70%),
and adopted an orientation very similar to that observed in human laforin (253).
3.2.6 TgLaforin is an active glucan phosphatase
Phospho-tyrosine specificity is conferred to PTPs through the ~40 amino acid
recognition domain that forms a deep catalytic pocket. In DSPs, however, the
recognition region is much shorter, which results in a shallower active site that
allows DSPs to dephosphorylate phospho-serine/threonine residues as well (284).
As with other DSP containing proteins, the TgLaforin recognition region is much
shorter than a typical PTP, confirming its placement in the DSP family. When
compared with other glucan phosphatases, the TgLaforin DSP domain also shares
many of the same glucan binding residues with human laforin, but not with plant
glucan phosphatases [(Figure 3.5b); residues highlighted in blue)].
These carbohydrate-binding residues identified in the DSP play a role in both
specific and selective activity against glucan substrates. To determine optimal
TgLaforin activity, we first tested its phosphatase activity against pNPP over a pH
range from 5.0-9.0 (Figure 3.11a). Over the range tested, TgLaforin displayed the
highest activity at pH 5.0. To determine if TgLaforin activity remains stable under
these acidic conditions, TgLaforin was pre-incubated in phosphatase buffer at
various pHs from 5.0-6.5 before the addition of substrate (Figure 3.11b). Strikingly,
TgLaforin lost activity over time if incubated at a pH of 5.0, but retained most of its
maximum activity level at higher pH values. Therefore, all the following pNPP
activity assays were conducted at pH 5.5. At pH 5.5, TgLaforin demonstrated
robust activity against pNPP that was both dose- and time-dependent (Figure
3.12a). Moreover, when the catalytic cysteine (C452) was mutated to a serine
(C452S), the activity was completely ablated, consistent with its role as the
catalytic nucleophile (Figure 3.11a and 3.12a).
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To test its activity against a biologically relevant substrate, we used a malachite
green-based assay to detect phosphate release from solubilized potato
amylopectin. We once again tested the optimal pH of TgLaforin activity against
amylopectin (Figure 3.11c). Generally, the activity of TgLaforin was higher at
acidic pH values, and activity at pH 6.5 was significantly higher than several other
basic pH values. Because malachite-green based glucan phosphatase assays are
typically conducted at pH 6.5, and TgLaforin activity was optimal at this pH, all
following amylopectin assays were conducted at pH 6.5. TgLaforin readily
dephosphorylated amylopectin in a time-dependent manner, whereas the
catalytically inactive C452S control did not (Figure 3.12b). Importantly, VHR, a
member of the DSP family lacking a CBM, was unable to release phosphate from
amylopectin (Figure 3.12b). Therefore, in addition to providing evidence for its
glucan phosphatase activity, these data also demonstrate the ability of TgLaforin
to bind carbohydrates and confirm the function of its split CBM.
Glucose within both starch and glycogen is phosphorylated at both the C3- and
C6-hydroxyl groups, and glucan phosphatases display varying specificities with
regards to the site that they dephosphorylate (289). SEX4 displays a preference
for dephosphorylating the C6-position while human laforin displays a preference
for the C3-position (252,261). LSF2, however, exclusively dephosphorylates the
C3-position (251). We tested TgLaforin for C3- or C6-selectivity by incubating it
with starch differentially radio-labeled at the C3- or C6-position. TgLaforin
displayed a strong preference for dephosphorylating the C3-position with 78% of
its activity directed against C3, and only 22% against C6 (Figure 3.12c). Together,
these data demonstrate that TgLaforin is a glucan phosphatase with a preference
for C3-phosphate.
3.2.7 Design, synthesis, and testing of a TgLaforin inhibitor
Because TgLaforin represents a possible therapeutic target as a critical
regulator of AG metabolism in T. gondii, we sought to exploit its observed unique
features to identify a specific inhibitor. We utilized the SulfoPhenyl Acetic Amide
(SPAA) platform for inhibitor development, which is a novel pTyr-mimetic derived
from the FDA-approved drug cefsulodin (299,300). Based on SPAA, potent and
specific inhibitors to several PTP enzymes have been developed, including SHP2,
mPTPA, mPTPB, and LMW-PTP (299-302). These inhibitors were discovered by
fragment-based combinatorial chemistry approach where a library of compounds
was prepared by reacting SPAA containing cores with a set of carboxylic acids or
amines. To increase the potency and selectivity of an inhibitor for TgLaforin,
molecular diversity was installed in order to capture additional and less conserved
interactions outside the pTyr binding cleft (i.e., active site), generating inhibitor
L319-21-M49 (Figure 3.13a). Screening and selection of this compound was
conducted at Purdue Institute for Drug Discovery under the direction of Dr. ZhongYin Zhang.
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To test the specificity and potency of L319-21-M49, we used the pNPP assay
with TgLaforin and a variety of other phosphatases (Figure 3.13b). To determine
a linear range of activity with respect to time, 50 nM TgLaforin was incubated with
pNPP and demonstrated to possess linear activity over the course of 10 min
(Figure 3.14a). To determine the optimal pNPP concentration for inhibitor analysis,
TgLaforin was incubated with a wide range of pNPP concentrations (Figure 3.14b)
to determine its Km (Figure 3.14c). Additionally, the linear time range of all other
phosphatases used in this study for inhibitor comparison (PTP1B, VHR, and CIP)
was verified (Figure 3.15a), and the Km for each phosphatase was determined
(Figure 3.15b). For inhibitor assays, each phosphatase was incubated with a
concentration of pNPP equivalent to the Km value for each respective enzyme
alongside a range of inhibitor concentrations.
Under these conditions, L319-21-M49 possessed an IC50 of 1.49 M against
TgLaforin (Figure 13.16a). Moreover, when tested against other phosphatases,
the inhibitor was remarkably specific to TgLaforin. L319-21-M49 was at least 100fold selective towards TgLaforin compared to another DSP (VHR), a general PTP
(PTP1B), and an alkaline phosphatase (CIP) (Figure 13.16a).
Next, L319-21-M49 was tested against the glucan phosphatase activity of
TgLaforin in the malachite green based assay at its linear activity range (Figure
3.15b). To do this, we incubated TgLaforin with amylopectin in the presence of the
inhibitor and detected phosphate release with malachite green. Importantly, the
inhibitor was also effective at preventing TgLaforin activity against soluble
amylopectin with an IC50 of 5.10 M (Figure 3.16b). Finally, we tested the
inhibitor’s ability to inhibit phosphate release using the radiolabel assay within
TgLaforin’s linear activity range (Figure 3.15c). L319-21-M49 was also effective in
preventing phosphate release from both the C3 and C6 positions with similar IC 50s
of 6.68 M and 6.47 M, respectively (Figure 3.16c). Thus, in L319-21-M49, we
have identified a first-in-class lead compound for the inhibition TgLaforin.
3.3 Discussion
In animals, glycogen breakdown provides substrates for epigenetic
modifications, central carbon metabolism, and protein post-translational
modifications (154,303,304). In plants, starch characteristically acts as both a
transient and long-term storage form of glucose, dictating the level of free sugars
and allowing for energy maintenance through dark periods (144). Interestingly, T.
gondii appears to utilize both plant-like and animal-like systems of glucan storage
and degradation making this system an appealing candidate for therapeutic
development. Glucan phosphatases are critical regulators of polyglucan
metabolism in both plants and animals. Here, we characterized the structure,
dynamics, and activity of the unique T. gondii glucan phosphatase TgLaforin,
demonstrating it possesses a single CBM20 N-terminal to its DSP, a dimerization
interface via the DSP domain, and preference for dephosphorylating the C376

hydroxyl position on glucose. Finally, we identified a first-in-class lead compound
that inhibits TgLaforin.
To elucidate the split nature of this novel CBM20, we employed the recently
developed AlphaFold2 neural network for an initial structural prediction. In
agreement with our sequence predictions and site-directed mutagenesis
experiments, the computational prediction of AlphaFold2 suggested that
TgLaforin’s CBM20 folds into a central core -sandwich with large unstructured
loops outside of this core. This orientation connects the -sheets so that they form
the canonical immunoglobulin-like fold. The linker regions were modeled with a
very low level of confidence by AlphaFold2, so we utilized HDX to define both core
and linker regions of the TgCBM20. Strikingly, HDX demonstrated that regions we
predicted to form the CBM20 core exhibited much lower solvent exchange.
Conversely, regions displaying the highest solvent uptake were also the lowconfidence regions of the AlphaFold2 model, potentially revealing intrinsically
disordered protein-like character of these inserts (305,306). Indeed, low
complexity inserts have been previously noted as being unusually abundant in the
proteome of T. gondii and other related parasitic protozoa, often confounding
protein identification (307-309).
We further demonstrated that each homologous region and the aromatic
residues within them are critical to the ability of TgLaforin to bind carbohydrates,
consistent with the fact that it indeed contains a single CBM20. This combination
of protein modeling, mutagenesis, and HDX-MS allowed us to define the first
reported split-CBM. We attempted to identify other proteomes containing a splitCBM20 using BLASTp and TgCBM as a query, but we were only able to identify
putative split-CBM20 orthologues in highly related T. gondii genera that are also
cyst forming members of the Phylum Apicomplexa such as Neospora, Besnoitia,
and Eimeria.
Therefore, despite its similarities to vertebrate glucan phosphatases, TgLaforin
employs a unique starch binding domain (SBD) in the form of a split-CBM20.
Currently, there are 88 CBM families identified in the CAZy database, fifteen of
which are SBDs (298). The accepted definition of a SBD requires that it must bind
to complex polysaccharides, and that it be a continuous and discreet domain of
about 100 amino acids. However, the discovery and characterization of a
Microbacterium aurum GH13 -amylase (MyAmyA) revealed the first bona fide
SBD containing 300 amino acid residues (CBM74), demonstrating that SBDs can
be much longer than the previously expected length (310). In characterizing the
CBM74, structural and mutagenesis studies were not performed, and 3D modeling
with the Phyre2 server, a previous modeling software, was unable to generate a
confident tertiary structure prediction for the domain. Phyre2 predicted 12 strands throughout the CBM74 domain, but no continuous sequence between
strands approached the length of the linkers in the TgCBM. Here, we describe a
CBM20 that is similar in length to CBM74, but distinct in that its carbohydrate
binding residues and secondary structures are split over approximately 325 amino
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acids. This split-CBM20 contains discreet regions of homology to other CBM20s,
separated by long linker regions with high solvent accessibility.
Recent work has demonstrated that glucan metabolism is not restricted to
bradyzoites in T. gondii, but is critical throughout the asexual lifecycle, playing a
role in parasite growth, morphology, and infection (203,206,228,235,311).
Tachyzoites have been recognized as containing a much smaller cytoplasmic
polyglucan that is not typically visible by electron microscopy but is detectable
using a carbohydrate-specific stain such as periodic-acid Schiff (PAS)
(203,228,234,312). This tachyzoite polyglucan is rapidly turned over as observed
in other protozoan glucans during their trophozoite stages (228,312,313). Of note,
Ca2+ dependent protein kinase 2, CDPK2, was identified as a regulator of AG
metabolism in tachyzoites and bradyzoites. The ability of CDPK2 to regulate
glucan metabolism in tachyzoites was mediated through its CBM20 domain. As
such, loss of CDPK2 results in parasites with aberrant cell morphology, excess AG
accumulation, and the inability to form tissue cysts in mice (228). Importantly,
multiple CDPK2 substrates are involved in glucan turnover including glycogen
phosphorylase, -amylase, debranching enzyme, and TgGWD. These data
highlight the critical role reversible phosphorylation might play in T. gondii beyond
its role in bradyzoites. Additionally, they suggest that enzymes involved in glucan
metabolism are potential drug targets throughout the parasite’s asexual lifecycle.
Historically, phosphatases have been difficult to specifically target (314).
However, recent breakthroughs have resulted in a number of successful
compounds being developed (315-321). For TgLaforin, we exploited differences in
phosphatase tertiary structure outside of the well-conserved PTP-loop to develop
an inhibitor. L319-21-M49 was selective for TgLaforin with >100-fold specificity
compared to VHR, another member of the DSP family. L319-21-M49 not only
inhibited the generic pNPP activity of TgLaforin, but it also inhibited the ability of
TgLaforin to dephosphorylate complex carbohydrates. Future studies will define
specificity and potency within the more closely related glucan phosphatase family.
Glucose metabolism plays a critical role in central carbon metabolism and
cellular signaling from bacteria to humans. Glucose storage and utilization in AGs
is beginning to be elucidated in T. gondii. Given that a glucose aggregate has now
been established in both life cycles that replicate in humans (55), the enzymes that
control AG metabolism are potential therapeutic targets, especially the enzymes
involved in AG reversible phosphorylation. Importantly, AG metabolism is
intricately linked to bradyzoite development (54), making AG reversible
phosphorylation in AGs an intriguing target. Our studies demonstrate the key
enzymatic features of TgLaforin as a glucan phosphatase and lay the groundwork
for targeting TgLaforin as a means to prevent T. gondii bradyzoite reactivation and
transmission.
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Figure 3.1 TgLaforin expression in BL21 E. coli and SDS-PAGE tracking of
protein throughout purification process.
A, 6xHis-SUMO-TgLaforin was expressed and SUMO-tag was removed with ULP
(left panel). Protein was purified using AEX (right panel). Yellow asterisk placed
above ULP removed by AEX, red asterisk placed adjacent to TgLaforin. B, 6xHisTgLaforin was co-expressed with chaperones (left and middle panel). Solubility of
TgLaforin was interrogated by western blot. Pellet (P) was probed separately due
to its intense signal (right panel). C, Purification of TgLaforin from inclusion bodies.
P1-P4 represent pellet washed with 2M Urea, Ex (extract) are inclusion bodies
solubilized with 6M guanidine. D, Soluble protein from refolding screen (conditions
correspond to Figure 2.1). E, DSF analysis of soluble protein from refolding
screen. Abbreviations: E = eluate; FT = flow through; GAM = goat-anti-mouse; In
= induced; P = pellet; S = supernatant; Un = uninduced; W = wash.
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Figure 3.2 Expression of TgLaforin in Sf9 insect cells.
A, Coomassie-stained SDS-PAGE of protein through purification process. B,
Western blot of expressed protein. C, Comparison of specific phosphatase activity
of E. coli expressed protein versus Sf9-expressed protein. Abbreviations: AEX =
anion-exchange; IMAC = immobilized metal affinity chromatography; Inf = infected;
P = pellet; SEC = size exclusions chromatography; S = supernatant; Un =
uninfected.
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Figure 3.3 DSF analysis of Sf9-expressed TgLaforin.
A, Raw fluorescence melt curves of TgLaforin with or without carbohydrate ligands.
B, First derivative of melt curves from 3.3a. C, Effect of various carbohydrates on
TgLaforin Tm. D, Dose-dependent stabilization of TgLaforin with DP7
(maltoheptaose; linear chain of 7 glucosyl units). E, Dose-dependent stabilization
of TgLaforin with solubilized potato amylopectin.
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Figure 3.4 Modeling and HDX data indicate that TgLaforin contains a splitCBM20.
A, Schematic of a previously proposed domain arrangement of TgLaforin (294). B,
TgLaforin modeled by AlphaFold2 with confidence levels mapped onto the
structure. CBM, DSP, and inserts are indicated. C, Deuterium uptake of TgLaforin
after 15 s as determined by HDX-MS mapped onto the AlphaFold2 model. D,
Normalized deuterium uptake by TgLaforin after 15 s deuteration represented in
2D, highlighting uptake in each domain of the protein. Other time-points from 15 s
to 15000 s displayed in Figure 3.6. Abbreviations: RD = recognition domain; VL =
variable loop; D = D-loop; PTP = protein tyrosine phosphatase loop; R = R-motif.
AlphaFold2 models generated, and confidence/HDX data superimposed by
Tiantian Chen.
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Figure 3.5 TgLaforin’s DSP domain.
A, AlphaFold2 models a typical DSP domain in TgLaforin containing a central sheet (magenta) surrounded by -helices (cyan). The critical catalytic residues are
brought into the active site. Side chain colors are as follows: carbon=salmon,
nitrogen=blue, oxygen=red, sulfur=yellow. B, Alignment of TgLaforin’s DSP
domain with DSP domains from other glucan phosphatases. Residues critical to
glucan binding, phosphate removal, and dimerization (for human laforin) are
compared alongside the motifs that define DSP domains with residue colors
defined in legend. Dark gray boxes indicate identical residues and light grey boxes
indicate similar residues. Arrows indicate -sheets and ovals indicate -helices.
Numbering corresponds to TgLaforin’s amino acid sequence.
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Figure 3.6 Deuteration level of TgLaforin peptides as a function of time.
The TgLaforin primary sequence is displayed above colored bars that represent
individual peptides from pepsin proteolysis. Bar color indicates the percent
deuteration of a peptide at a given time point, ranging from lowest deuteration
(purple) to highest deuteration (deep red) as indicated in the inset. Secondary
structure is displayed above primary sequence with arrows symbolizing -sheets
and ovals symbolizing -helices. CBM sub-domains and DSP motifs are labeled
using thick bars to indicate their predicted location, and numbers correspond to
amino acid positions.
HDX data analysis by Caden R. Pearson.
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Figure 3.7 TgLaforin’s CBM domain.
A, Multiple sequence alignment of laforin orthologue CBMs found across multiple
vertebrate species, overlaid with the predicted domain structure of TgLaforin. Black
lines connecting CBM20 fragments are predicted to be largely unstructured loops.
Residues highlighted in blue are involved in carbohydrate binding specificity, and
residues in orange are consensus residues needed to engage carbohydrates.
Arrows symbolize -strands, and numbering corresponds to the TgLaforin
sequence. B, AlphaFold2 model of TgLaforin’s split CBM20 highlighting the core
CBM predicted with high confidence in cyan and the low confidence insert regions
in grey. C, TgLaforin’s CBM core structure is predicted to bring together 3 putative,
canonical residues used in carbohydrate interactions: W29, K206, and W278.
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Figure 3.8. Expression of protein constructs used in this study.
A, 3D crystal structure of human laforin (4rkk) crystalized with maltohexaose
highlighting the concerted carbohydrate binding interactions of CBM20 domain.
Binding residues are highlighted in orange with N colored in blue, and
maltohexaose chain colored by element (C=green, O=red). Zoom displays
stacking interactions between glucose and W32/W99 (W29/W287 in TgLaforin),
and red dashed lines indicate hydrogen bonding between glucose hydroxyls and
K87 (K206 in TgLaforin). B, Schematic of constructs generated in this study.
TgCBM123, the full-length CBM, is referred to as “TgCBM.” C, Expression levels
of constructs in BL21 whole cell lysate demonstrates success or failure to express
each construct. D, TgCBM constructs after Ni-IMAC purification demonstrates
recovery of soluble protein. E, TgCBM3’s presence in the void volume as indicated
by its presence in early fractions from SEC demonstrates that it aggregates.
TgCBM constructs purified by: Carl D. Vander Kooi, MD.
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Figure 3.9 TgCBM characterization.
A, TgCBM SEC profile with MW prediction overlay determines that TgCBM MW is
36.6  6.8 kDa. B, TgCBM is stabilized in the presence of increasing
concentrations of maltohexaose, while mutagenesis of carbohydrate binding
residues no longer exhibit carbohydrate binding.
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Figure 3.10 TgLaforin is an antiparallel dimer.
A, SEC elution profile overlayed with MALS-measured mass (red) for two SEC
standards (grey; MW of standards indicated at elution volume on top) and
TgLaforin (blue). MALS predicts that TgLaforin is 136.6  0.6 kDa in solution. B,
AlphaFold2 model of TgLaforin as a dimer, showing high confidence regions
(pLDDT>70%). Subunits are shown in shades of blue and green. Residues critical
to glucan phosphatase function are shown highlighted with core CBM residues
depicted in orange, and the catalytic cysteine shown in red.
AlphaFold2 dimer model generated by Tiantian Chen.

88

Figure 3.11 Initial characterization of TgLaforin phosphatase activity.
A, pH dependence of TgLaforin activity against pNPP. B, The effect of pH on
TgLaforin activity against pNPP over time. C, pH dependence of TgLaforin activity
against potato amylopectin.
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Figure 3.12 Full-length TgLaforin is an active glucan phosphatase that
preferentially dephosphorylates starch at the C3 position.
A, TgLaforin activity against pNPP is both dose and time-dependent and
abrogated when the catalytic cysteine (C452) is mutated to serine (C/S). B,
TgLaforin releases phosphate from solubilized potato amylopectin, whereas the
C/S mutant and VHR cannot. C, TgLaforin preferentially dephosphorylates glucose
from insoluble, 33P-radiolabeld A. thaliana starch at the C3 position. Statistical
comparison of site specificity was done using an unpaired two-tailed t-test;
statistical significance: ****p<0.0001.
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Figure 3.13 Development of a novel glucan phosphatase inhibitor.
A, The structure the TgLaforin inhibitor L319-21-M49. B, Classification tree of the
phosphatases used in this study. Abbreviations: AP = alkaline phosphatase; CIP
= calf intestinal phosphatase; DSP = dual-specificity phosphatase; PTP = protein
tyrosine phosphatase; VHR = Vaccinia H1-related phosphatase
L319-21-M49 design, screen, and synthesis by Rongjun He, Ph.D., Jianping Lin,
Ph.D., and Li Wu under the direction of Zhong-Yin Zhang, Ph.D.
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Figure 3.14 Determination of TgLaforin kinetic parameters.
A, TgLaforin (50 nM) activity over the course of 10 min. B, TgLaforin activity over
time with varying substrate concentration. C, Determination of Km and Vmax of
TgLaforin by plotting initial velocities from 3.14b against substrate concentration.
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Figure 3.15 Linear range determination of phosphatases used in inhibitor
screening.
A, Phosphatase activity over the course of 10 min. B, Determination of Km and
Vmax of phosphatases by plotting initial velocities from against substrate
concentration. C, TgLaforin activity over the course of 10 min in amylopectin assay
(top panel) and site-specificity assays (bottom two panels).
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Figure 3.16 Testing of a novel glucan phosphatase inhibitor.
A, L319-M21-M49 inhibits TgLaforin activity against the model phosphatase
substrate pNPP with >100-fold specificity over other phosphatases. B, L319-M21M49 inhibits TgLaforin activity against soluble amylopectin, and C, activity against
insoluble starch with similar efficiency. Abbreviations: AP = alkaline phosphatase;
CIP = calf intestinal phosphatase; DSP = dual-specificity phosphatase; PTP =
protein tyrosine phosphatase; VHR = Vaccinia H1-related phosphatase.
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CHAPTER 4. BIOCHEMICAL AND BIOPHYSICAL CHARACTERIZATION OF
THE T. GONDII GLUCAN, WATER DIKINASE USING BOTH
CONVENTIONAL AND NOVEL METHODS
4.1 Introduction
The presence of covalently bound phosphate in starch has been recognized
since the 1970s (322,323), and its importance in facilitating starch breakdown via
a cycle of reversible glucan phosphorylation is discussed in sections 1.5.3 and
1.7.1. The introduction here will primarily serve to convey the general mechanistic
basis by which the glucan, water dikinase (GWD) both phosphorylates
carbohydrates (section 4.1.2) and binds to them (section 4.1.3).
4.1.1 The discovery of the role of GWD in starch phosphorylation and
degradation
The role of GWD in plant starch degradation was first documented in 1991
before any knowledge of its enzymology. Plants mutagenized by irradiation were
placed in the dark for 3 days, and those displaying starch-excess (sex) phenotypes
at the end of the dark stress were subsequently selected and studied (324). Of
particular interest in this initial study was the line designated “sex1,” in which
enlarged starch morphology was visualized both by iodine staining (324) and
electron microscopy (325), but the mechanistic basis underlying this phenotype
was not then ascribed to a glucan dikinase. The first indication that a glucan
dikinase played a role in starch phosphorylation and turnover was suggested in a
1998 study that knocked down a starch-associated kinase that was then named
“R1” (238). After knockdown of R1, mature leaves stained heavily with iodine
(indicative of a starch excess, i.e. sex, phenotype), starch granules from these
leaves had much lower phosphate levels, and degradation of starch during the
night was demonstrated to be diminished without R1.
Several years later, another group determined the DNA sequence of the sex1
locus and discovered that sex1 encoded an amino acid sequence with significant
homology to the R1 protein, suggesting that they may be the same protein (326).
It was also demonstrated that this protein contained a dikinase domain, multiple
“starch granule association domains,” and a chloroplast transit peptide (326).
Production of recombinant Solanum tuberosum (potato) GWD (StGWD) confirmed
these domain predictions in a subsequent study (167). Incubation of the protein
with various substrates then lead to the conclusion that GWD utilizes a dikinase
mechanism that transfers the -phosphate from ATP to starch, and simultaneously
releases orthophosphate and AMP. As such, this reaction was determined to have
3 substrates: ATP, H2O, and an -glucan, and to release 3 products: AMP,
orthophosphate, and a phospho--glucan.

4.1.2 The dikinase mechanism of GWD
The mechanism by which GWD/R1/SEX1 phosphorylates starch was
determined in a series of studies following its identification (167,266,327), depicted
in Figure 4.1. First, multiple groups determined that the -phosphate from ATP is
transferred directly to GWD in an autophosphorylation reaction that results in the
formation of a phospho-histidine enzyme intermediate. The phosphate is then
transferred from the catalytic histidine directly to the hydroxyl group of a glucosyl
reside in starch to form a phosphate-ester at the C6 position. This is accompanied
by the release of AMP, the -phosphate from ATP (orthophosphate), and the newly
phosphorylated glucan (167). The contribution of each GWD domain to this
catalytic activity was directly demonstrated using limited proteolysis and domain
truncations of StGWD, revealing that autophosphorylation depends on a
phosphohistidine (His) domain, and that ATP binding depended on a nucleotide
binding domain (NBD) (327). Importantly, the His+NBD domains constitute a
phosphoenolpyruvate-dikinase-like (PPDK-like) region of the protein (Figure
4.1a).
Protein dynamics were also determined by use of circular dichroism (CD) that
demonstrated a significant conformational change in StGWD upon
autophosphorylation, and this change was shown to be independent of ATP
binding. This data was consistent with previous studies that proposed a swivel
mechanism by which a His-domain could interact with both the NBD and its other
substrate binding domain after autophosphorylation through insights provided by
the crystal structure of the Cenarchaeum symbiosum PPDK (328,329).
With these mechanistic and structural data, the entire catalytic cycle by which
GWD phosphorylates glucans was proposed (327), and is presented in Figure
4.1a. Step 1: Apo-GWD binds ATP via Mg2+-dependent electrostatic interactions
within the NBD. Step 2: The catalytic histidine residue within the His-domain forms
a phospho-histidine intermediate with the -phosphate from ATP, with
simultaneous release of AMP and transfer of the -phosphate to H2O, releasing
orthophosphate. The His-domain also undergoes a long-range movement from the
NBD toward the CBM domains. Step 3: GWD binds to a glucan substrate via its Nterminal CBM domains, and the -phosphate is then transferred to the C6 position
of the glucan substrate. Step 4: The phospho-glucan is released, and the Hisdomain moves back toward the NBD.
The dynamics of the His-domain movement between the two substrate binding
domains is not well understood, but the His-domain has been noted to be flanked
by two flexible polypeptides that display both helical and disorganized
characteristics (328). Therefore, these linkers may allow for significant
displacement from either 1) autophosphorylation resulting in repulsion of the Hisdomain from the NBD domain, or 2) constant movement of the His-domain
between its substrate-binding domains.
96

4.1.3 GWD orthologues possess a CBM45 for starch binding
The N-terminus of GWD was determined to be critical in carbohydrate binding
as its domains were initially being classified (327), and the novelty of its N-terminal
CBMs was subsequently recognized in both primary amino acid sequence and
substrate preference (254). The N-terminal CBMs were shown to confer specificity
to amylopectin, as truncation constructs lacking the CBMs were able to
phosphorylate a wider variety of linear glucans such as amylose. No GWD
constructs, however, were able to efficiently phosphorylate glycogen,
demonstrating the specificity of this new CBM for crystalline, branched substrates.
Moreover, several tryptophans were classified as critical to carbohydrate binding,
as is often the case in CBMs (298). This unique CBM has since been classified as
a CBM45 (CAZy.org).
Thus far, CBM45s have been restricted to GWD orthologues and to plastidial
-amylase3 enzymes (AMY3) (330). No CBM45 structure has been published, but
it has been modeled using Phyre2 and is predicted to adopt the immunoglobulinlike fold that is common in starch binding domains (SBDs) (331). Interestingly,
CBM45s appear to be restricted to organisms that produce semi-crystalline
glucans such as starch (330). CBM45s are often present in tandem within the
same protein and possess a low affinity for starch that is believed to allow for their
dynamic association with starch granules.
4.1.4 A GWD orthologue in T. gondii
The presence of a GWD orthologue in T. gondii (TgGWD) has been well
documented (40,203,206,212,228), and TgGWD has been suggested to be a
target of CDPK2, a T. gondii plant-like kinase that orchestrates starch turnover in
T. gondii (228). To further elucidate the biochemical and biophysical underpinnings
of reversible phosphorylation in T. gondii we expressed recombinant TgGWD and
demonstrate that it employs the standard glucan, water dikinase mechanism
utilized by other GWD orthologues. Moreover, we define its site specificity,
demonstrate that it exists as a monomer in solution, and develop a novel assay by
which to monitor AMP release by TgGWD. The monitoring of AMP release will be
of use in dikinase inhibitor screening or as a means by which to more fully
understand the GWD mechanism.
4.2 Results
4.2.1 T. gondii encodes a putative glucan, water dikinase orthologue
The amino acid sequence of TgGWD was retrieved from ToxoDB.org
(TGME49_214260) and was analyzed using the conserved domain database
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(CDD). The CDD recognized only the PPDK region at its C-terminus, but the
remainder of the protein was undefined. To determine if TgGWD contains one or
more CBM45s as other GWD orthologues do (254), the undefined N-terminus was
aligned with CBM45 domains from StGWD and A. thaliana GWD (AtGWD) (Figure
4.1b). This alignment revealed that TgGWD indeed contains at least two CBM45s
at its N-terminus, each containing the consensus carbohydrate-binding tryptophan
residues characteristic of CBM45s. Moreover, TgGWD contains the required
catalytic histidine within its His-domain, demonstrating that TgGWD is composed
of the three domain types that are characteristic of GWD orthologues: two
CBM45s, a His domain, and an NBD (Figure 4.1b). Despite containing all the
required domains, TgGWD displays low sequence similarity and identify with other
GWD orthologues (Figure 4.1b). TgGWD is only ~36% similar and ~21% identical
to St- and AtGWD, respectively. These values are quite low in comparison to
StGWD and AtGWD sharing 77.8% and 66.1% similarity and identity, respectively.
Interestingly, it appears possible that transcription of TgGWD is upregulated in
bradyzoites by RT-PCR (40). The upregulation of TgGWD with the simultaneous
appearance of an insoluble glucan in T. gondii creates temptation to speculate
about the role of TgGWD in AG formation given its restriction to organisms that
possess an insoluble polyglucan. However, transcriptomic data made available on
ToxoDB.org does not support the RT-PCR data, and instead suggests that
TgGWD transcription remains constant across the asexual life stages (332)
(Figure 4.1c).
4.2.2 TgGWD utilizes a standard glucan dikinase mechanism
To determine if TgGWD is an active glucan, dikinase, we expressed full-length
recombinant 6xHis-TgGWD in Sf9 insect cells and purified it to >95% homogeneity
using size-exclusion chromatography (Figure 4.2a). To determine if TgGWD
autophosphorylates itself with the -phosphate from ATP, TgGWD was incubated
with both 33-ATP and 33-ATP for 30 mins before purified protein was separated
by SDS-PAGE to remove all excess radio-labeled ATP. The gel containing
TgGWD then was exposed to a phosphor screen, and then radioactive bands
corresponding to autophosphorylated protein were imaged. Detection of radiolabeled protein revealed that TgGWD-WT, like StGWD, autophosphorylates with
the -phosphate from ATP, and not the -phosphate (Figure 4.2b). Moreover,
mutation of the catalytic histidine to an alanine, H1241A (H/A), demonstrated that
TgGWD also utilizes the histidine residue identified via sequence alignment to form
a phospho-histidine intermediate with the -phosphate (Figure 4.2b). Curiously, it
was noted that the H/A mutant appeared to incorporate the -phosphate from ATP
whereas the H/A mutant of StGWD did not. A study noted the incorporation of phosphate into both St- and AtGWD previously (333), although it was not seen
here. GWD orthologues display a wide variety of specific activities (333), and it is
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possible that TgGWD incorporates -phosphate at a higher rate than StGWD. This
phenomenon was repeatable, but not explored further in this study.
After autophosphorylation, GWD then transfers phosphate from the phosphohistidine to its glucan substrate. To determine if TgGWD retains this ability,
TgGWD was incubated with both 33-ATP and 33-ATP in the presence of Atsex1-3 starch (phosphate-free starch) for 4 hours. Radioactive phosphate
incorporation into starch was then determined using a scintillation counter after
extensive washing to remove all other reaction components. As expected, TgGWD
utilizes the -phosphate from ATP to phosphorylate starch as evidenced by its
incorporation into starch, and not the -phosphate to any appreciable extent
(Figure 4.2c), demonstrating that TgGWD employs the same dikinase mechanism
seen in other GWD orthologues.
The incorporation of -phosphate into insoluble starch by TgGWD was then
monitored over the course of 12 hours by incubating TgGWD with phosphate-free
starch and 33-ATP (Figure 4.3a). TgGWD displayed time-dependent kinetics in
starch phosphorylation, and the catalytically inactive mutant, TgGWD-H/A, was
unable to transfer any phosphate to starch (Figure 4.3a). Plant starch is
phosphorylated at both the C6 and C3 positions. To determine if TgGWD
phosphorylates the C6 or C3 position of glucosyl units within starch, a previously
developed glucan dikinase site specificity assay was used (Figure 4.3b). Briefly,
TgGWD was incubated with phosphate-free starch and 33-ATP for 16 hours. To
determine where TgGWD places phosphate on glucosyl-residues, TgGWD-treated
starch was then incubated with a C3-specific phosphatase (LSF2), and the
supernatant from this reaction was monitored on a scintillation counter. LSF2
removed no phosphate from the TgGWD starch (Figure 4.3c), indicating that
TgGWD does not phosphorylate the C3-position. Starch was then
dephosphorylated with SEX4, a glucan phosphatase that removes both C6 and C3
phosphate (with a preference for C6), and the supernatant was measured. SEX4
released almost 20% of the TgGWD-added phosphate within 15 minutes,
indicating that TgGWD phosphorylates starch at exclusively the C6 position
(Figure 4.3c). Interestingly, this is the opposite site-specificity of TgLaforin (Figure
3.12c). It should be noted, however, that this does not result in the incompatibility
of these two enzymes, as TgLaforin does not exclusively dephosphorylate the C3
position and can also remove C6 phosphate.
4.2.3 Biophysical properties of TgGWD
To determine if TgGWD is stabilized in the presence of its various substrates,
dual scanning fluorimetry (DSF) was utilized to monitor the melting temperature
(Tm) of TgGWD with or without carbohydrates and ATP as done previously (185).
An increase in melting temperature in the presence of various substrates suggests
protein-ligand interaction. In the presence of linear oligosaccharides, TgGWD
displayed very little or no increase in stabilization (Figure 4.4a). This is not
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altogether surprising as linear glucans such as amylose have been demonstrated
to be a much poorer substrate for StGWD than a branched glucan, such as
amylopectin (266). However, in the presence of ATP, TgGWD was stabilized by
almost 4 oC in comparison to the apo-protein (Figure 4.4a).
It has been previously reported that StGWD forms a stable homodimer in
solution that is not dependent on autophosphorylation or substrate binding (266),
with dimerization most likely mediated through the PPDK domain (254). To
determine the quaternary structure of TgGWD, size-exclusion chromatography
coupled to multi-angle light scattering (SEC-MALS) was utilized to determine the
molecular weight of TgGWD in solution, as has been done previously with other
glucan binding recombinant proteins (262). As expected, TgGWD eluted as a
single peak at an earlier volume than the elution standards (Figure 4.4b). The
elution volume is consistent with its predicted molecular weight of 197.8 kDa that
exceeds those of the standards used in this study. Interestingly, TgGWD was not
retained on the column due to its CBM domains, a phenomenon that has been
previously reported in CBM20-containing laforin orthologues (262) and
demonstrated in Figure 3.10. Moreover, MALS analysis predicted that TgGWD
has a MW of 191.4  .5 kDa (Figure 4.4b). Compared with the calculated MW for
recombinant TgGWD of 197.8 kDa, the MALS prediction indicates that TgGWD is
a monomer in solution, unlike StGWD.
4.2.4 Development of a CE-based assay to monitor glucan dikinase activity
The standard for monitoring glucan dikinase activity relies on radioactive ATP
that is both a costly reagent with many associated laboratory regulations, and one
that requires extensive washing to remove background. Such issues are
prohibitive to high throughput inhibitor screens of glucan dikinases for downstream
use as potential therapeutics against parasitic organisms such as T. gondii.
The labeling of starch with the -phosphate from ATP is accompanied the
release of AMP and the -phosphate. Therefore, it was reasoned that monitoring
the release of AMP during the course of the dikinase reaction could provide an
alternative to monitoring 33P incorporation into starch and eliminate the need for
washing out the reaction. Capillary-electrophoresis (CE) is a technique that has
been used to analyze nucleotides previously (334). CE takes advantage of UVabsorbance by nucleotides for detection, and the ability of electrophoretic
techniques to separate nucleotides based on their migration through a charged
field (335). An important consideration in dikinase assays are the relatively low
amounts of AMP released in a reaction, resulting in mid-nM to low-M final
concentrations. Because the path length of light analyzed by CE is short, low
sample concentrations present a problem for this technique.
To circumvent the problem presented by low AMP concentrations, a method
known as whole capillary stacking has been developed for CE (267) (illustrated in
Figure 4.5a). Briefly, Step 1: a capillary is filled with a sample mixture containing
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a compound of interest using a vacuum to draw sample in. Step 2: a highly
negative charge is applied to the capillary to move compounds back toward the
buffer at the negative electrode, both removing positive compounds and
simultaneously stacking negative compounds at the buffer/capillary interface. This
step effectively concentrates low-abundance molecules into a small volume. Step
3: the voltage is reversed to a highly positive charge, and negative components
are separated over the volume of the capillary, and an absorbance detector is
utilized to monitor compounds at wavelengths of interest. In the case of monitoring
nucleotides, the UV-Vis detector is set to 256 nm.
To determine if AMP/ATP could be separated with buffer, injection, and voltage
conditions specified in section 2.1.15, 10 M AMP was mixed with 50 M ATP (the
amount used in in vitro labeling reactions) and run using the whole stacking
methodology. Peaks corresponding to AMP and ATP could be resolved from one
another (Figure 4.5b), as these retention times were confirmed with each
nucleotide alone. AMP always eluted at about 14 mins under the specified
conditions. To determine the linear range in which AMP could be detected, a range
of concentrations of AMP were run on the CE (Figure 4.5c), and the area under
each peak was determined and plotted against AMP concentration (Figure 4.5d).
Using this technique, the linear range of AMP detection was determined to be 100
nM up to 10 M, although concentrations outside of this range were not tested.
To determine if AMP release from a glucan dikinase reaction could be
monitored using this CE-based assay, 50 nM TgGWD was incubated with
phosphate-free starch and ATP, and the reaction was terminated at various time
points from 1-12 hours. After terminating reactions, starch was pelleted, and the
supernatant was saved for AMP analysis. Before analyzing the supernatant on the
CE, protein was filtered out using centrifugal filtration to provide cleaner UV-Vis
spectra. The flowthrough from the filtration containing the AMP was then analyzed
by whole capillary stacking on the CE. AMP release by TgGWD-WT could be
monitored using this technique in a time dependent manner, whereas TgGWD-H/A
released no AMP over the course of the reaction, validating that the assay was
specific to the dikinase mechanism (Figure 4.5e). Interestingly, AMP release
remained linear over the course of the 12 hour reaction, which contrasted with the
results obtained from direct incorporation of phosphate into starch that clearly level
off by 8 hours (Figure 4.3a). This prompted the direct comparison of the two
methods. Strikingly, release of AMP appears to occur at a much more rapid rate
than phosphate addition onto starch, even at early timepoints (Figure 4.5e). This
observation suggests the possibility that AMP production by TgGWD is
stoichiometrically uncoupled from its transfer of phosphate to starch.
4.3 Discussion
Herein, we demonstrate that T. gondii encodes an active glucan, waterdikinase that employs a standard GWD mechanism. TgGWD first utilizes the 101

phosphate from ATP to autophosphorylate itself on a conserved histidine residue
within its PPDK domain. Next, TgGWD transfers the -phosphate from the
phospho-histidine intermediate to the C6 position of a glucan substrate while
simultaneously releasing orthophosphate and AMP. Moreover, we developed a
CE-based assay for the detection of AMP released as a result of this reaction that
is specific to the catalytically active protein.
Importantly, demonstration of the activity of TgGWD in vitro paves the way for
the therapeutic targeting of this plant-like protein in the human parasite, T. gondii.
Such targeting could begin with widely available kinase inhibitor screens coupled
with the relatively high throughput CE-based assay that requires no radioactive
ATP, minimal centrifugation, and largely unmonitored analysis of AMP release.
While this assay cannot monitor the transfer of phosphate to a glucan substrate, it
monitors the hydrolysis of ATP to AMP+Pi during the autophosphorylation step.
Thus, identified kinase inhibitors would be specific to the ATP hydrolysis that
occurs in Steps 1 and 2 depicted in Figure 4.1a.
Previous studies have demonstrated that the GWD mechanism is likely more
complicated than the one that is typically presented (176,333). One study
demonstrated that levels of autophosphorylated GWD decreases over time after
separation from 33-ATP in the absence of any glucan, implying that phosphate
transfer from the catalytic histidine does not necessitate the presence of a glucan
(176). In fact, a follow up study demonstrated that 20% of ATP utilized by GWD
does not result in phosphate transfer to a glucan substrate (333), calling into
question the 1:1:1 stoichiometry that has been proposed for the products of the
reaction (167). Moreover, it was demonstrated that GWD can continuously
hydrolyze ATP in the absence of any glucan acceptor (333).
The data presented here support the observations that ATP hydrolysis is
uncoupled from the formation of glucosyl phosphate esters, as release of AMP far
exceeds the placement of phosphate on starch (Figure 4.5e). Moreover, the linear
reaction kinetics of AMP release versus the plateau effect seen during phosphate
transfer implies a potential saturation of the starch surface granule with phosphate.
Utilization of assays such as CE that monitor reaction products like AMP in
comparison with the generation of a phosphorylated glucan could help reveal the
limits of starch granule surface phosphorylation.
In addition to demonstrating GWD hydrolyzes ATP faster than it transfers
phosphate to starch, it was also previously demonstrated that both WT and H/A
mutants of GWD could autophosphorylate with the -phosphate from ATP (333).
This observation implies the presence of a histidine outside of the canonical active
site that can bind this terminal phosphate, possibly as the first step in generating
orthophosphate. Such a histidine, however, awaits identification. Once again, the
data presented here support the possibility of a second phospho-histidine
intermediate as significant labeling of TgGWD-H/A was also seen with 33-ATP.
Overall, these observations confirm the presence of a canonical GWD
orthologue in T. gondii, possessing multiple CBM45 domains and a PPDK domain.
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We demonstrated that TgGWD behaves as a standard glucan, dikinase, in both
the well characterized aspects of GWD enzymology and the newly suggested
peculiarities inherent to the mechanism. These observations also lay the
groundwork for dissecting the general GWD mechanism further through the use of
a novel method for the detection of AMP release, and thus provides another
perspective on GWD activity. Future work in identifying compounds to inhibit
TgGWD for testing as therapeutics can use the reagents and methods developed
here.
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Figure 4.1 TgGWD bioinformatics and expression.
A, Glucan, water-dikinase swivel mechanism. Steps 1-4 discussed in Section
4.1.2, figure adapted from Mikkelsen, et al. (2005) (327). B, Alignment of TgGWD
N-terminus and His-domain with AtGWD and StGWD. Orange residues are
conserved tryptophans found in CBM45s. % Similarity and % ID presented for fulllength proteins. C, Comparative levels of TgGWD mRNA in tachyzoites and
bradyzoites alongside levels of the bradyzoite marker, SRS9 for comparison.
Transcriptomic data was plotted from ToxoDB.org derived that is based on data
from Fritz, et al (332). Abbreviations: CBM = carbohydrate binding module; His =
phosphohistidine domain; NBD = nucleotide binding domain; PPDK =
phosphoenolpyruvate dikinase.
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Figure 4.2 TgGWD employs a standard dikinase mechanism.
A, TgGWD was expressed in Sf9 insect cells and purified by IMAC/SEC. Purity
was evaluated using Coomassie. B, Autophosphorylation assay with both WT
TgGWD and H1241A (H/A) mutant with StGWD used as a control. All four proteins
were incubated with both 33P-ATP and 33P-ATP and then separated by SDSPAGE. Autophosphorylated protein is presented above total protein loaded as
determined by Coomassie staining. C, Total radio-labeled phosphate transferred
to starch after 4 h from either the  or -phosphate in ATP.
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Figure 4.3 TgGWD phosphorylates glucose at the C6 position in a time
dependent manner.
A, Time course assay monitoring -33P incorporation by TgGWD-WT and -H/A into
starch. B, Schematic of glucan dikinase site specificity assay as described in
section 4.2.2. C, C3-bound phosphate was determined by treatment of TgGWDlabeled starch by LSF2 (C3-specific phosphatase), and C6-bound phosphate was
determined with follow-up treatment of TgGWD/LSF2-treated starch with SEX4
(C6/C3 specific).
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Figure 4.4 Biophysical properties of TgGWD.
A, DSF analysis of TgGWD stabilization in the presence of DP7 (maltoheptaose;
7 linear glucosyl units), a mixture of high-MW sugars, and ATP. B, SEC-MALS
analysis of TgGWD compared elution profiles and predictions for ADH and BSA.
TgGWD was predicted to have a MW of 191.4  .5 kDa.
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Figure 4.5 Development of a CE-based assay for monitoring dikinase
activity.
A, Schematic of whole capillary stacking utilized for AMP detection, adapted from
Brown, et al. (1998) (267). Steps 1-3 are explained in section 4.2.4. B, Retention
times of AMP and ATP after whole capillary stacking, monitored using absorbance
at 256 nm. C, Representative curves of AMP at various concentrations. D, AMP
standard curve generated from (C). E, AMP release from TgGWD over the course
of 12 hours as determined by CE, compared with phosphate incorporation into
starch by radio-labeled ATP assay.
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CHAPTER 5. LOSS OF THE GLUCAN PHOSPHATASE, TGLAFORIN, IN T.
GONDII REVEALS A ROLE FOR AMYLOPECTIN GRANULES ACROSS
THE ASEXUAL LIFE CYCLE
5.1 Introduction
Toxoplasma gondii as an opportunistic protozoan parasite of humans, and all
warm-blooded animals, that infects one-third of humans worldwide (336). Humans
are primarily infected through the consumption of an encysted form of the parasite:
either the oocysts shed in cat feces or tissue cysts found in undercooked meat
from a chronically infected animal (85). The acute phase of infection then begins
when encysted parasites convert into tachyzoites that rapidly divide and
disseminate throughout the body of the host (278). The chronic infection begins
under host immune pressure resulting in the conversion of tachyzoites into slowgrowing bradyzoites that populate tissue cysts and are found predominantly in the
CNS and muscle tissue (97). Tissue cysts are believed to persist for the lifetime of
the host and facilitate transmission via carnivory or reactivation into tachyzoites
within their current host. In the context of immunosuppression, reactivation can
result in the life-threatening conditions posed by systemic toxoplasmosis with
toxoplasmic encephalitis being the primary condition (114). Current therapeutic
options are poorly tolerated with prolonged use and only effective against
tachyzoites (120,123). Thus, there is a need for the development of new antiToxoplasma treatments that can clear tissue cysts or prevent their reactivation.
The current lack of insights into bradyzoite physiology in vivo, however,
precludes the basic understanding needed for the development of drugs that can
clear them (96). This is highlighted by the fact that until recently, this form of the
parasite was viewed as being entirely dormant and largely devoid of metabolic
activity. Moreover, tissue cysts have been treated as homogenous entities with
little consideration for the heterogeneity of the bradyzoites within them (101).
Contrary to these prevailing notions, we demonstrated that individual bradyzoites
can indeed replicate within a tissue cyst (55), and that bradyzoites are diverse
regarding their physiological status as viewed through the lens of mitochondrial
activity, replication status, and amylopectin granule (AG) accumulation (337). Such
heterogeneity has been speculated to provide bradyzoites the plasticity needed to
navigate the cell-cycle mediated decisions underpinning their choices to persist as
bradyzoites, reactivate into tachyzoites, or convert into sexual cycle merozoite
forms in felids (54).
At the core of all bradyzoite developmental choices, and thus their ability to
remain plastic, must be stored energy and biosynthetic building blocks needed to
execute such transitions. Although their function has not been confirmed, an
understanding of the roles of polysaccharides elsewhere (144) has resulted in the
assumption that amylopectin granules (AG) are such a source of energy and
biosynthetic potential needed for persistence, replication, reactivation, and

transmission. However, these assumptions remain to be tested, and thus much
like bradyzoites themselves, AGs are poorly understood. What is known, however,
is that AGs are large glucans found in the cytoplasm of bradyzoites that have
classically served as a morphological feature distinguishing them from tachyzoites
(196,338). Early studies characterized AGs as pure amylopectin (40), so AGs are
much like plant starch in that they are insoluble storage polysaccharides composed
of branched chains of glucose. Unlike plant starch, however, AGs contain no
detectable amylose (unbranched chains of glucose) (40,197). More recently, it has
been demonstrated that tachyzoites also contain a small, punctate glucan in their
cytoplasm only visible by periodic-acid Schiff (PAS) staining (228,234), and its
presence is dependent TgStarchSynthase (TgSS) (203). Like animal glycogen,
this tachyzoite storage polysaccharide is rapidly turned over (228), as has been
observed in other protozoa (209,312,313), and has been previously demonstrated
to provide glucose for glycolysis (203). These recent discoveries highlight how little
has historically been understood about glucan metabolism in T. gondii.
Glucose release from starch in plants utilizes a suite of degradation enzymes
including amylases, debranching enzymes, and a phosphorylase that collectively
release glucose in multiple forms: glucose monomers, linear and branched
oligosaccharides, and glucose phosphates (339). In other systems containing
insoluble glucans such as plants, access of starch degrading enzymes is
dependent on solubilization of the starch surface by a cycle of direct, reversible
glucan phosphorylation (340,341) (Table 1.1 and Figure 1.4). The cycle begins
with the addition of phosphate directly to glucose by the glucan, water-dikinase
(GWD) and phospho-glucan, water dikinase (PWD) that results in the unwinding
of glucose chains within starch, solubilizing the surface (167,168). Glucosereleasing enzymes (amylases) then degrade starch until the added phosphate
becomes a steric hindrance, at which point a glucan phosphatase is needed to
remove the phosphate and reset the cycle (169,170,172,173). T. gondii encodes
all the activities needed for glucan degradation and reversible glucan
phosphorylation (212) including the glucan phosphatase, TgLaforin, and T. gondii
GWD (TgGWD).
Glucan access through reversible phosphorylation is critical in plants and
animals. In Arabidopsis thaliana, loss of a glucan phosphatase, starch-excess 4
(SEX4), results in excess starch accumulation and aberrant starch morphology
(174,239). Additionally, loss of the glucan phosphatase in humans (laforin) results
in hyperphosphorylated glycogen that precipitates in neurons and causes a fatal,
neurodegenerative childhood dementia and epilepsy (184,187,283,342). In T.
gondii perturbations of several genes related to glucan metabolism also resulted
in aberrant glucan accumulation (Ca2+ dependent protein kinase 2 [CDPK2],
glycogen phosphorylase [TgGP], and -amylase [-AMY]), a rewiring of central
carbon metabolism (CDPK2 and starch synthase [TgSS]), and decreased cyst
formation in mice (CDPK2, TgGP, -AMY, and amylo--1,6-glucosidase
[debranching enzyme; Aa16GL]), highlighting the central metabolic role glucan
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metabolism might play in T. gondii (highlighted in section 1.6.3)
(203,206,228,234,311).
CDPK2 was shown to have several targets related to glucan metabolism (228).
Importantly, TgGWD was suggested as a potential CDPK2 target, indirectly
suggesting a role for reversible phosphorylation in the parasite’s glucan
metabolism. More recently, it has been extensively demonstrated that glucose
plays critical, diverse roles in T. gondii metabolism through its incorporation into
central carbon reactions, amino acids, and RNA (210,211,226). Taken together
with the findings that loss of the tachyzoite glucan has profound effects in the
parasite, an understanding of how AGs are accessed in T. gondii is needed.
In this study, we build on our understanding of reversible glucan
phosphorylation and its relevance to parasite metabolism in T. gondii. We have
recently demonstrated that the glucan phosphatase in T. gondii, TgLaforin, is an
active, unique, and druggable glucan phosphatase in vitro (Chapter 3) (204,205).
Here, we investigated TgLaforin’s role throughout the asexual stages by knocking
out TgLaforin in Type II ME49 parasites. In tachyzoites, we demonstrate that
dysregulation of glucan breakdown via TgLaforin knockout results in a profound
impact on central carbon metabolism that renders the parasites completely
dependent on glutamine. This defect most likely results in their highly attenuated
virulence and cyst forming ability in CBA/J mice. Moreover, loss of TgLaforin
resulted in bradyzoites, both in vitro and in vivo, with altered AG morphology,
packing density in tissue cysts, and tissue cyst diameter. These findings build upon
previous studies that are increasingly demonstrating a central role for glucan
metabolism throughout the parasite’s asexual life cycle.
5.2 Results
5.2.1 Background and generation of the T. gondii parental strain used in this
study
Considerable effort has been made to characterize the molecular and
epidemiological structure of T. gondii around the globe. Early studies using
PCR/RFLP analysis characterized strains primarily obtained from North America
and Europe into three clonal lineages/haplotypes: Type I, II, and III (343). Several
years prior to this study, parasites in the Type I lineage were recognized as being
the most virulent in mice with an LD 100=1 tachyzoite (IP injection) (344), but Type
I parasites are unable to efficiently form tissue cysts in mice. Type II and III
parasites are also much less virulent in mice, but are much more prevalent in
humans in the Western Hemisphere. Importantly, Type II parasites are more often
associated with cyst formation and reactivation in the context of HIV-AIDS (3).
While it remains true that these three lineages dominate North America and
Europe, more recent studies analyzing much a wider geographical sampling have
defined at least 16 haplotypes of T. gondii organized into 6 different clades using
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a mixture of low-resolution molecular techniques and whole-genome-sequencing
(345,346). These haplogroups represent a spectrum of virulence characteristics
that range from avirulent to those predominantly from South America that can
cause symptomatic disease in immune competent individuals.
In the present study, we sought to select a strain of T. gondii that was relevant
to human infection and that would allow for studies across the asexual phase of
infection. We chose to use the ME49 strain from the Type II haplogroup, first
isolated from sheep muscle in the 1960s (347,348). This strain, obtained from the
HIV-AIDS resource center, is also used as a reference strain for genome
annotation. Importantly for this study, ME49 parasites are only mildly virulent
(although anecdotal evidence indicates selection for increased virulence with serial
passage in tissue culture), and readily form tissue cysts in mice (349). ME49
parasites are extensively characterized with genomic, proteomic, and
transcriptomic data readily available on ToxoDB.org.
We modified the wildtype ME49 line to eliminate the hypoxanthine-xanthineguanine phosphoribosyltransferase (HXGPRT) gene as has been done in a
commonly used and widely available Type I line of parasites
(RHku80HXGPRT). The HXGPRT gene provides a powerful tool for positive
and negative selection through its participation in the purine salvage pathway in T.
gondii (350), and we desired such a tool for downstream genetic manipulations,
including the selection of complementation lines for gene knock-outs using DHFR
as the selection. The mechanism underlying this tool stems from T. gondii’s purine
auxotrophy that renders the parasite reliant on purine interconversion using its
purine salvage pathway (351). HXGPRT plays an critical role in purine
interconversions (detailed in Figure 5.1a), and its enzymatic activity can be taken
advantage of using subversive purine analogues such as 6-thioxanthine (6-TX)
(350). HXGPRT converts 6-TX to the IMP dehydrogenase (IMPDH) inhibitor, 6thioXMP, which results in a guanine nucleotide deficiency (Figure 5.1a, bottom)
(352). Because loss of HXGPRT can be circumvented by other enzymes in the
salvage pathway, HXGPRT parasites can be selected for using 6-TX with no
growth penalty imposed on the mutant parasites (6,353). Restoration of HXGPRT
can be selected for using mycophenolic acid (MPA) with Xanthine
supplementation. MPA is also an inhibitor of IMPDH (an enzyme also critical in
circumventing loss of HXGPRT), which when supplemented with xanthine
provides HXGPRT+ parasites the substrate needed for XMP synthesis (an
HXGPRT activity) in the absence of functioning IMPDH (Figure 5.1a, top) (350).
Deletion of HXPGRT thus allows for genetic manipulations linked to its restoration,
including gene complementation and epitope tagging (354).
To knockout HXGPRT using a CrispR-CAS9 based strategy, three synthetic
guide RNAs (sgRNA) were selected from a previous study to target three separate
exons and transfected alongside CAS9 to introduce double stranded breaks
throughout the gene (Figure 5.1b) (10). As has been shown previously in T. gondii,
this is an efficient way to allow nonhomologous end-joining (NHEJ) machinery to
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create insertions or deletions that ultimately disrupt the gene in the parasite (268).
As loss of HXGPRT provides its own drug selectable marker, only the
CRISPR/Cas9 system utilizing the three sgRNAs was transfected in the absence
of any additional drug resistance genes. HXGPRT parasites were selected with
6-TX, and disruption of the HXGPRT gene was confirmed using sequencing
(Figure 5.1c). In the clonal line of HXGPRT parasites that were selected, NHEJ
joined the double strand breaks introduced in exon 2 and exon 5 resulting in a
1214 nucleotide deletion in the HXGPRT gene and a fusion of these two exons.
Moreover, exon fusion resulted in a downstream frameshift that introduced a stop
codon in exon 5 (Figure 5.1c). For the remainder of this study, ME49HXGPRT
parasites are used as the parental line and will be designated as wild type “WT.”
5.2.2 T. gondii tachyzoites contain, punctate, cytoplasmic glucan granules
Previous studies have presented biochemical evidence for rapid glucan
turnover in T. gondii Type I RH tachyzoites (228). Moreover, small PAS+ granules
have also been noted in the cytoplasm of tachyzoites as well (203,228). Under
acid-stress conditions, these tachyzoite glucans have been biochemically
characterized as pure amylopectin, and resemble AGs seen in bradyzoites (197).
To further characterize the nature of this glucan found tachyzoites, we utilized
multiple methods to visualize them under normal media conditions (Figure 5.2a,
top). Type II ME49 tachyzoites contain small punctate glucan granules distributed
throughout the cytoplasm with 5-10 granules being noted per parasite. To
determine if these PAS+ granules were more glycogen- or starch-like in
unstressed tachyzoites, they were next stained with IV58B6, an anti-glycogen IgM
monoclonal antibody that has previously been demonstrated to be specific to
glycogen (355,356) and is has been shown to recognize glycogen branch-points
(357). Moreover, IV58B6 does not detect other glucans such as amylopectin or
amylose (the primary constituents of plant starch) (358). Tachyzoites stained with
a similar pattern to PAS-stained parasites, containing 5-10 small punctate granules
distributed throughout the cytoplasm (Figure 5.2a, top), suggesting that the glucan
found in tachyzoites is more glycogen-like than starch like. Finally, as is wellknown, T. gondii tachyzoites contain almost no visible glucan within their
cytoplasm by TEM (Figure 5.2a, top), suggesting that the glucan detected by both
PAS staining and IV58B6 is either soluble or too small to be resolved by TEM,
another suggestion that this glucan may be like glycogen (the distinguishing
properties of starch and glycogen are presented in section 1.5.1 and Figure 1.3).
Bradyzoites have been extensively characterized as containing a starch-like
glucan known as amylopectin granules (AGs) (40,135,196,197). Upon in vitro
conversion to bradyzoites, much of the cytoplasm becomes PAS+, precluding the
ability to count individual AGs (Figure 5.2a, bottom). Interestingly, IV58B6
staining intensity appeared to correlate negatively with Dolichos lectin (DBA)
staining intensity that defines the cyst wall, suggesting that IV58B6 does not stain
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the PAS+ glucan in mature bradyzoites, further reinforcing that structurally distinct
polysaccharides exist in tachyzoites and bradyzoites (Figure 5.2a, bottom).
Finally, AGs are easily identified as electron-lucent structures throughout the
bradyzoite cytoplasm by TEM. Notably, these structures do not appear to stain
with IV58B6.
To verify the specificity of PAS and IV58B6 for glucose polymers, tachyzoites
and bradyzoites were treated with acid--amyloglucosidase (GAA) before staining.
GAA cleaves both -1,4- and -1,6-glycosidic bonds and can therefore completely
digest any glucan. Indeed, GAA treatment resulted in the disappearance of both
stains (Figure 5.2b), demonstrating their specificity for glucose polymers.
5.2.3 TgLaforin colocalizes with the tachyzoite glucan
Because T. gondii contains a glucan phosphatase, TgLaforin, that is more
animal-like than plant-like (204,205), we epitope-tagged TgLaforin to determine if
it co-localizes with the potentially glycogen/animal-like glucan in tachyzoites.
TgLaforin was epitope-tagged using a CRISPR/Cas9 mediated strategy as has
been done previously (269); a sgRNA was transfected into T. gondii Type II
ME49HXGPRT targeting a PAM immediately downstream of TgLaforin’s stop
codon, and this construct was introduced alongside a donor patch containing the
3’-end of TgLaforin fused to a 3xHA tag (Figure 5.3a). The HA-tagged gene was
linked to the HXGPRT gene, allowing for selection of TgLaforin-HA-tagged
parasites with MPA/xanthine. Successful HA-tagging was confirmed by the
presence of an ~60-kDa HA-tagged protein by western-blot (Figure 5.3b).
Immunofluorescence (IF) analysis of T. gondii tachyzoites indicated that TgLaforin
is present in small puncta throughout the cytoplasm, similar to the distribution of
the tachyzoite glucan (Figure 5.3c). Surprisingly, we saw TgLaforin was seemingly
absent in in vitro bradyzoites by IF analysis.
To verify that TgLaforin levels decrease during the tachyzoite to bradyzoite
transition, we converted T. gondii tachyzoites to bradyzoites using alkaline stress
for 6 days and compared equal numbers of parasites by western blot. As seen by
IF staining, TgLaforin-HA expression decreases dramatically over the course of
bradyzoite differentiation (Figure 5.4a), even though transcriptomic data obtained
from a previous study (332) indicates that transcript levels of TgLaforin do not
change (Figure 5.4b). This indicates the possibility that post-translational
regulation of TgLaforin is responsible for its decline in bradyzoites, and that the
down regulation of TgLaforin may be related to the growth and appearance of
crystalline AGs by TEM.
To determine if TgLaforin colocalizes with the glucan present in tachyzoites or
with AGs in bradyzoites, we co-stained TgLaforin-HA-tagged tachyzoites and
bradyzoites with either PAS or IV58B6 along with an anti-HA antibody. In
tachyzoites, TgLaforin almost completely colocalized with both PAS (Figure 5.3d)
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and with IV58B6 (Figure 5.3e), suggesting its involvement in the metabolism of
the tachyzoite glucan.
5.2.4 Loss of TgLaforin and its impact on T. gondii tachyzoites and bradyzoites
To further dissect TgLaforin’s role in relation to glucan metabolism in T. gondii,
TgLaforin was knocked out using a CRISPR/Cas9-GFP approach (268). Cas9 was
targeted to the first exon of TgLaforin and was transfected alongside a
pyrimethamine-resistant form of DHFR (DHFR-TS*) under an NcGRA7 (Neospora
caninum GRA7 promotor) (359) with the goal of gene replacement using the DHFR
marker (Figure 5.5a). To achieve this, the linear DFHR-TS* construct was flanked
by 40nt homologous sequence to TgLaforin in Exon 1 and 3’UTR on the 5’ and 3’
end, respectively, using PCR (Figure 5.5b). Transfected parasites were allowed
to recover for 24 hours post-transfection, and then GFP+ parasites expressing
Cas9 were selected to enrich the pool of successful transformants (Figure 5.5c).
In agreement with previous reports (10), TgLaforin is a non-essential gene under
standard cell culture conditions, as a TgLaforin-KO clone was successfully
recovered (TgLaf). Integration of the DHFR construct into the TgLaforin locus
was verified using inside/out PCR at the chimeric locus (Figure 5.5d) along with
verifying the loss of TgLaforin transcription (Figure 5.5e).
To evaluate the effects of loss of TgLaforin on T. gondii, we first compared
glucan levels in WT and TgLaf tachyzoites using our suite of glucan detection
techniques (Figure 5.6a). Surprisingly, the size and number of PAS+ granules
were unchanged in TgLaf tachyzoites relative to WT parasites. Levels of IV58B6
also remained unaltered after the loss of TgLaforin, and no aberrant glucan
accumulation was observed by TEM as has been observed previously when genes
related to AG or central carbon metabolism were knocked out (206,228,234,235).
To determine if loss of TgLaforin resulted in bradyzoite conversion defects or
aberrant AG accumulation, parasites were converted to bradyzoites in vitro under
alkaline stress and monitored for defects related to the loss of TgLaforin (Figure
5.6b-c). During differentiation, the parasitophorous vacuole (PV), the replicative
niche established by tachyzoites within host cells, converts into the cyst wall that
surrounds bradyzoites within their host cell (100,360). In general, the cyst wall is
heavily glycosylated and contains N-acetylgalactosamine (Gal-NAc) that is
detectible by the lectin Dolichos biflorus agglutinin (DBA) (361). Using DBA
intensity as a marker for the progress of differentiation, we again saw no penalty
imposed by the loss of TgLaforin on cyst wall formation over the course of six days,
indicating that TgLaf parasites are not defective in the initial stages of bradyzoite
differentiation (Figure 5.6b). Moreover, when we stained bradyzoites with PAS
over the course of six days, we again saw no difference in accumulated AG levels
(Figure 5.6c).
Because PAS is not specific to glucans and can stain other glucose-containing
molecules such as glycosylated protein, and provides no resolution on glucan
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morphology, we utilized TEM to gain higher resolution on bradyzoite differentiation.
After 6 days of conversion, it was noted that a TgLaf parasites contained irregular
AGs that were not commonly found in WT parasites (Figure 5.7a). In WT parasites,
the AGs were largely white in appearance and organized in ovoid or circular
shapes. However, the TgLaf parasites contained AGs that were often gray, with
the appearance of being flattened and irregular in shape that seemed to occupy
more of the cytoplasm than the WT granules occupied. To quantify this, the area
of AGs was calculated relative to the parasite area in both WT and TgLaf strains
(Figure 5.7b). Strikingly, AGs occupied approximately 4x more area in KO
parasites when compared to WT. Additionally, when analyzed on an 8-bit gray
scale, AGs in TgLaf parasites were significantly grayer than those found in WT
parasites (Figure 5.7b).
To demonstrate aberrant AG accumulation in in vitro bradyzoites was specific
to the loss of TgLaforin, the TgLaf line was complemented with an HA-tagged
TgLaforin cDNA under its native promoter containing the HXGPRT selectable drug
marker (Figure 5.8a). The complementation construct was inserted into a locus
previously identified in Chromosome VI as having no coding sequences or
regulatory elements (270). Therefore, true complementation was achieved by
leaving the TgLaf/DHFR-TS* knockout scar intact. A complemented line was
successfully identified (COMP) by PCR (Figure 5.8b), and TgLaforin expression
was verified using Western Blot (Figure 5.8c), and the cytoplasmic, punctate
staining was restored by IF analysis (Figure 5.8d). Importantly, western blot
analysis demonstrated that endogenous levels of expression were restored
(Figure 5.8c).
After examination and quantification of AGs in the COMP line, it was noted that
the COMP line did accumulate a low level of aberrant AGs, but COMP parasites
did not demonstrate a statistically significant difference in AG levels as was found
in TgLaf parasites (Figure 5.7a-b), suggesting complementation was successful.
Moreover, complementation restored AGs that were more similar to those found in
WT parasites as they were also whiter in appearance.
5.2.5 Loss of TgLaforin results in upregulation of glutaminolysis in tachyzoites
Despite the fact that loss of TgLaforin had no gross morphological effect on the
tachyzoite glucan, the observation that its loss did indeed impact AGs in
bradyzoites implies that TgLaforin does have a role in glucan metabolism in T.
gondii. Because glucan catabolism is significantly affected by the presence of
covalently bound phosphate, we speculated that loss of TgLaforin resulted in the
inability of T. gondii bradyzoites to breakdown their AGs efficiently. To first
determine if this was having any metabolic effects in tachyzoites, a more tractable
stage for such studies where TgLaforin expression is higher, we employed GC/MS
steady-state metabolic analysis of intracellular tachyzoites (Figure 5.9).
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While metabolite levels remained unaltered across much of the TCA cycle,
metabolites immediately downstream of glutamine were much more abundant in
TgLaf parasites than in their WT counterparts. Previously, it was demonstrated
that T. gondii tachyzoites primarily utilize glucose and glutamine for synthesis of
macromolecules and normal progression through the lytic cycle (226). Glucose is
utilized primarily to fuel glycolysis, and glutamine undergoes glutaminolysis to fuel
the TCA cycle. In the absence of glucose, T. gondii can upregulate both
glutaminolysis and gluconeogenesis to make up for the loss of glucose (211,226),
suggesting that TgLaf parasites are deficient in glucose metabolism. This finding
further suggests that the turnover of the tachyzoite glucan serves as a potential
intermediate in overall glucose metabolism.
5.2.6 Loss of TgLaforin renders T. gondii tachyzoites dependent on glutamine
Without both glucose and glutamine, parasites are significantly hampered in
their ability to invade and establish plaques (226). To determine if the loss of
TgLaforin resulted in impaired access to glucan stores in tachyzoites, and thus a
dependence on glutaminolysis, we performed plaque assays in the presence and
absence of glutamine (Figure 5.10). In the presence of glutamine, TgLaf
parasites formed plaques that were slightly larger than both the WT and COMP
lines. Upon removal of glutamine after the parasites had invaded the HFF
monolayer, however, TgLaf parasites were completely unable to form plaques,
whereas the WT and COMP lines were able to form plaques with normal efficiency.
Importantly, the growth of the COMP line under glutamine depleted conditions
indicated that glutamine dependence was specific to the loss of TgLaforin,
suggesting that loss of TgLaforin results in loss of normal glucose metabolism.
5.2.7 Analysis of lytic cycle
Plaque formation is the result of the cumulative effects of invasion replication
and egress extended over multiple cycles. To determine how glutamine deprivation
was impacting the lytic cycle in the TgLaf parasites, we analyzed replication and
egress (Figure 5.11). In each assay, parasites were pre-starved of glutamine for
48 hours before the assay. In the replication assay, replication was analyzed 24
hours after invasion (72 hours of glutamine starvation total). Among the three lines,
we saw no significant difference in replication under glutamine replete or depleted
conditions (Figure 5.11a). Thus, glutamine depletion appeared to have no overall
effect on replication without TgLaforin. The fact that the glutamine starved
parasites were able to establish the infection argued against a major defect in
invasion, and invasion efficiency was not explored further here.
Finally, we analyzed egress efficiency among the three lines with two different
small molecules (Figure 5.11b-c). First, we used the calcium ionophore, A23187
(Figure 5.11b), that results in rapid increases of cytoplasmic calcium, microneme
117

discharge, and subsequent egress. Secondly, we tested zaprinast (Figure 5.11c),
a phosphodiesterase inhibitor that results in rapid increase of cGMP levels that
then trigger the signaling pathway that ultimately leads to egress. Surprisingly, no
induced egress defect was seen when parasites were treated with either 3 M
A23187 or 500 M zaprinast.
We hypothesized that WT parasites were able to survive in the absence of
glutamine partially due to their ability to access internal glucan stores to which the
TgLaf parasites may not have efficient access. To determine if glutamine
starvation resulted in differential utilization of the tachyzoite glucan, parasites were
starved of glutamine for 72 hours and then evaluated for glucan content using
IV58B6. Interestingly, it appears that IV58B6 staining is lower in mutant parasites
after glutamine starvation than their WT counterparts, but more rigorous
quantification of this phenomenon will need to be performed (Figure 5.12).
Regardless, we did see a slight decrease in IV58B6 staining in both lines with
glutamine starvation, implying that the absence of glutamine might result in the
utilization of AGs.
5.2.8 Loss of TgLaforin results in attenuated virulence and cyst formation in vivo
While TgLaf parasites grew normally in nutrient replete media, they were
unable to grow without glutamine. We therefore hypothesized that while loss of
TgLaforin might not impose a penalty under the ideal conditions of cell culture, it
may impose a steeper penalty under the stresses and potential nutrient scarcities
encountered in vivo. To test the importance of TgLaforin in the acute phase of
infection in mice, we infected equal numbers of male and female CBA/J mice with
100 tachyzoites IP and monitored the mice daily using previously developed a fivestage body index score (Table 2.6) to track the severity of symptoms associated
with a tachyzoite infection over the course of 28 days (Figure 5.13a).
The acute phase of infection was highly attenuated by the loss of TgLaforin.
Mice infected with WT parasites began demonstrating symptoms of infection 10
days after infection with tachyzoites (Figure 5.13a). However, mice infected with
TgLaf parasites did not begin to experience symptoms until 15 days after
infection. Moreover, mice that became symptomatic from WT parasite infections
often proceeded through all stages of symptomology, and only a minor proportion
of mice that became sick were able to recover from infection (>50% of mice
proceeded to stage 4 (moribund)). Infection from TgLAF-KO parasites, however,
resulted in a majority of mice that only developed mild symptoms (Stage 2 or less)
with many of these mice recovering (Figure 5.13a). The inability of the TgLaf
parasites to cause symptoms in mice was reflected in the mortality rates of the
infected mice: infection with WT parasites resulted in 73% mortality rate after 28
days whereas TgLaf parasites only caused 17% mortality (Figure 5.13b).
Complementation of TgLaforin rescued this defect in virulence as COMP parasites
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resulted in an earlier onset of symptomatic infection at Day 11, and the majority
(53%) of mice dying after 28 days (Figure 5.13a-b).
Because the acute phase of infection was significantly attenuated by the loss
of TgLaforin, we hypothesized that cyst numbers would be significantly lowered.
To determine the number of cysts formed after 28 days of acute infection, we used
a previously established protocol for harvesting and counting tissue cysts from
infected mice (55,275). Briefly, brain homogenate from infected mice was layered
on a discontinuous Percoll gradient and centrifuged to separate brain material and
red blood cells from cysts. Fractions were then collected from the bottom of the
Percoll gradient proceeding from most dense (bottom of Percoll gradient) to least
dense (top of Percoll gradient). In all cases, red blood cells (RBCs) traveled the
furthest through the Percoll gradient and defined the fraction with the highest
density in which cysts could be found, with brain homogenate on the top defining
the fraction of least density. Cysts were thus harvested from the fractions between
the RBCs and brain homogenate.
Indeed, after isolating tissue cysts and counting them, it was determined that
mice infected with TgLaf parasites contained significantly fewer tissue cysts than
those infected with WT (Figure 5.13c). Most likely, the lower cyst number in the
TgLaf parasites was a result of failure to establish WT levels of virulence during
the acute phase of infection, and not in actual bradyzoite conversion, as in vitro
conversion assays demonstrated no defect in cyst formation (Figure 5.6b). Due to
the low survival rate of the mice infected with the COMP parasites, only two data
points could be generated for this parasite line as each data point is the average
of cyst-counts from 2 mouse brains. Therefore, this low statistical power precluded
statistical analysis. However, the two data points that were obtained for the COMP
line almost identically represented the range of cyst burden detected in WTinfected mice. One of the data points was far outside of the range that the TgLaf
parasites were able to generate. Therefore, it appears that complementation of
TgLaforin at least partially restored the defect in cyst formation.
5.2.9 TgLaf tissue cysts can re-establish infections in naïve mice
To determine if the physiological defects we observed of in vitro cysts
translated into a lower level of infectivity, brain homogenate containing 20 cysts
from each line of parasites was injected IP into CBA/J mice, and symptomology
and death were once again monitored for 28 days. The symptoms related to
infection resulting from cysts was much milder than that from tachyzoites (Figure
5.14a), and this held true across all three lines of parasites. Moreover, the death
rate related to cyst infection was much lower than seen in tachyzoites across all
three lines. After 28 days, cyst burdens were established from each line.
Interestingly, the death/illness rate was slightly higher in the WT and COMP lines.
Again, TgLaf parasites were much less competent at forming cysts in vivo.
However, the COMP line was unable to rescue this defect in cyst formation (Figure
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5.14b), suggesting that physiological and metabolic changes associated with the
loss of TgLaforin manifest differently based in the life cycle stage impacting their
capacity to be complemented.
5.2.10 Proper AG formation relies on the presence of TgLaforin
To understand if a loss in cyst infectivity was related to the formation of aberrant
AGs in TgLaf bradyzoites as seen after 6 days of in vitro conversion, we devised
an efficient way to utilize TEM to investigate AG morphology in purified in vivo
derived tissue cysts. Our protocol was developed based on a previously developed
method for imaging rare cell populations that we coupled with our previously
developed cyst harvesting protocol (276,277). After isolating tissue cysts from
CBA/J mice as described above, Percoll was washed out and cysts were fixed and
then suspended in low-melt agarose before gelling, post-staining, and embedding
in Epon (see Materials and Methods). TEM imaging revealed that while WT
parasites formed largely normal/canonical AGs in vivo as seen in vitro [Figure 5.15
(compare with Figure 5.7a)], TgLaf parasites contained almost exclusively
aberrant AGs that mirrored the same morphological defects seen in vitro (Figure
5.15 and Figure 5.16). Namely, AGs were irregularly sharpened with a flat, multilobed appearance. Importantly, COMP parasites did not over-accumulate or form
aberrant AGs, demonstrating that this defect is specific to loss of TgLaforin.
In addition to containing aberrant AGs, the internal morphology of TgLaf
parasites appeared to be altered by the presence of the AGs. Significant organelle
displacement was noted. Moreover, many of the TgLaf parasites appeared hollow
or “ghost-like” in appearance as a result of their unstained cytoplasm. We
interpreted this to mean that a significant number of the TgLaf bradyzoites were
dead within the cyst (additional images of ghost-like parasites depicted in Figure
5.16b).
Because TgLaf contained high levels of AGs, we hypothesized that this would
result in an altered density of mutant cysts in Percoll gradients relative to the WT .
To determine if the TgLaf cysts exhibited a different density profile, we analyzed
the distribution of cysts across Percoll fractions. To account for potential
differences in gradients preparations across experiments, we standardized the
distribution based on the location of the RBC layer the Percoll prep (fraction 0;
highest density-typically corresponding to fraction 8-10 in individual gradients)
proceeding up to the brain homogenate layer (fraction 12; lowest density).
Surprisingly, we noted that the overall distribution of cysts remained relatively
constant among the 3 lines. This indicated that despite the increase in AGs in the
TgLaf bradyzoites, their ability to travel through Percoll remained unchanged
(Figure 5.17a).
To understand how other factors might contribute to this outcome, we analyzed
the packing density of bradyzoites in each line. This previously defined metric
establishes a relationship between the number of bradyzoites within a cyst and the
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overall volume of the cyst. This is achieved through counting the number of
bradyzoite nuclei within an optical section of a cyst using BradyCount 1.0 (55) and
dividing that number by the volume of the optical section. When we analyzed the
packing density of each line of parasites, we noted that TgLaf parasites had
significantly lower packing density than that of the WT or COMP parasites (Figure
5.17b), indicating that loss of TgLaforin indeed resulted in significant parasite
death. Moreover, when analyzing cyst diameter, we also saw a significant
decrease in overall cyst size (Figure 5.17c). We interpreted these data as
indicating that although TgLaf bradyzoites contain many more AGs than either
WT or COMP bradyzoites, their overall lower packing density and cyst size
counterbalance their potential increase in overall density. Therefore, their overall
distribution through the Percoll gradients remained unchanged.
5.3 Discussion
We investigated the role of TgLaforin, and by extension polysaccharide
storage, throughout the asexual cycle in T. gondii. Through comparative
microscopy, we first characterized a potentially glycogen-like glucan in the
cytoplasm of ME49 tachyzoites. To determine the role of reversible
phosphorylation on this glucan, we knocked out the parasite’s glucan
phosphatase, TgLaforin. We showed that tachyzoites become dependent on
glutamine in the absence of TgLaforin, and this nutrient defect appeared to result
in highly attenuated parasite virulence in vivo and defective cyst formation as
measured by multiple metrics. Moreover, while perturbation of TgLaforin did not
result in any obvious defects related to the tachyzoite glucan, it did result in
bradyzoites containing AGs with significant morphological defects.
Therefore, our studies demonstrate a fundamental role for reversible glucan
phosphorylation in T. gondii. As predicted, loss of proper AG turnover in
bradyzoites resulted in aberrant AG morphology, as seen previously in other
protozoa, plants, and vertebrates. These defects appeared to result in smaller
cysts with a lower packing density—upending the trend previously reported in
ME49-WT bradyzoites that smaller cysts typically demonstrate higher packing
density (55). Most interestingly, however, these studies add to the growing
literature pointing to the importance of glucan metabolism in tachyzoites. This
study suggests that tachyzoites utilize glucans for glucose allocation as suggested
in a study examining the role of the T. gondii starch synthase (TgSS) (203), as loss
of glucan access via TgLaforin results in complete glutamine dependence. As T.
gondii tachyzoites primarily utilize exogenous glucose and glutamine to support
their rapid growth, this dependence on glutamine implies upregulation of
glutaminolysis to fuel gluconeogenesis, highlighting the possibility that loss of
TgLaforin resulted in deficient glucan degradation and glucose allocation in
tachyzoites.
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These results are consistent with previous studies that disrupt glucose and/or
glucan metabolism, but also contrast them in significant ways (Figure 1.7).
Disruption of TgGT1, the only plasma-membrane glucose transporter in T. gondii
(225,226), or TgHK, T. gondii-hexokinase, resulted in upregulation of
glutaminolysis and gluconeogenesis, and thus parasite growth was highly
attenuated with glutamine depletion (211). However, neither of these mutants
became entirely dependent on glutamine as in the present study. Most strikingly,
TgSS parasites displayed no dependence on glutamine and, in fact, grew faster
than WT parasites when both glucose and glutamine were removed from the
culture media (203). Perturbations of other glycolytic enzymes also demonstrated
varied effects related to the presence of glutamine: loss of the essential GAPDH1
could be rescued with high levels of glutamine (362), but glutamine could not
rescue pyruvate kinase (TgPYK1) knockdown parasites (235). Therefore, while
many other studies have demonstrated that perturbations in glucan metabolism
result in an increased importance of glutamine through gluconeogenic flux, only
loss of TgLaforin and GAPDH1 demonstrate a complete dependence of
tachyzoites on glutamine to our knowledge at the time of writing this manuscript.
Regardless, loss of TgLaforin renders the parasites much more sensitive to the
nutrient composition of their environment. This was most clearly seen in their
attenuated virulence and cyst burden in mice. Like other studies of glucan
perturbations, the number of cysts formed by TgLaf parasites was much lower
than its WT counterparts (206,228,234,311). The cysts that were formed also
appeared to be highly defective. Interestingly, there was a large increase in the
number of parasites containing high levels of aberrant AGs in when comparing
TgLaf bradyzoites converted in vitro (6 days) vs in vivo (>6 days). This suggests
that either the in vitro conversion conditions are not adequate to produce this
phenotype, or that the accumulation of these aberrant AGs is time dependent. If
true, one could assume that an increase in the duration of the chronic infection for
these mutants may lower the infectivity of their cysts, a possibility that is supported
by a large number of parasites that appeared to no longer be viable by TEM. Our
in vivo work highlights that targeting the parasites on the level of reversible
phosphorylation, especially in the context of its interaction with CDPK2, may inhibit
the parasite’s ability to reactivate. This process utilizes several plant-like enzymes
that represent ideal drug targets in humans (TgGWD and CDPK2), and we recently
developed an inhibitor to TgLaforin (Chapter 3).
The present study has many strengths that allow for the detailed dissection of
in vivo bradyzoites. This includes the utilization of our previously developed cyst
purification protocol and automated computer-based methods that allowed us to
accurately count, measure, and determine packing density on all cysts in this
study. Moreover, we developed a method to concentrate purified cysts into
agarose blocks which allowed for the relative ease of cyst visualization by TEM
that would otherwise have been much more difficult if searching through brain
homogenate as is done traditionally. The limitations of this study were primarily
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related to our inability to purify the tachyzoite glucan from ME49 parasites and
inability to pinpoint the exact reason for arrest of parasite growth. With these data,
a more precise mechanism could be described. While the exact mechanism
related to the parasite’s inability to grow without glutamine is unknown at present,
the rescue of this defect by complementation ensures the effects we observed
were indeed specific to TgLaforin. Moreover, the limitations posed here did not
prevent a detailed, thorough characterization of many aspects of glucan
phosphatase biology.
Therefore, future work should seek to characterize the nature of the glucan in
tachyzoites with respect to chain length and phosphate content. Such a
characterization would determine the overall architecture of the glucan and allow
for classification as more glycogen-like or amylopectin-like, as well as reveal what
is stored within. Curiously, loss of TgLaforin resulted in the selective disruption of
AG morphology in bradyzoites while seemingly having no effect on tachyzoites as
it did in other knockouts such as such as -amylase, CDPK2, and glycogen
phosphorylase (in which bradyzoites also accumulated excess AGs).
Understanding if/how the tachyzoite glucan is broken down in the absence of a
glucan phosphatase would yield insights into the requirements of glucan
degradation in T. gondii. Overall, this work necessitates such a characterization as
it advances what is known about the role of storage polysaccharides in both
tachyzoites and bradyzoites, what results from the fact that they are present and
inaccessible and opens up reversible glucan phosphorylation as both a window
into understanding AGs and into developing therapeutics.
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Figure 5.1 Generation of a parental ME49 line by knocking out HXGPRT.
A, Purine interconversion pathways in T. gondii and the drugs used in HXGPRT+/selection; adapted from (352). B, Schematic of HXGPRT locus and PAM sites
used in this study. Numbered exons depicted as blue boxes and introns as black
lines. CRISPR/Cas9 nuclease sites are 3-bp upstream of PAM sites. C, Depiction
of modified HXGPRT locus after 1214-bp deletion resulted in the fusion of partial
exons 2 and 5, creating a TGA codon in exon 5. Sequencing of the fusion site is
depicted below. Abbreviations: 6-thioXMP = 6-thioxanthosine monophosphate;
AMP = adenosine monophosphate; GMP = guanosine monophosphate;
HXGPRT/HX = hypoxanthine-xanthine-guanine phosphoribosyl transferase; IMP
= inosine monophosphate; IMPDH = IMP dehydrogenase; MPA = mycophenolic
acid; PAM = protospacer adjacent motif; XMP = xanthine monophosphate.
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Figure 5.2 Glucan dynamics in T. gondii ME49 parasites.
A, Microscopy-based glucan evaluation of T. gondii tachyzoites and bradyzoites
using PAS, IV58B6 (-glycogen IgM mAb), and TEM. B, GAA digest of AGs in
tachyzoites and bradyzoites results in disappearance of IV58B6 and PAS signal
by IF analysis. Abbreviations: AG = amylopectin granule; DBA = Dolichos biflorus
agglutinin; GAA = acid -glucosidase; PAS = periodic acid-Schiff; TEM =
transmission electron microscopy.
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Figure 5.3 Endogenous tagging and localization of TgLaforin.
A, Schematic depicting the TgLaforin 3xHA-epitope tagging strategy. B,
Successful tagging of TgLaforin (62 kDa) was verified using immunoblot analysis
with an -HA antibody with SAG1 used as a loading control. C, IF analysis in
WT/tagged parasites with -HA antibody. D, IF analysis of TgLaforin colocalization
with PAS. Pearson’s coefficient: 0.765. E, IF analysis of TgLaforin colocalization
with IV58B6. Pearson’s coefficient: 0.737. All scale bars = 5 m. Abbreviations:
HX = hypoxanthine-xanthine-guanine phosphoribosyl transferase; PAS = periodic
acid-Schiff.
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Figure 5.4 Downregulation of TgLaforin in T. gondii bradyzoites.
A, Western blot analysis of TgLaforin expression levels in tachyzoites and
bradyzoites. GAP45 is the loading control, and loss of SAG1 serves as
confirmation of tachyzoite to bradyzoite conversion. B, Comparative levels of
TgLaforin mRNA in tachyzoites and bradyzoites alongside levels of the bradyzoite
marker, SRS9 for comparison. Transcriptomic data was plotted from ToxoDB.org
derived that is based on data from Fritz, et al. (332). In this study, in vitro
bradyzoites were harvested at 4 days after induction.
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Figure 5.5 Schematic of TgLaforin knockout strategy, and PCR
confirmation of DHFR disruption of TgLaforin.
A, Schematic of TgLaforin KO strategy: the pyrimethamine-resistant DHFR* gene
containing 40-nt homologous arms (hashed boxes) was inserted into the TgLaforin
locus by eliminating most of the gene by homologous recombination. A double
stranded break was induced using CRISPR/Cas9-GFP with a PAM site in the first
exon. B, PCR amplification of NcGra7-DHFR cassette with 40-nt homologous
arms. C, Representative image of FACS plot used to select GFP+ parasites. Area
circled indicates gating used to select GFP+ parasites that were chosen for further
drug selection. D, Inside/out PCR verification of DHFR integration into TgLaforin
locus. Amplicons (PCR1-4) illustrated in (A). E, Loss of TgLaforin mRNA was
confirmed by generating cDNA from both WT and TgLaf knockout strains. Actin
cDNA amplification serves both as a loading control and as a control to verify the
absence of gDNA. Abbreviations: DHFR = dihydrofolate reductase; FACS =
fluorescence-activated cell sorting; PAM = protospacer adjacent motif.
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Figure 5.6 Loss of TgLaforin selectively alters glucan morphology in
bradyzoites with no AG defects in tachyzoites.
A, Analysis of glucan levels in TgLaf tachyzoites using three different
approaches: PAS and IV58B6 immunofluorescence, and TEM. B, in vitro
tachyzoite to bradyzoite conversion efficiency of TgLaf vs WT parasites as
measured by DBA. C, Change in PAS levels during bradyzoite conversion by PAS
levels. Abbreviations: AG = amylopectin granule; DBA = Dolichos biflorus
agglutinin; PAS = periodic acid-Schiff. Statistical comparisons were done with an
ordinary one-way ANOVA using Tukey’s post-hoc test to correct for multiple
comparisons. Statistical significance is indicated as follows: ****p<0.0001.
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Figure 5.7 TEM images of in vitro bradyzoites.
A, Representative images of bradyzoites from each parasite line. At 4300x
magnification, scale bar = 2 m; at 8600x magnification, scale bar = 1m. COMP
= complemented parasites generated by complementing TgLaf parasites with
TgLaforin cDNA. Arrowhead = canonical AG (white, round/ovoid); Arrow = aberrant
AG (grey, flattened, multi-lobed). B, Quantification of relative parasite AG content
and grayness across lines used in this study. Statistical comparisons were done
using an ordinary one-way ANOVA with Tukey’s post-hoc test to correct for
multiple comparisons. Statistical significance is indicated as follows: *p<0.05,
***p<0.01, ****p<0.001, ns=p>0.05.
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Figure 5.8 Schematic of TgLaforin complementation strategy and
confirmation of successful expression of TgLaforin.
A, Schematic of TgLaforin complementation into TgLaf parasites in which a PAM
site was chosen at a neutral locus previously identified in Chr. VI (270) to insert
TgLaforin cDNA containing its endogenous promoter. The TgLaforin construct was
connected to the HXGPRT selectable drug marker and inserted using NHEJ. B,
PCR confirmation of integration of TgLaforin construct into Chr. VI. Primer sets are
indicated above amplicons. WT amplicon demonstrates restoration of TgLaforin,
and KO amplicon confirms that KO locus is still intact. WT/TgLaf gels serve as
controls for these PCR reactions. C, Western blot confirmation of expression of
TgLaforin in complemented parasites. Tagged LAF-HA parasites confirm the
correct MW (~60 kDa) and expression level. D, IF analysis demonstrates
restoration of cytoplasmic, punctate localization of TgLaforin. Scale bar = 5 m.
Abbreviations: NHEJ = non-homologous end joining; PAM = protospacer-adjacent
motif.
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Figure 5.9 Steady-state metabolomics reveals upregulation of
glutaminolysis in TgLaf parasites.
Metabolite levels of intracellular tachyzoites were analyzed after 48 hours of
growth in HFFs by GC/MS analysis.
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Figure 5.10 Loss of TgLaforin renders T. gondii tachyzoites dependent on
glutamine.
Representative plaque assay pictures are presented for each line and condition.
Total plaque area was measured in ImageJ and plotted in arbitrary units. Statistical
comparisons were done using an ordinary one-way ANOVA using Tukey’s posthoc test to correct for multiple comparisons. Statistical significance is indicated as
follows: *p<0.05, ns=p>0.05.
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Figure 5.11 The effects of glutamine deprivation on the tachyzoite lytic
cycle.
A, Replication assay in which parasites were pre-starved of glutamine for 48 hours,
seeded into HFFs, and counted after 24-hours of growth. Data is the average of 3
biological replicates with at least 70 vacuoles counted per replicate. B, Calcium
ionophore stimulated egress assay in which parasites were pre-starved of
glutamine for 48 hours, seeded onto HFFs and allowed to grow for 48 hours to
produce vacuoles containing >16 parasites, and stimulated with 3-M A23187.
Egress was monitored by video microscopy and time to egress was monitored as
described in Materials and Methods. Data is the average of 3 biological replicates.
C, Zaprinast stimulated egress assay performed as described for ionophore,
however 500-M zaprinast was used to stimulate egress. Error bars depict SD
from the mean. Statistical comparisons were done using an ordinary one-way
ANOVA using Tukey’s post-hoc test to correct for multiple comparisons. Statistical
significance is indicated as follows: ns=p>0.05.
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Figure 5.12 The effects of glutamine starvation on IV58B6 staining.
Parasites were starved of glutamine for 72-hours total before monitoring the effect
of glutamine starvation on tachyzoite AG levels. Scale bar = 5 m.
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Figure 5.13 Loss of TgLaforin attenuates virulence and cyst burden in mice.
Equal numbers of male and female CBA/J mice were infected IP with 100
tachyzoites from each group for symptoms and death: A, Symptomology
throughout acute phase of infection. Mice were monitored 1-2x/day and assigned
a body score index ranging from asymptomatic (Stage 0) to moribund/deceased
(Table 2.6). WT and TgLaf groups contain 24 mice each, and COMP group
contains 16. B, Kaplan-Meier curve of mouse survival during acute tachyzoite
infection. C, Mice that survived 4-weeks were euthanized, and brains were
homogenized in pairs, layered over Percoll for purification of cysts, and cysts were
counted as done previously (55,275). Error bars depict SD from the mean.
Statistical comparison for Kaplan Meier curve is indicated on plot, and statistical
comparison of cyst burden resulting from WT/TgLaf infection was done using an
unpaired t-test. Statistical significance: *p<0.05, ***p<0.0002.
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Figure 5.14 Mouse infection with TgLaf tissue cysts results in less
symptomology, death, and lower cyst burden.
CBA/J mice were infected IP with 20 cysts taken from previously infected mouse
brains and monitored for symptomology and death. A, Symptomology throughout
acute phase of infection as described in Figure 6B. B, Cysts/brain after 4-week
bradyzoite infection. Cyst numbers were determined as described in Figure 6C.
Statistical comparisons were done using an ordinary one-way ANOVA using
Tukey’s post-hoc test to correct for multiple comparisons. Statistical significance is
indicated as follows: *p<0.05, ns=p>0.05.
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Figure 5.15 T. gondii bradyzoites accumulate excess AGs in the absence of
TgLaforin.
Left panels: scale bar = 5 m; right panels (zoom of boxed region from left panel):
scale bar = 2 m.
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Figure 5.16 Additional images of in vivo tissue cysts.
A, WT tissue cyst (too large to fit in camera view) with two zooms depicted below.
B, TgLaf tissue cyst also with two zooms depicted below. Asterisks highlight
empty nuclei and arrow shows example of rhoptry displacement by AGs.
Top row scale bar = 5 m; Zoom scale bars = 2 m.
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Figure 5.17 Cysts formed by TgLaf parasites are smaller and contain a
lower bradyzoite packing density.
A, Distribution of cysts in Percoll gradient after centrifugation. Fraction 1 is defined
as the furthest traveling fraction adjacent to the RBC layer (most dense), and
fraction 12 is the least mobile fraction adjacent to brain homogenate (least dense).
Shaded area corresponds to SEM for each fraction. B, Packing density
comparison among WT, TgLaf, and COMP lines, a metric that describes cyst
occupancy that has been described previously (55). Calculations were made using
BradyCount1.0 to identify and quantify nuclear profiles from DAPI-stained tissue
cysts. C, Cyst diameter comparison among WT, TgLaf, and COMP lines as
measured in ImageJ. Statistical comparisons were done using an ordinary oneway ANOVA using Tukey’s post-hoc test to correct for multiple comparisons. Error
bars in (B) and (C) depict SD from the mean. Statistical significance is indicated
as follows: *p<0.05, **p<0.01, ns=p>0.05.
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CHAPTER 6. CONCLUDING REMARKS
6.1 Summary
After the discovery of reversible glucan phosphorylation in both plants
(167,174,239) and animals (184,186,191,247), it was suggested that this cycle
might also play a role in red alga and starch accumulating protists of red algal
descent such as T. gondii (204,205). Herein, we demonstrated the functionality of
the cycle of reversible glucan phosphorylation in T. gondii. We demonstrated that
both the glucan phosphatase (TgLaforin, TGME49_205290) and glucan, water
dikinase (TgGWD, TGME49_214260) are active against glucan substrates in vitro.
We also defined the unique biophysical and biochemical properties of these
enzymes using a wide range of techniques. In characterizing TgLaforin, we
provided the first biophysical evidence for a split CBM domain, we demonstrated
that TgLaforin is an anti-parallel DSP-mediated dimer, and we found that TgLaforin
is an active glucan phosphatase that prefers to dephosphorylate the C3-position
of glucosyl residues (Chapter 3). Moreover, we exploited the unique active site
topology of glucan phosphatases to identify an inhibitor of TgLaforin that is
selective against other DSPs and PTPs. In characterizing TgGWD, we showed
that TgGWD is a monomer, we discovered that it phosphorylates exclusively the
C6-position of glucosyl units, and we created a CE-based AMP detection assay
for use in studying the general GWD catalytic mechanism (Chapter 4).
To explore the relevance of reversible glucan phosphorylation in T. gondii
across its asexual life cycle, we first investigated the nature of the tachyzoite
glucan that has been recently recognized by PAS staining and 14C-glucose pulsechase experiments (203,212,228,363,364). Through comparative microscopy
techniques, we demonstrated that the PAS+ tachyzoite glucan is not visible by
TEM, but that it is recognized by an anti-glycogen antibody, IV58B6. We then
verified that this tachyzoite glucan co-localizes with TgLaforin. Loss of TgLaforin
did not appear to result in aberrant glucan morphology in tachyzoites as was
expected, but it did result in tachyzoite dependence on glutamine. Further, loss of
TgLaforin resulted in parasites with decreased virulence in mice and defective cyst
formation with regard to glucan content, size, and bradyzoite packing density
(Chapter 5).
In summary, this work builds upon recent work that recognizes the importance
of glucan turnover in tachyzoites through the contribution of glucan turnover to
central carbon metabolism, and its influence in acute virulence and cyst formation
in mice. Together with the identification of an inhibitor to TgLaforin, the entirety of
this work has characterized a valuable therapeutic target in the process of
reversible glucan phosphorylation in T. gondii. Such a target is unique in that it has
the potential to reduce the efficiency of reactivation, as T. gondii cysts lacking
TgLaforin appear to be less virulent than their wildtype counterparts.

6.2 Discussion
6.2.1 The role of reversible glucan phosphorylation in tachyzoites
Our study supports the hypothesis that the glucan in T. gondii tachyzoites plays
a crucial role in providing glucose for central carbon metabolism, as loss of
TgLaforin, and thus loss of functioning reversible glucan phosphorylation and
turnover, in tachyzoites appears to necessitate glutaminolysis and
gluconeogenesis to make up for a glucose defect.
The mechanism potentially underlying this hypothesis is explained by recent
discoveries in T. gondii and other systems. In T. gondii, the metabolic alterations
seen in the starch synthase (TgSS) knockout are highly suggestive that AGs play
a role in glucose allocation, as loss of TgSS resulted in a decreased flux of glucose
through glycolysis (203). In other systems, such a function has been attributed to
mammalian glycogen as it has been demonstrated that the majority of glycolytic
intermediates in mammals are provided by glycogen, and not directly by circulating
glucose (365). This suggests that glucose storage precedes utilization and thus
implies a degree of metabolic compartmentalization and buffering against
fluctuating glucose levels (365). Such a model is consistent with a recent study
performed in Leishmania parasites that demonstrated mannogen, the Leishmania
carbohydrate reserve, is constantly cycled in the amastigote life stage, acting as a
proposed “metabolic rheostat” to buffer metabolic flux (313). A similar function of
AGs is supported by continuous incorporation of glucose into and breakdown of
AGs in WT parasites (228,312). In fact, the term “futile metabolic cycling” was
applied to T. gondii metabolism in light of the discovery that both glycolytic and
gluconeogenic enzymes are co-expressed and constitutively active in tachyzoites
(Figure 1.7). This is hypothesized to allow maximum metabolic flexibility and
steady levels of hexose phosphates at all times (209). Continuous storage and
liberation of glucose into and out of AGs may serve a similar function.
Loss of TgLaforin might be enough to disrupt the efficiency of this cycle in
providing needed glucose without completely halting it, explaining the lack of
glucan overaccumulation. Such a model would involve continuous storage and
degradation of glucose into and out of AGs under normal conditions, akin to the
charging and discharging of a battery (Figure 6.1a). Glucose liberated from AGs
would then be utilized for glycolysis, the TCA cycle, the pentose phosphate
pathway, and in providing substrates for glycosylation. In the absence of reversible
glucan phosphorylation, the liberation of glucose from AGs might be significantly
slowed such that glutaminolysis and gluconeogenesis are needed to provide
carbon to fuel central carbon reactions, and possibly carbon for the creation of
glucose needed to make AGs, as this possibility has also been previously
demonstrated (Figure 6.1b) (235). Without glutamine, however, the glucose
liberated from AGs in the context of a TgLaforin knockout might not be enough to
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sustain the rapidly dividing tachyzoite, explaining why glutamine imposes such a
strong penalty in the absence of TgLaforin (Figure 6.1c).
This mechanism does not explain why other disruptions of glucan/glucose
metabolism do not also result in a complete glutamine dependence. Recently, our
understanding of glycogen’s role in metabolism has changed to include functions
beyond energy storage, as there is now evidence that glycogen may provide
substrates for epigenetic modifications in the nucleus (282) and for protein
glycosylation (154). An impairment in glucan access might also extend beyond
glucose deprivation, as very recent studies demonstrated glycogen in humans is
not entirely composed of glucose (154). Glycogen is comprised of 25%
glucosamine in neurons. Loss of laforin in humans was shown to result in N-linked
protein glycosylation defects, and this was due to sequestration of glucosamine
into glycogen that could not be liberated efficiently without HsLaforin. Therefore,
the distinct mechanism underlying the TgLaf parasite’s inability to survive in the
absence of glutamine may indeed be a result of hindered access to glucose, but
potentially glucosamine as well. Under such a mechanism, glutamine would play
two roles in TgLaf parasites that it would not necessarily be playing in the GT1
or HK parasites: 1) providing a carbon skeleton to operate the TCA cycle and
gluconeogenesis in the absence of efficient glucan turnover, and 2) providing an
amino group for the formation of glucosamine that may be sequestered away.
Alternatively, it was recently demonstrated that glutamine deprivation resulted
in the downregulation of the arginine transporter TgApiAT1 (366), indicating that a
lack of glutamine may initiate a generalized starvation response in T. gondii. Under
such conditions, TgLaf parasites would not have easy access to internal energy
stores as their WT counterparts might, providing another possible mechanism that
explains this phenotype.
6.2.2 The role of reversible glucan phosphorylation in stage conversion
Strikingly, and somewhat unexpectedly, we discovered that TgLaforin
expression decreases during the tachyzoite to bradyzoite conversion in vitro even
though its transcript levels do not change (Figure 5.4a-b). Moreover, a previous
study indicates the possibility that transcript levels of TgGWD increase during the
course of differentiation (40). During differentiation, both in vitro and in vivo, the
appearance of crystalline AGs is also observed, raising the possibility that
expression levels of these two enzymes relative to one another may contribute to
the crystallinity of the T. gondii glucan. Loss of glucan phosphatases, and thus
increased glucan phosphate content, results in enlarged granule morphology in
plants (137), and the precipitation of glycogen into amylopectin-like Lafora bodies
in animals (186). The programmed downregulation of TgLaforin and upregulation
of TgGWD in T. gondii might result in the fine-tuned precipitation of the tachyzoite
glucan into the bradyzoite AG. As such, T. gondii might provide a system in which
to explore the interplay of these two enzymes and their contributions to crystallinity
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through their controlled expression, and the controlled phosphorylation of glucans.
Moreover, expression levels of branching and debranching enzymes, the two
enzymes that have the biggest impact on glycogen and starch crystallinity in other
systems (166), have not been explored during stage conversion in T. gondii.
Because the enzymology related T. gondii starch synthesis and degradation is
relatively simple compared to plants and green algae (199), the interplay of these
limited number of enzymes could be more easily untangled and provide models
for more complex systems in plants.
6.2.3 The role of reversible glucan phosphorylation in bradyzoites
In bradyzoites, the proposed roles of AGs traditionally been rooted in inferred,
albeit reasonable, observations. AGs are believed to serve bradyzoites in
persistence, reactivation, and transmission; essentially, they function as glucosestorage molecules to be used in situations of uncertainty such as the digestive
system of a new host or in weathering nutrient fluctuations in the brain. These roles
are attributed to AGs for a number of reasons, one being that such storage
molecules are used in plants and algae for survival when photosynthesis is not
possible (144). Further support of their role comes from the observations that the
only life stages of T. gondii that accumulate large, visible AGs are those that are
responsible for transmission, and that encounter the most challenging
environments: the bradyzoite and the sporozoite (134,367). Indeed, in Eimeria, it
was shown that the levels of amylopectin in sporozoites was directly correlated
with their ability to invade chicken cells in cell culture (368), lending further
legitimacy to this assumption in T. gondii. Some direct evidence has been provided
for these assumptions as well—a study from Stanislas Tomavo’s lab provided an
undocumented observation that bradyzoites in cell culture lose their AGs upon
conversion to tachyzoites (196), and the recent knockout of TgSS demonstrated
that bradyzoite conversion to tachyzoites was significantly reduced compared to
its WT counterpart (203). In light of the discovery that bradyzoites undergo cyclical
bursts of replication (55), it has been suggested that AGs serve as a marker for
replication potential and fuel these events as well (101,369). Toward an
understanding of this relationship, software for the analysis of AGs, replication, and
mitochondrial activity has recently been developed to untangle the relationships
among these three physiological parameters (337).
The role of TgLaforin in the context AG metabolism in bradyzoites is, therefore,
possibly more straightforward than its role in tachyzoites. Loss of TgLaforin results
in bradyzoites with a “starch-excess” phenotype as has now been observed in
plants, animals, and red algae (174,187,207). Moreover, this phenotype is
progressive, as in vitro TgLaf bradyzoites (day 6) display a milder defect in
overaccumulation of AGs than in vivo bradyzoites (>day 6). However, by the time
mature tissue cysts have formed in mice, many TgLaf bradyzoites appear dead.
Interestingly, TgLaf bradyzoites are capable of reinfecting new mice when
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injected IP. It should noted, however, IP injection allows for the bypassing of the
stomach where cysts usually initiate infections in new hosts, and thus does not
provide any insight into whether or not these parasites would be able to survive an
oral route of infection, or if they could reactivate in the context of the immune
system.
6.2.4 Limitations and future directions of these studies
While AG turnover in T. gondii was partially characterized through the lens of
reversible phosphorylation in these studies, several limitations prevented a full
mechanistic understanding of TgLaforin’s role in T. gondii. Primarily, purification of
the T. gondii glucan from tachyzoites or bradyzoites was unsuccessful, most likely
due to attempted purifications from an insufficient quantity of parasites. Because
T. gondii is an obligate, intracellular pathogen, extensive washing and filtration of
parasites is required to rid them of host material, such as host glycogen that could
easily confound parasite glucan analysis. Extensive washing and filtering results
in the loss of at up to 95% of parasites over the course of purification (370).
Therefore, we were unable to directly characterize relevant properties of the glucan
such as phosphorylation status, chain length, and crystallinity in both WT and
TgLaf parasites. With regard to metabolomics, we were unable to visualize
glycolysis using GCMS analysis, and we have not yet performed stable isotope
tracing of glucose or glutamine. Therefore, while we speculate that glutaminolysis
is being upregulated in TgLaf parasites due to the inaccessibility of a
hyperphosphorylated glucan, we have yet to complete the studies that would prove
this.
Toward understanding TgLaforin’s role in tachyzoites, we have also not yet
identified what precisely results in the inability of TgLaf tachyzoites to form
plaques in the absence of glutamine. While we have explored replication and
egress, neither of these components of the lytic cycle seem to be affected in the
simultaneous absence of both TgLaforin and glutamine. The fact that TgLaf
parasites were identified and counted in replication assays with the same ease as
WT parasites argues against a significant invasion defect. In replication assays
performed in this study, parasites were pre-starved of glutamine and then
subsequently forced to reinvade host cell monolayers and divide for 24 hours
before counting. Therefore, the defect in TgLaf growth under glutamine depleted
conditions likely lies in either a natural egress defect, as opposed to the stimulated
egress assays we utilized, or in a progressive decline in overall parasite fitness
during the course of glutamine starvation that is not specific to any portion of the
lytic cycle.
Finally, restoration of TgLaforin into TgLaf parasites did not result in a perfect
complementation, despite its having been restored under its native promoter to
near identical expression levels found in WT parasites (Figure 5.8e). Importantly,
complementation did restore the ability of the parasite to grow in the absence of
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glutamine, tachyzoite virulence in mice, and its ability to form normal cysts from
tachyzoite infection. However, in cyst re-infection studies, complementation did not
rescue the number cysts formed in the TgLaf line. This suggests that the lower
cyst burden from reinfection is either unrelated to TgLaforin and possibly the result
of an off-target effect of CRISPR/Cas9, or that loss of TgLaforin resulted in
metabolically re-programmed parasites that could not be completely returned to
WT levels. To further explore these possibilities, conditional knockdown of
TgLaforin could address if the lower cyst burden during re-infection with cysts is
specific to TgLaf parasites or the result of some other mechanism. Recently, an
auxin-inducible degron (AID) system has been adapted to T. gondii. AID
knockdown of AID-tagged proteins relies on indole-3-acetic acid (IAA) treatment
that can be safely administered to mice to maintain the knockdown (9).
These studies also present the opportunity for future directions in
understanding basic glucan metabolism in T. gondii. So far, the glucan within
tachyzoites has not been biochemically characterized under unstressed
conditions. Moreover, it has not been characterized throughout the tachyzoite lytic
cycle. Future studies could address whether the glucan is utilized during energy
intensive processes such as invasion, replication, egress, or motility. Correlations
between glucan levels and the parasite’s progress through each of these events
could be easily monitored in conjunction with well-established assays used in
evaluating each of the components of the lytic cycle. We demonstrated the
disappearance of IV58B6 staining during bradyzoite differentiation (Figure 5.2) as
a mature cyst wall develops. Future studies can also examine the reasons for this
disappearance. For example, does IV58B6 staining disappear because the
fundamental properties of the tachyzoite glucan shift toward amylopectin-like
crystallinity? Or does IV58B6 staining disappear because the tachyzoite glucan is
completely degraded while the bradyzoite AGs are synthesized de novo?
Experiments exploring the staining patterns over the course of differentiation in
conjunction with determining the biochemical characteristics of the parasite’s
glucan over the course of differentiation could begin answering these questions.
HsLaforin and the role of phosphate in glycogen have often been the subject
of debate as it has been difficult to separate the importance of its catalytic
phosphatase activity from its scaffolding roles in bringing other degradation
machinery to glycogen (189). Thus, future work could include investigating the
nuanced functions of TgLaforin through a dissection of the relevance of its catalytic
activity versus its scaffolding activity by mutating TgLaforin’s catalytic cysteine in
vivo, or attempting complementation of the TgLaf parasites with catalytically
inactive versions of the protein. Notably, TgLaforin’s CBM domain contains large
unstructured inserts (Chapter 3). While the role of these inserts is unclear, it is
possible that these intrinsically disordered regions (IDRs) in TgLaforin might play
a role in protein-protein interactions. IDRs are unusually abundant in parasitic
protozoa (308) and have been speculated to be crucial in protein-protein
interactions in Plasmodium (307). Therefore, further work could characterize
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TgLaforin’s interacting partners. Toward this end, we collaborated with Hybrigenics
Services (Paris, France) to conduct a yeast-two-hybrid screen utilizing TgLaforin
fused to both an N-terminal LexA and Gal4 DNA-binding domain as bait against a
fragment-based library of the T. gondii proteome (Table 6.1) and discovered
several putative interacting partners related to glucan metabolism including
debranching enzyme, CDPK2, and TgGWD. Of note, the LexA fusion screen
indicated the possibility that TgLaforin interacts with BFD1, a transcription factor
recently identified as being both necessary and sufficient for bradyzoite
differentiation (107). However, the confidence in this interaction was low. Further
immunoprecipitation experiments with the TgLaforin-HA epitope-tagged line that
we generated could determine which of these interactions are relevant in vivo.
6.3 Conclusion
From its initial discovery (1,2), T. gondii was initially mis-identified as
Leishmania in both labs that first found it (371). Since then, T. gondii has not
ceased in its ability to surprise and confuse scientists. Such attributes are
especially evident in its glucan biology, which itself has provided surprising insights
into the evolutionary history of T. gondii.
Herein, we build on the recent surprise that glucan biology is relevant in T.
gondii tachyzoites and provide evidence that the tachyzoite glucan may have
glycogen-like properties that distinguish it from AGs in bradyzoites. We then
demonstrated that TgLaforin colocalizes with this glucan in tachyzoites but is likely
downregulated in bradyzoites coinciding with the appearance of crystalline AGs.
We also characterized the enzymology TgLaforin alongside TgGWD. We
demonstrated that TgLaforin contains an incredibly unique CBM20 domain that is
split by flexible linkers that possibly allow for protein-protein interactions and
provide evidence that the enzymatic activity of TgLaforin can be selectively
inhibited. Analysis of a TgLaforin knockout in vivo suggested the value in such an
inhibitor as we further built on recent discoveries suggesting that the tachyzoite
glucan might also behave like animal glycogen in its potential metabolic buffering
capacity. Critically, through loss of TgLaforin, we saw that reversible glucan
phosphorylation, and thus glucan degradation, play a critical role in T. gondii’s
ability to survive nutrient scarcity, establishment of virulence in mice, formation of
proper AGs in bradyzoites.
In summary, this work has contributed not only to our knowledge of T. gondii
biology, but to more general themes of glucan solubility versus crystallinity, the
diversity of CBM organizations, and diversity of DSP domain active sites. Future
work should seek to exploit these unique traits in TgLaforin to further home in on
more effective T. gondii therapeutics.
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Table 6.1 Yeast-two hybrid screen to identify TgLaforin interacting proteins.
Yeast two hybrid screen using TgLaforin as bait. Table lists prey interacting
domains, indicating the amino acid residues of prey and which domain prey falls
into, along with the name and accession number of the protein. PBS = protein
biological score, an indicator of confidence in the interaction, proceeding from
highest (A) to lowest (E).
Interaction
Fusion
ToxoDB
domain [AA#
construct Accession #
Protein name
(Pfam ID)]
PBS
Debranching
857-1039
TGME49_226910
B
enzyme
(CBM48)
TGME49_225490
CDPK2
1-118 (CBM20) B
Hypothetical
TGME49_206640
630-993
B
protein
Serine/threonine
1538-1785
TGME49_223985
protein
B
(CBM48)
phosphatase
Gal4
RNA polymerase 20-52 (subunit
TGME49_254140
C
II
CX)
TGME49_268960
AMPK -subunit 80-192 (CBM48) D
TGME49_214260
TgGWD
1-324 (CBM45) D
Hypothetical
TGME49_229260
1668-2268
D
protein
Hypothetical
TGME49_215520
145-315
E
protein
LexA
TGME49_200385
BFD1
2562-4092
E
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Figure 6.1 Proposed mechanism underlying TgLaf tachyzoite dependence
on glutamine.
A, Unperturbed conditions in which reversible glucan phosphorylation allows for
efficient glucan degradation in tachyzoites. Glucose and glutamine usage is
balanced as seen in Figure 1.7. B, Loss of TgLaforin results in upregulation of
glutaminolysis due to loss of glucan breakdown efficiency. Glutamine-derived
carbon fuels the entire TCA cycle and provides glycolytic intermediates through
gluconeogenesis. C, Removal of glutamine from TgLaf parasites removes the
only carbon source, resulting in the complete loss of central carbon metabolism.
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